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Zusammenfassung 
Zusammenfassung 
 
Die zahlreichen immunologischen Ausweichstrategien, welche im HIV-1 envelope (Env) 
Glykoprotein verkörpert sind, stellen für die Entwicklung eines sicheren und effektiven 
Vakzins weiterhin ein enormes Hindernis dar. Zu den herausfordernsten 
Ausweichmechanismen zählt die unermessliche genetische Diversität, welche mit der 
Immundominanz hoch variabler Regionen von Env assoziiert wird. Die derzeitigen 
Impfstoffansätze zielen darauf hin, breitneutralisierende Antikörper (bnAK) 
hervorzurufen, von denen einige in der Lage sind mehr als 90% der kursierenden HIV-1 
Stämme zu neutralisieren. Allerdings wird die Entwicklung von bnAK aufgrund der 
komplexen Koevolution von Virus und humoraler Immunantwort erheblich beeinträchtigt. 
Daher bedarf es neuartiger Env Immunogene sowie innovativer Selektionstechnologien für 
deren Identifikation, um diesen Prozess zu begünstigen. 
Der erste Abschnitt dieser Dissertation beschäftigte sich intensiv mit der biologischen 
Prozesstechnik einer auf Env basierten sequentiellen Permutationsbibliothek, mit 
besonderem Schwerpunkt auf Charakterisierung und Qualitätskontrolle der Bibliothek. 
Jede Position des außenliegenden Env-Bereiches wurde durch 20 natürliche Aminosäuren 
ersetzt, wodurch eine Bibliothek bestehend aus 658 Unterbibliotheken und 
schätzungsweise 13.000 Varianten hervorgeht. Gleichzeitig wurden die jeweiligen stabilen 
Zelllinien durch stabile Transfektion jeder Unterbibliothek in Flp-InTM T-Rex 293 Zellen 
hergestellt. Das Ziel bestand darin, diese Bibliothek einer Selektionstechnologie beruhend 
auf einer Zellsortierung zu unterziehen, um Env Varianten mit verbesserter Antigenität zu 
identifizieren. Sowohl die Plasmid-DNA- (pDNA), als auch die Zelllinien-Bibliothek wurden 
umfassend auf ihre Qualität kontrolliert. Die eingehende Analyse der pDNA offenbarte 
Deletionen verschiedenster Länge hauptsächlich in der Env-Region, welche etwa 48% der 
Bibliothek betreffen. Allerdings traten diese Deletionen in einem kleinen Bruchteil 
innerhalb der Unterbibliotheken auf, womit die tatsächliche Kontamination jeweils nur 
zwischen 6-18% lag. Mit dem Schwerpunkt auf der CD4-Bindestelle von Env, wurden 
Diversität und Verteilung der Aminosäuren der pDNA, sowie der stabilen Zelllinien mittels 
Next Generation Sequencing (NGS) ermittelt. Während die pDNA eine durchschnittliche 
Variabilität von 19 Aminosäuren und eine nahezu ideale Verteilung aufwies, zeigten die 
stabilen Zelllinien sowohl einen etwa 38%-igen Rückgang in der Diversität, als auch eine 
beträchtliche und zufallsbedingte Ungleichverteilung der Aminosäuren. Es wurde 
ersichtlich, dass die unzureichende Integration von Env bei der Herstellung der stabilen 
Zelllinien maßgeblich zu diesem Variabilitätsverlust beitrugen. Dementsprechend wurden 
einige vielversprechende Ansätze zur Optimierung der Herstellung stabiler Zelllinien 
eingeleitet, mit dem Ziel eine bessere Diversität und Aminosäureverteilung zu erlangen. 
Das zweite Projekt beruhte auf der Identifikation von verbesserten Env-Kandidaten mit 
vorteilhaftem Antigenitätsprofil. Zu diesem Zweck wurde eine Selektionstechnlogie 
angewendet, die auf einer Zellsortierung beruht und folgende Vorteile in sich vereinigt: i) 
Integration einer einzigen Env Variante in eine definierte FRT-Stelle pro Zelle, was eine 
Kopplung zwischen Geno- und Phänotyp zur Folge hat, ii) induzierbare Env Expression, um 
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Zytotoxizitätseffekten vorzubeugen, iii) translationale Verknüpfung von GFP und Env zur 
indirekten Normalisierung auf die induzierte Env Expression und iv) Expression der Env 
auf Hek293T Zellen, um native Faltung und Säugetierglykosylierung zu gewährleisten. In 
einem einzelnen Selektionszyklus wurden jeweils 12 Env Varianten mit erhöhter oder 
verminderter Affinität für den bnAK VRC01 aus der Zelllinien-Bibliothek angereichert. 
Auffallend dabei war, dass keine der Varianten mit erhöhter, und nur drei Varianten mit 
erniedrigter Bindungsfähigkeit mittels FACS-basierter Gleichgewichtstitration eindeutig 
validiert werden konnten. Da die Selektionstechnologie zuvor an einer Bibliothek getestet 
wurde, welche nur fünf Varianten umfasst, lag es der Vermutung nahe, dass die Methoden 
für komplexere und größere Bibliotheken weiter ausgebaut und adaptiert werden müssen. 
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Abstract 
Abstract 
 
The numerous immune evasion strategies embodied in the HIV-1 envelope (Env) 
glycoprotein still represent a daunting challenge in the development of a safe and effective 
vaccine. Among the most defying of these evasive mechanisms is the tremendous genetic 
diversity associated with the immunodominance of highly variable regions of Env. Current 
vaccine design efforts aim to elicit broadly neutralizing antibodies (bnAb), some of which 
are able to neutralize more than 90% of circulating HIV-1 strains. However, a complex co-
evolution of virus and humoral immune response considerably impairs the development of 
bnAbs. To facilitate this process, novel Env immunogens as well as innovative selection 
technologies for their identification are required. 
The first part of this thesis concentrated on the biological engineering of an envelope-based 
sequential permutation library, specifically focusing on characterization and quality 
control of the library. Each residue in the external part of Env was substituted by 20 natural 
amino acids, thus creating a library of 658 sublibraries and approximately 13.000 variants. 
Simultaneously, the respective stable cell lines (SCL) were generated by stably transfecting 
every sublibrary into Flp-InTM T-Rex 293 cells with the goal to utilize the stable cell line 
library in a mammalian cell display- and cell sorting-based screening technology to identify 
Env variants with improved antigenicity. Comprehensive quality controls of plasmid DNA 
library and the respective stable cell line library were conducted to assess potential 
limitations. In-depth analysis of the pDNA revealed deletions of various lengths mainly in 
the Env region affecting about 48% of the library. However, these deletions occurred only 
in a small fraction within the sublibraries, thus the actual contaminations amounted to 6-
18%, respectively, deeming the library still eligible to work on. Focusing on the CD4 binding 
site (CD4bs) of Env, diversity and amino acid distribution of the pDNA- and the stable cell 
line-library was analyzed by Next Generation Sequencing (NGS). Whereas pDNA exhibited 
an average diversity of 19 amino acids in the sublibraries with a nearly ideal distribution, 
stable cell lines demonstrated a considerable decrease in diversity by approximately 38%, 
as well as a highly uneven and random distribution of amino acids. It became apparent that 
particularly insufficient integration of Env during the generation of stable cell lines 
contributed to this substantial loss of diversity. Accordingly, several promising approaches 
were tested to optimize the stable cell line generation aimed to improve the diversity and 
amino acid distribution. 
The second project focused on the identification of improved Env candidates with favorable 
antigenicity from the stable cell line library. For this purpose, a mammalian cell display- 
and cell sorting-based technology was applied that combines the benefits of i) single 
integration of Env into a distinct FRT site resulting in the linkage of genotype and 
phenotype, ii) inducible Env expression to prevent cytotoxicity effects, iii) translational 
coupling of Env and GFP enabling an indirect normalization for induced Env expression and 
iv) display on Hek293T cells, thus ensuring native folding and mammalian glycosylation. 
Using the CD4bs SCL library, twelve Env variants demonstrating increased (gain of binding, 
GoB) and decreased (loss of binding, LoB) affinity for the bnAb VRC01, respectively, were 
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selected in a single round of cell sorting procedure. Strikingly, none of the detected GoB 
variants and merely three LoB candidates could be unequivocally validated by means of a 
FACS-based equilibrium titration. As the selection technology was previously tested on a 
five-variant library, there were grounds for supposition, that the methods require further 
development and adaptation to be utilized for more complex and extensive libraries. 
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1 Introduction 
 
1.1 Epidemiology of HIV 
 
In June 1981, the U.S. Centers for Disease Control and Prevention (CDC) released a report 
describing cases of a rare lung infection called Pneumocystis carinii pneumonia (PCP) in 
five young, previously healthy gay men in Los Angeles 1. Concurrently, an increased 
incidence of an unusually aggressive cancer known as Kaposi’s Sarcoma was recognized 
in New York and California 2. At this point in time, no one established a connection 
between the two obviously different diseases. It was only two years later that scientists 
discovered a common thread of impaired cellular immunity that linked these 
malignancies and other opportunistic infections 3,4. Eventually, the human 
immunodeficiency virus (HIV) was identified as causative agent of the substantially 
increasing cases of severe immune deficiency worldwide. Due to symptoms and 
progression of an HIV infection, the term acquired immune deficiency syndrome (AIDS) 
was established by the CDC in 1982. Since then the virus spread globally, causing one of 
the most debilitating pandemics ever recorded in human history. 
Approximately 80% of HIV infections occur during sexual intercourse with an infected 
partner through direct contact with semen and rectal or vaginal fluids 5. Blood-to-blood 
transmissions such as through sharing of needles or contaminated blood transfusions 6, 
as well as mother-to-child transmissions during pregnancy, childbirth or breastfeeding 
7, represent another 20% of all contracted HIV infections. 
Natural progression of HIV infection encompasses three stages: an acute phase, followed 
by an early/clinically latent phase, and finally by the immune collapse/AIDS. The acute 
or primary phase lasts several months and is characterized by high level viral replication 
that is reflected in substantial concentrations of virus in plasma and lymphoid tissue. 
After initial viral decline, concurrent with the appearance of virus-specific CD8+ 
cytotoxic T cells 8, the plasma viral load usually stabilizes at a steady state. This so-called 
‘set-point’ is the consequence from the equilibrium between the HIV-1 replication and 
the corresponding immune responses and represents the beginning of the second stage, 
a long clinical latency. Ultimately, the regenerative CD4+ T cell population slowly 
diminishes below a crucial threshold rendering the immune system vulnerable to 
opportunistic infections, thus causing progression to AIDS. 
According to the World Health Organization (WHO) more than 70 million people have 
contracted HIV and an estimated 35 million people have died from AIDS-related illness 
since the beginning of the pandemic. As of 2015, approximately 36.7 million [34.0–39.8 
million] individuals were living with HIV, representing 0.8 % [0.7–0.9 %] of adults aged 
15-49 years worldwide (figure 1). Although the prevalence of HIV varies considerably 
among countries, 70 % of all accounted infections arise in Africa, specifically in the Sub-
Saharan regions. While there is currently no cure for HIV, the infection can be 
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suppressed by a combination of antiretroviral drugs, thus substantially reducing 
morbidity and mortality. At the moment, approximately 18.2 million [16.1-19.0 million] 
HIV patients are receiving antiretroviral agents, termed combination antiretroviral 
treatment (cART). However, the low treatment rate, in addition to severe side effects 
from the medicaments, drug interactions and resistance demonstrate the importance of 
discovering a vaccine to finally conquer HIV infections globally. 
 
 
Figure 1 - Global prevalence of HIV in 2016. The illustration shows that an estimated 0.8% [0.7-0.9%] 
of adults aged 15-49 years worldwide are infected with HIV. Areas that are most severely affected, such 
as Sub-Saharan Africa, are indicated in dark red. Figure was adapted from WHO Global Health Observatory 
(GHO) data HIV/AIDS. 
 
 
1.2 Origin and phylogeny of HIV 
 
HIV appears to have its origin in the simian immunodeficiency virus (SIV) that infects 
non-humate primates in West and Central Africa. Zoonotic transmission presumably 
occurred as a consequence of hunting and butchering of primates and keeping of 
monkeys as pets 9,10. Two distinct HIV types emerged from the transmissions, HIV type 
1 (HIV-1) that descends from chimpanzees 9,11, and HIV type 2 (HIV-2) which is closely 
related to the SIV of sooty mangabeys 12. Whereas HIV-2 is relatively uncommon and 
majorly concentrated in West Africa, HIV-1 represents the predominant virus 
worldwide. 
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HIV is characterized by tremendous genetic variability and rapid evolution. Several 
factors contribute to the extensive heterogeneity, such as the error-prone nature of the 
HIV-1 reverse transcriptase (RT) 13, host selective immune pressure 14,15, as well as 
genetic recombination events during replication 16. Due to this variability, the HIV-1 
strains can be classified into four phylogenetic groups, which constitute the groups M 
(main), O (outlier), N (new or non-M, non-O) and P 17,18. Among these, group M viruses 
are globally the most prominent and can be further divided into nine genetically distinct 
subtypes or clades (A-D, F-H, J and K) 19. Furthermore, recombination events between 
strains and groups give rise to an increasing number of circulating recombinant forms 
(CRFs) 20,21 (figure 2). 
 
 
Figure 2 - Global distribution of HIV-1 subtypes and recombinants. Pie charts illustrate the 
percentage distribution of HIV-1 subtypes represented by different colors in each region. The distribution 
was calculated according to data gathered from 2004 to 2007. The figure was adapted from 22. 
 
 
1.3 Genomic organization and structural biology 
 
According to the International Committee on Taxonomy of Viruses (ICTV) the human 
immunodeficiency virus (HIV) is classified as a Retrovirus belonging to the genus 
Lentivirus. It features a roughly spherical morphology with a diameter of about 145 nm 
23. The approximately 10 kb genome is situated in the viral capsid as two non-covalently 
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linked positive stranded RNA molecules 24,25, and comprises nine open reading frames 
coding for 15 mature proteins (figure 3) which are divided into three classes 26,27: i) the 
major structural proteins, Gag, Pol and Env, ii) the regulatory proteins, Tat and Rev and 
iii) the accessory proteins, Vpu, Vpr, Vif, and Nef. 
 
 
Figure 3 – Genomic organization and structure of HIV. (A) Structure of the RNA genome of HIV-1 that 
consists of roughly 10.000 nucleotides (nts). Open reading frames of nine genes are shown as rectangles 
that overlap in some cases. (B) The HIV genome encodes 15 proteins that are categorized into enzymes 
(PR – protease, RT – reverse transcriptase, IN – integrase) as well as structural (MA - matrix, CA – capsid, 
NC – nucleocapsid), auxiliary, surface (Env – envelope, gp – glycoprotein) and regulatory proteins. Colors 
of genes and their respective gene products are matched. (C) Schematic structure of a mature HIV-1 
particle. The enveloped virus features one surface protein, the trimeric envelope glycoprotein (Env) 
comprising three gp120 and g41 subunits, respectively. Matrix proteins (MA, p17) line the host-derived 
membrane. The conical capsid (CA, p24) contains two copies of (+)-strand RNA molecules complexed with 
the nucleocapsid protein (NC, p7). The viral enzymes protease (PR, p10), reverse transcriptase (RT, 
p66/p51), integrase (IN, p32) are indicated in green, whereas the auxilliary (Vif, Vpr, Vpu) and regulatory 
proteins (Tat, Rev, Nef) are not shown. 
 
 
Gag is synthesized as a 55 kDa (Pr55Gag) precursor polyprotein on cytosolic ribosomes 
and contains matrix (MA, p17), capsid (CA, p24), nucleocapsid (NC, p7), p6 domains, as 
well as two spacer peptides SP1 & SP2, thus, comprising all of the viral elements required 
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for virus assembly 28–30. Every Gag protein (MA, CA, NC, p6) performs distinct functions 
during the viral assembly. The viral genome of HIV-1 is housed within a capsid that 
assembles into a conical outer shell 31,32. Matrix proteins are responsible for intracellular 
trafficking and binding of Gag to the plasma membrane 33,34, as well as directing the 
incorporation of the sole surface envelope glycoprotein (Env) into virions 33,35. NC serves 
as facilitator for viral replication 36 and is a key component of RNA packaging, as well as 
Gag multimerization 31,37. Lastly, the p6 domain mediates budding and release of viral 
particles from the plasma membrane 38,39. 
All essential enzymatic functions are provided by the three Gag-Pol proteins (Pr160Gag-
Pol), protease (PR), reverse transcriptase (RT) and integrase (IN) 27,40. 
HIV-1 entry into host cells is initiated by envelope glycoproteins by mediating virion 
attachment 41,42, as well as interaction with cellular CD4- and co-receptors 43,44 (see 
below). 
The proteins Tat and Rev assist in essential gene regulatory functions 45,46, while the four 
accessory proteins Vif, Vpr, Nef and Vpu contribute to infectivity and evasion of immune 
mechanisms 47–49. 
 
 
1.4 The HIV-1 life cycle 
 
HIV is able to infect cells which express CD4 molecules on their surface. Primarily, these 
are macrophages and CD4+ T cells 50,51. In this context, the HIV-1 envelope (Env) 
glycoprotein is crucial in the virus replication cycle by mediating the fusion between 
viral and host cellular membranes during the entry process. After attachment of Env to 
the cellular surface 41,42,52 and subsequent binding to the CD4 receptor 53–55 (figure 4), a 
cascade of conformational changes in gp120 and gp41 occurs 56, augmenting its affinity 
for a co-receptor 57. The relevant chemokine co-receptors for HIV-1 are CCR5 (R5) and 
CXCR4 (X4) 58,59. Upon engagement of gp120 with the co-receptor, additional 
conformational changes in gp41 trigger a membrane fusion reaction that delivers the 
viral core into the host cell 60–62. Subsequently, the viral RNA genome is transcribed into 
double-stranded DNA by the viral enzyme reverse transcriptase (RT) 63. Following 
synthesis, viral DNA is translocated across a nuclear pore in the form of a nucleoprotein 
complex (pre-integration complex, PIC) into the nucleus and integrated as a provirus 
into the host cell genome 64, leading to a life-long reservoir of infected CD4+ T cells. The 
virus-encoded integrase (IN) protein is a component of the PIC that mediates the 
integration process 65. After transcription, viral RNAs are transported into the cytoplasm 
where translation of the viral proteins occurs. At the plasma membrane, virion assembly 
takes place, wherein newly synthesized proteins as well as two single-stranded copies 
of viral RNA are packaged and bud from the cell as immature particles 66. Concomitant 
with virion release, maturation takes place by proteolytic processing of Gag which leads 
to a morphological rearrangement within the particle 66–68. The resulting virus is then 
able to infect new cells. 
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Figure 4 - Schematic illustration of the main steps in the HIV-1 life cycle: (1) After attachment of the 
viral Env glycoprotein to cell surface proteins CD4 and a co-receptor (CCR5 or CXCR4), fusion of the viral 
and host cell membranes is mediated (2) enabling entry of the viral capsid into the cell. Once the capsid is 
uncoated and the viral RNA along with viral proteins are released into the cytoplasm, RNA is reverse 
transcribed to double stranded DNA (3) and translocated into the cell nucleus. Following successful 
integration (4), transcription of the provirus takes place resulting in viral RNAs, which are translated into 
proteins and transported (5) from the nucleus. Upon arrival on the cell surface, viral RNA and proteins are 
assembled into immature virions (6) that bud from the cell (7). Proteolytic processing of polyproteins 
initiates maturation (8), resulting in mature virions that are capable of infecting new cells. Many steps of 
the HIV life cycle can be inhibited by drugs which are displayed in the rectangles. With permission from 
69. 
 
 
1.5 The envelope glycoprotein 
 
The envelope glycoprotein (Env) is one of the most important proteins of HIV as it 
mediates host cell entry by binding to CD4 receptors. In addition, Env represents the sole 
target for the host’s humoral immune system, and therefore serves as target for HIV-1 
neutralizing antibodies 58,70,71. Thus, Env is the major subject of investigation in respect 
to vaccine development which focusses particularly on the humoral immune response 
to the protein. 
 
 
1.5.1 Env synthesis and trafficking 
 
Env proteins are synthesized as heavily glycosylated gp160 polyprotein precursor 
molecules from a singly spliced, bicistronic vpu/env mRNA on the rough endoplasmic 
reticulum 72,73. After folding and oligomerizing 74,75, gp160 is transported to the Golgi 
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complex where it is subjected to various processing events, such as oligosaccharide 
modification and proteolytic cleavage 76. Proteolytic processing is mediated by cellular 
furin proteases within the trans-Golgi network (TGN) to yield the gp120 and the gp41 
subunits that are required for viral infection of HIV-1 77–79. Three molecules each of 
gp120 and gp41 assemble into the final heterotrimeric Env spike, held together by meta-
stable, non-covalent interactions 80,81. Following exit from the TGN, the glycoproteins 
traverse to the plasma membrane 74 where Env either interacts with Gag and gets 
incorporated into viral particles, or alternatively is endocytosed again 82,83. In general, 
an average of 14 to 20 trimers are integrated into virions 84. Endocytosis of Env or 
disintegration of the trimeric structure into monomeric gp120 and gp41, also termed 
‘shedding’, as a result of the non-covalent gp120-gp41 interactions can be attributed to 
the low incorporation events 85,86. Presumably, low surface spike density serves as an 
evasion mechanism against the host immune system 87. 
 
 
1.5.2 Env structure 
 
The envelope glycoprotein is a trimer of heterodimers comprising a complex of trimeric 
gp120 and gp41, respectively (figure 5C). The gp120 subunit is divided into 
discontinuous segments of constant and variable regions (figure 5A). Five variable 
domains (V1-V5) alternate with five relatively constant domains (C1-C5) 37,88–90. As 
already indicated by the name, variable regions feature a high degree of sequence and 
length diversity derived from recombination events, point mutations, insertions and 
deletions, with the V1V2 domain having the most variation in loop length (50-90 amino 
acids) and number of glycosylation sites. Typically, the variable regions are arranged in 
loops which are separated and delimited by disulfide bonds. 18 highly conserved 
cysteine residues, located throughout gp120 and gp41, form nine intramolecular 
disulfide bridges that are crucial in establishing the proper tertiary structure of Env 91,92. 
However, no disulfide bridge resides between the gp120 and g41 subunits. 
Several N-linked glycans, with a small additional contribution of O-linked sugars, are 
located on the surface of gp120 (figure 5 D) comprising about 50% of its total mass. 
Importantly these glycans have been shown to protect Env from host immune 
recognition, to influence Env conformation/oligomerization, as well as to affect viral 
entry, infectivity and antibody recognition 93. 
The gp120 core consists of a highly conserved inner domain (figure 5B), facing the 
trimer axis, and a heavily glycosylated outer domain, which is mostly exposed on the 
surface of the trimer 94,95. One of the most relevant features of gp120 is represented by 
the CD4 binding site (CD4bs) (figure 5C), which comprises the principal contact sites of 
CD4. It is arranged in six discontinuous segments , consisting of residues that are highly 
conserved 92,94,96,97. Considering the functional conservation among diverse HIV-1 
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isolates, the CD4 binding site is a favorable target for neutralizing antibodies, and thus 
also for vaccine design. 
Anchored in the viral membrane, the gp41 subunit of Env comprises three major 
domains: an ectodomain, a transmembrane domain (TM), and a cytoplasmic tail (CT) 98 
(figure 5A). All major fusion determinants are located in the ectodomain, including an 
N-terminal fusion peptide (FP) 99,100, two hydrophobic heptad repeat regions (HR1 and 
HR2) 101,102 (figure 5B) and a highly conserved tryptophane-rich domain referred to as 
the membrane-proximal external region (MPER) 103,104. The gp41 TM anchors Env in the 
lipid bilayer and is involved in fusion and modulation of immune responses during viral 
infection 61,105,106. Last but not least, the cytoplasmic tail mediates intracellular 
trafficking and incorporation of Env into virions 37,83. 
 
 
Figure 5 – Structure of the HIV-1 envelope glycoprotein. Structures are based on the BG505 DS SOSIP 
trimer (PDB 5U1F) (A) Schematic representation of the HIV-1 gp160 envelope. The gp120 trimer 
comprises five constant regions (C1-C5) that are interspersed with five variable regions (V1-V5). The 
fusion peptide, heptad repeats 1 and 2, membrane proximal external regions, transmembrane domain 
(TM) and cytoplasmic tail (CT) are located in the gp41 trimer. Glycans are represented by tree-like 
symbols. (B) Structure of an Env protomer consisting of an outer and inner domain that are connected by 
the bridging sheet. The heptad repeats 1 and 2 (HR1, HR2) are located at the base of gp41, whereas fusion 
peptide is positioned at the interface of gp120. (C) Side and (D) top views of the Env trimer. Variable loops 
(V1-V5) and the CD4 binding site (CD4bs) are shown. Structures of the membrane proximal external 
region (MPER), transmembrane domain (TM) and cytoplasmic tail (CT) are not included in the illustration 
since they have not yet been determined. Glycans are shown in teal (only in one protomer). Figure was 
freely reproduced from 70. 
 
 
1.5.3 Immune evasion mechanisms of Env 
 
The virus features a multitude of evasion strategies to escape an efficient humoral 
immune response, most of them embodied in structural properties of the envelope 
protein. As previously mentioned, low density of viral spikes (14-20) on the surface of 
HIV virions 107 as well as shedding of Env represent effective evasion strategies 108. The 
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tremendous genetic diversity of Env which can exhibit up to 35% sequence variability 
between subtypes and 20% within a clade 108 is particularly problematic for HIV vaccine 
design. This diversity is a result of the error-prone nature of the reverse transcriptase 
and high rates of viral replication 109,110. Many structures, especially the five variable 
loops (V1-V5), possess a high-level tolerance for point mutations 111,112, and even 
insertion and deletion of whole sequence stretches without loss of viral fitness 113,114. As 
a consequence, a multitude of escape variants can arise in fast succession, thus 
continuously evading the host’s hummoral immune responses. However, as Env is 
essential for cell entry, the variability is limited to non-conserved regions in order to 
maintain its functions. 
In addition to the vast sequence diversity of the variable regions, the location and 
arrangement of structural features of Env lead to conformational masking. This 
phenomenon describes the capability of certain structures to conceal functionally 
essential regions of HIV from the immune system. For instance, Env trimer formation 
results in the burial of neutralizing epitopes within oligomeric interfaces 115,116. 
Furthermore, variable loops can successfully occlude conserved regions such as the CD4 
binding site, thus restricting access for neutralizing antibodies 117,118. Extensive 
glycosylation covering the surface of Env is also able to shield exposed surfaces 119. In 
combination with the ability of repositioning of glycans in response to the selection 
pressure, this ‘glycan-shield’ (figure 6A) limits immunogenicity and obstructs binding of 
certain antibodies to Env. 
Last but not least, unliganded Env was revealed to be intrinsically dynamic, transitioning 
between different conformations 120 (figure 6C). During this so-called ‘breathing’ 
different non-essential epitopes are presented to the immune system resulting in the 
generation of non-neutralizing antibodies 121. 
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Figure 6 – Evasion mechanisms of HIV-1 Env. (A) N-linked glycosylation and (B) sequence variability 
of Env (left) in comparison with influenza virus H3 haemagglutinin (HA) (middle) and RSV fusion 
glycoprotein subtype A (right). Conservation of glycans is represented in light green (conserved: > 90% 
conservation) or dark green (variable: < 90% conservation). Likewise, sequence variability is depicted in 
light or dark purple (B). Figure was adapted from 122 with minor modifications with permission from 
Nature Publishing Group. (C) Conformational states of Env. The pre-fusion trimer is assumed to be present 
in various reversible conformations that fluctuate between open and closed states which is referred to as 
‘trimer breathing’. An antibody-bound state is also shown (right). The conformation remains in a more 
open state after binding the antibody (in this case b12). Figure was adapted from 123 with minor 
modifications with permission from Nature Publishing Group. 
 
 
1.6 Humoral immune response to HIV infection 
 
1.6.1 Ontogeny of the antibody response during HIV infection 
 
Soon after HIV transmission, the B cell branch of the newly infected person’s immune 
system becomes activated. The first antibody response to HIV-1 can be detected within 
the first week of infection in the form of immunoglobulin (Ig) IgM and IgG antibodies 
mainly targeting free-floating virions 124. However, the initial antibody responses do not 
possess the ability to neutralize the virus. A few days later, circulating anti-gp41 
antibodies are generated, followed by anti-gp120 antibodies that are primarily directed 
against the V3 loop 125. Even though these antibodies have seemingly no effect on the 
infecting viral strain, as they are directed mostly against dissociated gp120 and gp41 
subunits or aberrantly folded proteins 126, the antibodies seem to be able to convey Fc-
mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC) or 
antibody-dependent cellular phagocytosis (ADCP) 127. Several months post infection, the 
first strain-specific autologous neutralizing antibodies occur which exert selective 
pressure on the virus leading to the generation of escape mutants 124,128. After several 
years of continuing co-evolution of escaping virus and the following adaptation of the 
humoral immune response, antibodies with increased neutralization breadth and 
potency can emerge in a small percentage of chronically infected individuals 129. Some 
of these antibodies are able to neutralize more than 90% of circulating HIV strains 130. 
Notably, the infected patients cannot benefit from the elicited bnAbs, as they acquired 
escape mutants from said antibodies. 
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1.6.2 Broadly neutralizing antibodies 
 
Despite the multitude of viral defense mechanisms, approximately 10-30% of the 
chronically infected individuals develop cross-reactive antibodies that are capable to 
neutralize various heterologous virus strains 131,132 as a result of the co-evolution 
between HIV-1 escape variants and antibody affinity maturation. Furthermore, about 
1% of the patients are described as ‘elite neutralizers’, pertaining to HIV-1-infected 
people with unusually potent cross-reactive neutralizing antibody response against a 
majority of HIV-1 subtypes 133. The monoclonal antibodies are referred to as broadly 
neutralizing antibodies (bnAbs) and target specific key sites of vulnerability on the 
envelope (figure 7): i) the CD4-binding site 134,135 (e.g. bnAbs VRC01 136, NIH45-46 130), 
ii) the glycopeptide epitopes of the variable region 1 and 2 137 (e.g. PG9 and PG16 136, 
PGT145 138), iii) the glycan-associated variable region 3 139 (e.g. PGT121-134 140, iv) the 
membrane proximal external region (MPER) on gp41 141,142 (e.g. 4E10 143, 10E8 144) and 
v) a gp120-gp41 spanning interface 145 (e.g. PGT151 146, 35O22 145). In order to overcome 
the many viral defenses, bnAbs have acquired one or more unusual characteristics, such 
as extremely long or short heavy-chain complementarity-determining region 3 loops 
(HCDR3) 147,148, insertions and/or deletions 149 and polyreactivity 150. In addition, many 
bnAbs undergo extensive somatic hypermutation (SHM) 151,152 to achieve neutralization 
breadth and potency. To accumulate such degree of mutation can require a long time 
and might explain the unusual duration until cross-neutralizing antibodies occur in HIV-
1 infected individuals and why it proved to be challenging to elicit bnAbs so far. 
 
 
Figure 7 – Location of bnAb epitopes on the HIV-1 Env trimer. So far, five sites of vulnerability were 
discovered that include the CD4 binding site (CDbs), the trimer apex (V1V2), the glycan-dependent V3 
region, the gp120/gp41 interface and the membrane-proximal external region (MPER). Figure was 
adapted from 153. 
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1.7 HIV-1 vaccine development 
 
After more than 30 years since the discovery of the HIV-1 pandemic, an effective vaccine 
for clinical use to prevent infection still remains elusive. Notwithstanding the significant 
efforts that have been undertaken toward developing an HIV remedy, from over 218 
trials only seven vaccines advanced to clinical phase III trials 154–159. The first studies 
were performed in the late 1980s and early 1990s and involved the usage of 
recombinant gp120-based vaccines derived from the isolates MN and B (AIDSVAX B/B’) 
in the VAX004 trial and from clades B/E in the VAX003 trial. The efficacy for both 
vaccines was estimated at 0.1% and therefore failed to demonstrate protection against 
HIV-1 infection 160. 
Thus, research was redirected toward reduction of viral load setpoints or delay of 
disease progression by eliciting cytotoxic T-lymphocyte (CTL) responses 161. Pursuing 
this strategy, the Step trial (HVTN502 in 2004) and Phambili trial (2007) were 
conducted by Merck and the HIV Vaccine Trials Network (HVTN), respectively. The 
vaccine candidate comprised a recombinant Adenovirus 5 (Ad5) vector expressing HIV-
1 Gag, Pol and Nef 161. Although the trials demonstrated CD8+ T-cell responses, both 
studies were stopped early on the basis of interim data proving futility and due to 
increased HIV incidence among vaccine recipients 154,162,163. 
In September 2009, the first promising results were reported for the RV144 or Thai trial 
that was performed by the U.S. Military Research Program in collaboration with several 
Thai institutions. The vaccination strategy comprised a combination of a recombinant 
canarypox vector vaccine prime (ALVAC-HIV, Sanofi Pasteur) and the bivalent gp120 
protein boost (AIDSVAX B/E) previously utilized in the VAX003 trial. Although only a 
mediocre efficacy of 31.2% 164 was acknowledged, immune correlates could be identified 
suggesting that non-neutralizing antibodies directed against V1/V2 may have 
contributed to protection against HIV infection by elicitation of antibody-dependent 
cellular cytotoxicity (ADCC) 165. 
The HVTN505 trial was designed to evaluate the regimen’s effect on viral load. In this 
respect, a prime/boost vaccination approach was applied which consisted of a DNA 
prime with Clade B gag/pol/nef and multiclade env followed by a boost with Ad5 vector 
from the Step study. However, the trial was stopped in 2013 due to futility 166. 
The HVTN702 trial which started in November 2016 aims to provide greater and more 
sustained protection than the Thai trial. To achieve this an improved vaccination 
regimen was adapted to address HIV subtypes that predominate in southern Africa. In 
this respect, an ALVAC vector containing a clade C Env insert followed by bivalent clade 
C recombinant gp120 protein were applied in the vaccination regimen 167. This trial is 
still ongoing. 
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1.8 Elicitation of broadly neutralizing antibodies 
 
Results from the RV144 trial led to a general shift in the major focus of research toward 
an antibody-based HIV-1 vaccine. This concept was additionally substantiated by 
multiple in vivo challenge studies demonstrating that passive administration of bnAbs 
into humanized mice or non-human primates repeatedly conferred protection against 
HIV-1 infection 119,168–171. Thus, there is currently a well consolidated expectation that 
vaccines able to elicit bnAbs upon immunization would prevent HIV-1 infection. 
 
 
1.8.1 Engineering of envelope immunogens to induce cross-neutralizing 
antibody responses 
 
Significant efforts have been undertaken to develop an Env immunogen able to induce 
broadly neutralizing antibodies. Early strategies were based on the successful Hepatitis 
B vaccine design and thus involved monomeric gp120 subunits as immunogens. 
Unfortunately, the antibody responses were relatively weak and were only able to 
neutralize a very limited spectrum of sensitive viral strains 172,173. The many failures led 
to a change in the general mindset of immunogen design and more attention has been 
focused on candidates that simulate the natural Env structure. A strategy referred to as 
structure-based reverse vaccinology was devised that first determined the 
crystallographic structure of a complex between antibody and Env and then 
reconstructed the respective epitopes 173,174. So far however, this approach produced 
only little tangible progress in the elicitation of broadly neutralizing antibodies 
(reviewed in 175–177). It is assumed that instability of Env was the major obstacle in the 
induction of bnAbs 178, thus many efforts have been undertaken to prevent dissociation 
of the glycoprotein. Approaches encompassed the generation of furin cleavage-deficient 
Env proteins. This was achieved by mutating the primary recognition sites of the furin 
protease that ocurr at KAKRRWQR508EKR511AVGIGALFLGFLGAAG between residues 
508 and 509 or between 511 and 512 179,180. Accordingly, substitution of the motif REKR 
with REKS or SEKS resulted in cleavage-incompetent Env proteins which prevented 
dissociation of the protomers 181–183. Similarly, cleavage sites were replaced with a 
glycine-serine peptide linker resulting in native flexibly linked (NFL) envelopes 184. 
Another strategy to increase stability of Env was successfully accomplished by 
introducing appropriately positioned cysteine residues in the ectodomains of Env which 
created an engineered disulfide bond (SOS) between the two subunits 185,186. 
Furthermore, this strategy was combined with the trimer stabilizing mutation I559P 185 
(IP), as well as with an improved 6xR furing cleavage site instead of REKR, leading to 
fully cleaved and well-folded trimers that were referred to as BG505 SOSIP.664 Envs 185. 
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Many new discoveries corroborated the focus of vaccine research on natural, trimeric 
immunogens. First and foremost, it was revealed that many bnAb epitopes are strongly 
(trimer apex, gp120-g41 interface 187) or partially quaternary-dependent (CD4 binding 
site 188). Additionally, several CD4bs-specific bnAbs require contact to a second 
protomer within the trimer 188,189, thus constraining the presentation of epitopes. 
Consequently, even though monomeric Env immunogens exhibit the same epitopes, they 
are not presented in the precise orientation of native spikes 190. This could potentially 
complicate the elicitation of bnAbs. 
Recent approaches focused on the simulation of the co-evolution between Env and the 
humoral immune response. For this purpose, directional immunogens were designed to 
activate germline receptors on B cells that gradually guided the immune system towards 
the development of mature bnAbs over several intermediate stages. Some success was 
accomplished in several murine model systems by following this strategy. In a first 
approach, eight mutations were introduced into an engineered envelope variant (eOD-
GT8) with the goal to impart affinity for VRC01 germline antibodies 191. Sequential 
immunization of transgenic mice with the germline-targeting constructs, as well as 
several intermediates and mature envelope (BG505 SOSIP N276D), finally resulted in 
the elicitation of VRC01-class neutralizing antibodies 192. Furthermore, the successful 
development of mature PGT121 bnAbs in mice was demonstrated after following a 
similar sequential immunization strategy 193. Ultimately, these approaches lead to the 
necessity of immunogens exhibiting high affinity towards germline, intermediate or 
mature antibodies, as well as appropriate methods to identify such improved Env 
variants. 
 
 
1.8.2 Advantages of Env-based gene variant libraries 
 
Despite continued advances in the field of protein structure and function, many aspects 
still cannot be predicted. Therefore, protein engineering according to combinatorial 
strategies is highly appealing. One fundamental component of such approaches 
encompasses the construction of protein libraries which usually comprises a nucleic 
acid library from which the protein library is then translated. This provides the benefit 
that any protein can be directly identified by DNA sequencing. A wide variety of methods 
have been devised to generate gene variant libraries. One approach focusses on 
introducing sequence variation at random positions by physical (i.e. UV radiation) and 
chemical mutagens (i.e. alkylating agents), mutator strains (i.e. XL1-Red strain) as well 
as error-prone PCR 194. Recombination methods can rearrange already existing diverse 
sequences into novel combinations. These techniques include DNA shuffling 195,196 and 
the staggered extension process 197. More controlled randomizations to specific 
positions can be achieved with direct synthesis of mixtures of DNA molecules and their 
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subsequent incorporation into genes via PCR or cloning, as in the case of Gibson 
Assembly 198. 
Gene mutant libraries offer beneficial possibilities to study properties, biological 
functions and structure biology of many proteins simultaneously. As early as 1991, a 15-
mer random peptide libraries has been successfully utilized to map epitopes recognized 
by the antibodies targeting the V3 loop of Env 199,200. Similarly, critical residues in the 
epitope of the antibody 4E10 were revealed by screening of a 12-mer peptide library 201. 
Another study demonstrated the identification of engineered soluble CD4-inhibitors 
(sCD4) by combining structure-based design with sequential panning of a large mutant 
library against different HIV-1 envelopes 201. The detected CD4-mutants displayed great 
increase in affinity to gp120, neutralization of pseudoviruses and exhibited significant 
inhibitory activities in clinical trials. Furthermore, Jardine et al (2016) were able to 
demonstrate the detection of specific Env variants with improved binding affinity for 
germline antibodies by screening of large mutant libraries 191. Overall, the positive 
results from many previous studies consolidated that gene mutant libraries could 
facilitate the search for Env variants with specific and favorable properties. Thus, a 
multivariant genomic Env library provided the foundation of this PhD thesis. 
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2 Objective 
 
The elicitation of broadly neutralizing antibodies still constitutes a major challenge. 
However, the long-time search for immunogens able to induce bnAbs finally 
demonstrated the first successes. Recent studies suggested that the complex co-
evolution between Env and the immune system can be mimicked by sequential 
immunization with germline-targeting, intermediate and finally mature variants of Env 
192,193. Such positive results emphasized the demand to develop methods for effective 
engineering, display and screening of envelope proteins with specific properties, such 
as improved binding affinities for bnAbs. 
The focal point of this PhD thesis was the bioengineering and quality control of a 
sequential permuation Env library, as well as the implementation of methods that 
facilitate the work with complex and large libraries. The secondary objective focused on 
identifying and characterizing trimeric Env immunogens with improved antibody 
recognition from the library by using a mammalian cell display and cell sorting-based 
panning approach. 
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3 Materials and Methods 
 
3.1 Molecular Biology 
 
Unless stated otherwise, all methods were performed in agreement with common 
protocols of molecular biology 202 or of the respective manufacturers. A detailed list of 
all oligonucleotides and DNA constructs utilized in this work can be found in section 8.2. 
Vector backbones for cloning purposes were generated by digestion with the 
appropriate restriction endonucleases and treatment with CIP to prevent re-ligation. 
Subsequently, the desired DNA-fragment was isolated from a 0.8-1.0% agarose gel. 
Inserts were created according to one of the following methods: 1) Amplification by PCR 
using eligible oligonucleotides and digestion with suitable restriction enzymes. PCR for 
analytical purposes was performed with GoTaq Green Master mix (Promega), whereas 
for preparative applications, Phusion DNA polymerase (NEB) was used. 2) Annealing of 
complementary oligonucleotides followed by phosphorylation of the 5‘-ends with T4-
PNK. 3) Direct recovery from plasmids by restriction digestion and subsequent gel 
extraction. 
Vector DNA was then mixed with a 3-fold molar excess of insert DNA and ligated using 
the Quick Ligation Kit (NEB). Subsequently, the ligation mixture was used for the 
transformation of chemically competent E.coli DH5α or DH10B according to standard 
protocols 203. 
After cultivation of bacterial cultures in LB or TB medium containing the appropriate 
antibiotic, plasmid DNA was isolated by alkaline lysis 204 or by usage of the GeneJET 
Plasmid Miniprep Kit/Plasmid Midi/Maxi Plus Kit. The concentration and purity of the 
purified DNA was determined spectrophotometrically by measuring absorbance at 260 
nm and 280 nm or Agilent 2100 Bioanalyzer (Agilent) using the High Sensitivity DNA Kit 
(Agilent). 
In order to confirm the correctness of the construct, restriction digestion and Sanger 
sequencing (Seqlab) were performed. 
 
Oligonucleotides Biomers, Eurofins 
Restriction endonucleases New England Biolabs, Fermentas, Thermo Fisher 
Scientific 
Alkaline Phosphatase, Calf Intenstinal (CIP) New England Biolabs, M0290L 
QIAquick Gel Extraction Kit Qiagen, 28706 
GoTaq® Green Master Mix Promega, M7123 
Phusion ® High-Fidelity DNA Polymerase New England Biolabs, M0530 L 
QuickLigation Kit New England Biolabs, M2200 
T4-PNK New England Biolabs, M0201 
GeneJET Plasmid Miniprep Kit Thermo Fisher Scientific, K0502 
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Plasmid Midi/Maxi Plus Kit Qiagen, 12945, 12965 
High Sensitivity DNA Kit Agilent, 5067-4626 
 
E.coli DH5α F- supE44 dlacU169 (fi 80 lacZdM15) hsdR1recA1 endA1 gyrA96 thi-1 relA1 
E.coli DH10B F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 endA1 
araD139 Δ(ara leu) 7697 galU galK rpsL nupG λ– 
Lysogeny broth  
(LB medium) 
1% Bacto tryptone; 0.5% Bacto yeast extract; 1% NaCl; pH 7.5 
Terrific broth medium 
(TB medium) 
1.2% Bacto tryptone; 2.4% Bacto yeast extract; 0.5 % glycerol; 0.17 M 
KH2PO4; 0.72 M K2HPO4 
 
 
3.2 Next Generation Sequencing 
 
3.2.1 Illumina Sequencing by Synthesis Technology 
 
Next Generation Sequencing (NGS) represents a variety of sequencing methods which 
transcends the capacity of traditional DNA sequencing technologies in respect to cost, 
speed and data output, thus enabling an in-depth study of biological systems by rapid 
sequencing of whole genomes. One of the most prevalent NGS technologies was 
developed by Illumina and is referred to as ‘Sequencing-by-synthesis‘ (SBS) 205. This 
method supports massively parallel sequencing proving to be especially beneficial for 
questions that demand extensive information regarding highly diverse genomic 
libraries. The sequencing workflow is composed of four basic steps: i) sample 
preparation, ii) cluster generation, iii) sequencing and iv) data analysis. 
In general, NGS sample preparation includes fragmentation of DNA sequences into 
suitable sizes (~ 300 bps) due to the limitation of reading length of the NGS device 
(figure 9, (1)) and the annealing of adapters (2) by PCR. The resulting product consists 
of a sequence of interest flanked 5‘ and 3‘ by the adapters P5 and P7 (figure 8), which 
allow attachment to the surface of a flow cell coated with a lawn composed of 
complementary adapter oligonucleotides (3). Additional motifs are also introduced 
during sample preparation, such as the NGS sequencing primer binding site and indices. 
The indices or barcodes allow distinction among a multitude of samples. 
 
             
Figure 8 – Schematic illustration of a ready-to-load index library eligible for NGS. The DNA fragment 
of interest is shown in grey. P5 (red) and P7 (green) indicate the adapters. Rd1 SP (yellow) and Rd2 SP 
(blue) designate the binding sites for NGS-specific sequencing primers. Barcodes or indices are 
represented in black. 
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After binding of samples to the flowcell, the DNA strand folds over and the adaptor 
region hybridizes to the second type of oligo on the flow cell (4). Polymerases create a 
complementary strand forming a double stranded bridge (5) which is subsequently 
denatured, resulting in two single stranded copies of the molecule (6). The process is 
repeated over and over so that millions of DNA ‘clusters’ are generated (7). Cluster 
densities have large impact on sequencing performance in terms of data quality and 
output. 
Sequencing begins with the extension of the first sequencing primer to produce the first 
read (8). With each cycle, four fluorescently tagged reversible terminator bases compete 
for incorporation into the growing chain. Only one nucleotide is integrated, based on the 
sequence of the template while non-incorporated nucleotides are washed away. 
Subsequently, clusters are excited by a light source and a characteristic fluorescent 
signal is emitted which is acquired as image by a camera (9). Emission wave length along 
with the signal intensity, determine the base call. The length of the read is determined 
by the number of cycles. The entire process generates millions of reads representing all 
fragments which then can be separated based on the unique indices introduced during 
the sample preparation. Forward and reverse reads are paired creating contiguous 
sequences that are aligned back to the reference genome for variant identification. 
Sequencing coverage describes the average number of reads that align to known 
reference bases. 
 
 
Figure 9 – Outline of Illumina NGS technology. After fragmentation of the samples (1), adapters are 
annealed to the ends of the sequence (2). Fragments attach to the flowcell (3) by hybridization to oligos 
complementary to the adapters (4). Subsequently, bridge amplification occurs to produce clusters of 
fragments (5-7). During each sequencing cycle, one fluorophore-attached nucleotide is added to the 
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growing strands (8). The fluorophores are then excited by a laser and signals from each fragment cluster 
are detected and recorded as images (9). Illustration was adapted from 206. 
 
 
3.2.2 Sequencing library preparation 
 
The sequential permutation (SeqPer) library was the foundation for all steps involving 
Next Generation Sequencing. A key step in the NGS library sample preparation is 
generating the input for sequencing. In general, the library preparation was composed 
of four stages: i) DNA amplification, ii) attachment of oligonucleotide indices and 
adapters to the ends of the amplified fragments, iii) purification and iv) final library 
quantification and quality control. 
 
 
3.2.2.1 Generation of amplicon libraries 
 
In the course of this PhD thesis, polymerase chain reaction was utilized to produce 
amplicons in the size of approximately 300 bps. These amplicon libraries were 
generated by two sequential PCRs using specific primers which carry the attachments 
required for NGS. In the first PCR, NGS-specific primer binding sites were introduced 
into the target DNA template. Fusion of indices and adapters was achieved by the second 
PCR (figure 8). The input DNA for the first PCR was derived from the plasmid DNA of the 
SeqPer library purchased from GeneArt or was isolated from the respective stable cell 
lines as genomic DNA (see 3.2.2.2). 
For the amplification 20 ng plasmid DNA was applied in the first PCR. As the 
concentration of isolated genomic DNA was always below the detection limit, 10 µL of 
the extract was utilized for PCR1. Accordingly, 10 µL from the first amplification was 
applied in the second PCR. The respective primers for PCR1 and PCR2 can be obtained 
from section 8.2.1. Notably, only the reverse primers for PCR2 varied, whereas the 
forward primer (ILLUMINAseq_fwd) remained the same. In general, a 50 µL reaction 
was prepared containing 1 µL dNTPs (10 mM), 2.5 µL forward and reverse primer (10 
µM), respectively, 1.5 µL DMSO, 0.5 µL Phusion DNA polymerase, 10 µL 5xHF Phusion 
buffer, template DNA as mentioned above and nuclease-free water (see table 3). To 
reduce accumulation of errors from the polymerase, 22 cycles were applied for both 
amplification steps. The thermocycling conditions can be obtained from table 4. PCR 
samples were stored temporarily (usually over night) at 4°C if it was not possible to 
proceed with the experiment. 
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Table 3 – Composition of PCR 1 and 2 for generation of amplicon libraries. 
Component PCR 1 PCR 2 
Nuclease-free water to 50 µL to 50 µL 
10 mM dNTPs 1 µL 1 µL 
10 µM forward primer 2,5 µL 2,5 µL 
10 µM reverse primer 2,5 µL 2,5 µL 
DMSO 1,5 µL 1,5 µL 
Phusion DNA polymerase 0,5 µL 0,5 µL 
Template DNA 1 ng pDNA/ 10µL 
gDNA extract 
10 µL from PCR 
1 
5x Phusion HF buffer 10 µL 10 µL 
total 50 µL 50 µL 
 
 
Table 4 – Thermocycling conditions for PCR 1 and 2. 
PCR 1 
98°C 1 min 
98°C 10 sec  
22 cycles 
 
68°C 30 sec 
72°C 6 sec 
72°C 5 min 
8°C ∞ 
 
 
 
 
3.2.2.2 Extraction of genomic DNA 
 
Extraction of genomic DNA was performed by using the QIAamp DNA Mini Kit according 
to the protocol ‘DNA purification from blood and body fluids’. Unless stated otherwise, 
2x105 cells were utilized for gDNA isolation. If less than 10.000 genomic equivalents 
were present, 10 µg/mL carrier DNA (polyadenylic acid, poly dA) was added to the 
sample in order to enhance the recovery of DNA and to prevent the small amount of 
target nucleic acid from being irretrievably bound. 
PCR 2 
98°C 1 min 
98°C 10 sec  
22 cycles 
 
64°C 30 sec 
72°C 10 sec 
72°C 5 min 
8°C ∞ 
Deoxynucleotide (dNTP) Solution Mix New England Biolabs, N0447L 
Dimethyl Sulfoxide (DMSO) SigmaAldrich, D8418-100ML  
Phusion ® High-Fidelity DNA Polymerase New England Biolabs, M0530 L 
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As a first step, 20 µL QIAGEN protease was pipetted into the bottom of a 1.5 mL tube. 
Subsequently, a 200 µL solution containing 2x105 cells in PBS together with 200 µL AL 
buffer were added to the tube and mixed by pulse-vortexing for 15 sec. The mixture was 
then incubated at 56°C for 10 minutes and briefly centrifuged to remove drops from the 
inside of the lid. 200 µL ethanol (96-100%) were added to the sample, mixed by pulse-
vortexing for 15 sec and briefly centrifuged. In the following, the solution was applied to 
the QIAamp Mini spin column in a 2 mL collection tube and centrifuged at 8.000 rpm for 
1 min. After discarding the filtrate, 500 µL AW1 buffer was added to the column and 
centrifuged for 1 min at 8.000 rpm. A second washing step with 500 µL AW2 buffer was 
performed at 13.000 rpm for 3 min. To eliminate the chance of possible AW2 buffer 
carryover, the filtrate was discarded, the spin column was placed in a new collection 
tube and centrifuged at full speed for 1 min. Finally, gDNA was eluted into a new 1.5 mL 
tube by adding 30 µL water to the column, incubating at room temperature for 1 min 
and centrifuging at 8.000 rpm for 1 min. Aliquots of 10 µL extracted DNA were generated 
and stored at -20°C to reduce damaging of DNA by repeated thawing cycles. 
 
 
 
3.2.2.3 Generation of stable cell line samples for NGS 
 or Body Fluid 
The stable cell line library (see 4.2) was analyzed at three stages: i) stock directly after 
thawing, ii) before induction with doxycycline and iii) after induction to assess potential 
changes in the quality and amino acid composition. As a first step, cells were thawed (see 
3.3.4.2) and resuspended in 1 mL preheated DMEMSCL. After determining the cell count, 
2x105 cells were withdrawn for gDNA extraction (see 3.2.2.2) and subsequent NGS 
sample preparation. This sample was referred to as ‘stock’. The remaining cells were 
transferred to a T75 flask, expanded and split after a confluency of 80% was reached 
(see 3.3.1). After the third passage (figure 10), 2x105 cells were withdrawn for gDNA 
extraction and to generate the non-induced sample, whereas the remaining cells were 
placed back into the T75 flask and induced with 1 µg/mL doxycycline. On the following 
day, medium was replaced with 15 mL fresh DMEMSCL and the cells were detached from 
the flask by resuspension. 2x105 cells were then withdrawn for gDNA extraction and the 
subsequent generation of the ‘induced’ sample for NGS. 
Poly(A), Polyadenylic acid SigmaAldrich, 10108626001 
QIAamp DNA Mini Kit Qiagen, 51304 
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Figure 10 – Workflow for the primary sample preparation of stable cell lines for NGS analysis. After 
thawing, stable cell lines (SCLs) were expanded and passaged three times before they were induced with 
doxycycline (Dox). On the next day, cells were harvested and further analyzed. To generate stock, non-
induced and induced samples for NGS, 2x105 cells were withdrawn after the thawing process, as well as 
prior to and post induction with doxycycline, respectively. Subsequently, genomic DNA was extracted 
from the cells. 
 
 
3.2.3 Purification of amplicon libraries 
 
Successful Next Generation Sequencing is highly dependent on the quality of the samples 
used. Therefore, removal of any remaining primer dimer and adapter dimer was 
essential to prevent their binding to the NGS flow cells. 
 
 
3.2.3.1 Agarose gel electrophoresis 
 
DNA of amplicon libraries was purified from an agarose gel after PCR1 and PCR2, 
respectively, to remove primer dimer and adapter dimer. Due to the size of the 
amplicons and to improve fragment separation (~279 bps from PCR1 and 399 bps from 
PCR2) a 2% agarose gel was prepared which was run at 160 V for 2 hours. Subsequently, 
the appropriate band was excised and the DNA was isolated using the QIAquick Gel 
Extraction Kit according to the manufacturer’s instructions. 
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3.2.3.2 Magnetic beads purification 
 
Amplicons were also purified using the Agencourt AMPure XP magnetic beads (Beckman 
Coulter) purification protocol after PCR1 and PCR2, respectively. Sample preparation 
was performed in DNA LoBind tubes (Eppendorf) to maximize DNA yield. Briefly, 1,8x 
sample volume (typically 30 µL of DNA eluted from gel extraction columns in water) of 
AMPure magnetic beads was supplemented to the amplified DNA and mixed thoroughly 
by pipetting. After incubation for five minutes the samples were placed into a magnetic 
rack until the solution was clear. Subsequently, two washing steps were performed. This 
was achieved by adding 500 µL of freshly prepared 70% ethanol and incubating for 30 
seconds while turning the cups in the magnetic rack two times. After aspirating the 
ethanol without disturbing the pellet, tubes were centrifuged and the remaining 
supernatant was removed using a 20 µL pipette. The pellets were air-dried for three 
minutes on the magnetic rack to remove residual ethanol. Subsequently, DNA was eluted 
by adding 30 µL nuclease free water and vortexing for 15 seconds. After one minute on 
the magnetic rack, the supernatant was transferred into DNA LoBind tubes. 
 
Agencourt AMPure XP Beckman Coulter, A63881 
1.5 mL LoBind microcentrifuge tubes Sigma Aldrich, Z666548 
 
 
3.2.4 Quantitation of amplicon libraries 
 
3.2.4.1 Quantitation with the Agilent 2100 Bioanalyzer 
 
In addition to the high quality of amplicons, success of NGS is also dependent on an 
accurate quantitation. Therefore, the concentration and purity of the DNA were 
determined by the Agilent 2100 Bioanalyzer. Based on concentrations obtained 
spectrophotometrically by measuring absorbance at 260 nm and 280 nm, all samples 
were diluted to a final concentration of 500 pg/µL and loaded on a DNA chip according 
to the instructions provided by the Agilent High Sensitivity DNA Kit as follows: 
Prior to analysis, the gel-dye mix was prepared. For this purpose, all reagents were first 
equilibrated to room temperature for 30 minutes. The High Sensivity DNA dye 
concentrate was vortexed for 10 seconds, briefly centrifuged and added (15 µL) to the 
High Sensitivity DNA gel matrix vial. The tube was then vortexed for 10 seconds and the 
complete gel-dye mix was transferred to the receptacle of a spin filter to be centrifuged 
for 10 minutes at 6.000 rpm at room temperature. 
Before loading of the gel-dye mix, a High Sensivity DNA chip was placed on the chip 
priming station. In the following, 9 µL gel-dye mix were pipetted to the bottom of the 
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well marked ‘G’, the top of the station was closed and the gel was dispensed by pressing 
down the plunger of the syringe from the priming station until it was held by the clip. 
After 60 seconds, the plunger was released and slowly pulled back to the 1 mL position 
of the syringe. Subsequently, reagents were pipetted into the wells as described in the 
following: i) 9 µL of gel-dye mix in each of the remaining wells marked ‘G’, ii) 5 µL of High 
Sensitivity DNA marker into all remaining wells, iii) 1 µL DNA ladder into the well 
marked with the ladder symbol, and iv) 1 µL of sample into the sample wells. The chip 
was placed horizontally in the adapter of a IKA vortex mixer and vortexed for 60 seconds 
at 2.400 rpm. Finally, the chip was inserted into the Bioanalyzer and the dsDNA assay 
was selected from the file menu. 
 
Agilent High Sensitivity DNA Kit Agilent Technologies, 5067-4626 
 
 
3.2.4.2 Generation of library pools and quantification by quantitative PCR 
 
Quantification of samples by bioanalyzer and generation of library pools were 
performed on the same day to prevent deviation in the concentrations due to freezing 
and thawing processes. In general, a 20 nM DNA-pool was generated. For this purpose, 
12 µL of a 20 nM solution (resuspended in water) for each amplicon library was 
prepared, of which 10 µL were combined, respectively, to create the library pool used 
for NGS. 
Library pools were quantified by qPCR and bioanalyzer. The latter provided additional 
important information such as average sequence length of the amplicons and potential 
contamination with primer dimer. Furthermore, the analysis served as confirmation for 
results obtained from the qPCR. 
As adviced by Illumina, the KAPA Library Quantification Kit (KAPA Biosystems) was 
utilized for accurate quantification. In brief, a 10-fold dilution series of the library pool 
in 10 mM Tris/HCl, pH 8.0 was prepared in 1.5 mL LoBind tubes. In this respect, six data 
points were collected in triplicates comprising a 0.1x10³-, 1x10³-, 1x104-, 1x105-, 1x106-
, and 1x107-fold dilutions. Per 20 µL reaction, 12 µL of KAPA SYBR FAST master mix 
containing the forward and reverse primers (provided by the manufacturer), 4 µL of 
each library dilution or DNA standard and 4 µL PCR-grade water were combined in a 
MicroAmpTM Optical 96-well reaction plate. The DNA standards were provided with the 
kit and comprised six concentrations in a ten-fold dilution series (ranging from 20 pM 
to 0.0002 pM). The plate was then sealed with MicroAmpTM Optical 8-cap strips, briefly 
vortexed and spinned down. Quantification was performed using a standard curve 
analysis protocol provided by the StepOnePlus device (Applied Biosystems). Cycler 
conditions can be seen below in table 5. All quantifications were performed on the day 
of NGS analysis. 
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Table 5 – Cycler conditions for the quantitative PCR. 
Step Temperature Duration Cycles 
Initial denaturation 95°C 5 min 1 
Denaturation 95°C 30 sec 
35 
Annealing/Extension 60°C 45 sec 
 
KAPA Library Quantification Kit KAPA Biosystems, KK4824 
MicroAmp Optical 96-well reaction plate ThermoFisher Scientific, 4316813 
MicroAmp Optical 8-Cap Strips ThermoFisher Scientific, 4324032 
 
 
3.2.5 Denaturation and dilution of NGS libraries 
 
Prior to loading of prepared samples on the NGS flow cell, library pools were denatured 
and diluted. For this purpose, a mixture comprising the library pool and PhiX Control V3 
with a final concentration of 2 nM in 10 µL water was created. The composition was 
calculated by the following formulas (1-3): 
 
𝑉𝑜𝑙𝑢𝑚𝑒(𝐿𝑖𝑏𝑟𝑎𝑟𝑦) =  
𝐶𝑓𝑖𝑛𝑎𝑙
𝐶𝑠𝑡𝑎𝑟𝑡
𝑥 𝑓𝑖𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 µ𝐿 𝑥
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑙𝑖𝑏𝑟𝑎𝑟𝑦
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑡𝑜𝑡𝑎𝑙
     (1) 
Cfinal – final concentration of the library for denaturation, 2 nM; Cstart – starting concentration of the 
quantified library in nM; final volume in µL – 10 µL, percentage library – fraction of library present in the 
mixture including the PhiX fraction; percentage total – 100% 
 
𝑉𝑜𝑙𝑢𝑚𝑒(𝑃ℎ𝑖𝑋) =  
𝐶𝑓𝑖𝑛𝑎𝑙
𝐶𝑠𝑡𝑎𝑟𝑡
𝑥 𝑓𝑖𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 µ𝐿 𝑥
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑃ℎ𝑖𝑋
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑡𝑜𝑡𝑎𝑙
     (2) 
Cfinal – final concentration of the PhiX control for denaturation, 2 nM; Cstart – starting concentration of 
PhiX, 10 nM; final volume in µL – 10 µL; percentage PhiX – fraction of PhiX present in the mixture including 
the library fraction; percentage total – 100% 
 
𝑉𝑜𝑙𝑢𝑚𝑒(𝐻2𝑂) = 10 µ𝐿 − 𝑉𝑜𝑙𝑢𝑚𝑒(𝐿𝑖𝑏𝑟𝑎𝑟𝑦) − 𝑉𝑜𝑙𝑢𝑚𝑒(𝑃ℎ𝑖𝑋)     (3) 
 
On the example of a 20 nM library and a spike-in of 20% PhiX this results in a library 
volume of 0.8 µL, a PhiX volume of 0.4 µL and water volume of 8.8 µL. The PhiX control 
was added due to the low diversity of the utilized library. Generally, a 20 to 30 % PhiX 
spike-in was used for the NGS experiments. 
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For denaturation of the samples, 10 µL of freshly prepared 0.2 N NaOH solution diluted 
in water was prepared and added to the sample. After incubation for five minutes at 
room temperature, the denatured sample was diluted with prechilled HT1 (provided in 
the kit) to a final concentration of 8-10 pM in a volume of 1 mL and loaded on the flow 
cell provided with the MiSeq Reagent Kit v2. The chosen loading concentration 
depended on the cluster density from preceding NGS runs. Typically, a run yielded 
between 300,000 and 800,000 clusters/mm². 
Before sequencing, the sample sheet was created using the following parameter settings 
in the MiSeq control software: i) FastQ only, and ii) sample prep kit: true seq small RNA 
After designating the sample names and the respective indices used during sample 
preparation, cycles were manually adjusted in the sample sheet to 2x151 reads to obtain 
sequencing from both the 5’ and 3’ end. NGS was conducted on the MiSeq device 
(Illumina) at the laboratory of Prof. Dr. Gunter Meister. 
 
MiSeq Reagent Kit v2 (300 cycles) Illumina, MS-102-2002 
PhiX Control v3 Illumina, FC-110-3001 
 
 
3.2.6 Analysis of NGS data 
 
Analysis of NGS results was performed with the CLC Main Workbench 7. Briefly, after 
importing the FastQ files into CLC, sequences containing the corresponding forward and 
reverse reads were paired (‘Paired reads’ function during importing). Overlapping pairs 
were merged into one file (‘Merge overlapping pairs’ function) and subsequently aligned 
with a reference sequence (‘Assemble sequence to reference’ function). Finally, results 
were exported as SAM files and further investigated with an analyzer tool that was 
programmed for this specific purpose by Dr. Benedikt Asbach. The programme was 
designed to count every codon at each position and deliver a table with the absolute 
numbers of amino acids. 
 
 
3.3 Cell Biology 
 
3.3.1 Cultivation of cell lines 
 
Eukaryotic cell lines were cultivated at 37°C and 5% CO2 according to common 
protocols. In general, adherent cells were split in ratio of 1:10 upon reaching a 
confluency of about 80% by washing with PBS, detaching with Trypsin/EDTA solution 
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and resuspending of the cells in DMEMFPS. The cell count was determined by Trypan Blue 
staining of the cells. In this respect, the cell sample was diluted in a 0.4% Trypan Blue 
solution in a 1:1 ratio (usually 50 µL of each). As the cell membrane of dying cells is 
compromised, Trypan Blue can enter the cells and stain them blue, whereas viable cells 
remain unstained. After filling a hemocytometer with the mixture, cells were counted 
under the microscope in four 1x1 mm squares of the hemocytometer chamber. 
Expi293F suspension cells were mainly utilized for the expression of antibodies. 
Cultivation was carried out in 1 L Erlenmeyer flasks at 37°C and 8% CO2 at up 125 rpm 
to a maximal density of 2.5x106 cells per mL in Expi medium. The cells were passaged 
every 3-4 days by harvesting the cells via centrifugation, discarding the supernatant and 
resuspension in the required volume of fresh medium. 
Flp-InTM T-Rex 293 cells with the stable integration of envelope variants in their genome 
received the same treatment as the adherent cells described above. For their cultivation, 
DMEMSCL medium was used consisting of DMEM with 5 % FCS, 1% Pen/Strep, 
hygromycin (100 μg/ml) and blasticidin (15 μg/ml). 
 
HEK293T cells Ad5-transformed immortalized human kidney fibroblast cell line, stably 
transfected to express the SV40 large T antigen, ATCC® CRL-11268 
Expi293FTM cells Ad5-transformed immortalized human kidney fibroblast cell line, 
variant of the 293 cell line, Thermo Fisher Scientific A14527 
Flp-InTM T-Rex 293 cells Ad5-transformed immortalized human kidney cell line containing 
pFRT⁄lacZeo and pcDNA™6⁄TR stably integrated, Thermo Fisher 
Scientific, R78007 
Tetracycline free FCS Fetal Calf Serum, Biochrom, S0115 
Pen/Strep 10000 U/ml penicillin, 10 mg/ml streptomycin, PAN Biotech, P06-07100 
Trypsin/EDTA 0.05% trypsin and 0.02% EDTA in PBS, Pan Biotech, P10-023500 
DMEM Dulbecco’s Modified Eagle Medium, Thermo Fisher Scientific, 11995-065 
DMEMFPS DMEM + 10% FCS, 1% Pen/Strep 
DMEMSCL DMEM + 5% FCS, 1% Pen/Strep, 100 µg/mL Hygromycin, 15 µg/mL 
Blasticidin 
Hygromycin B Gold InvivoGen, ant-hg-5 
Blasticidin InvivoGen, ant-bl5 
 
 
3.3.2 Transient transfection of mammalian cells 
 
3.3.2.1 Cationic-polymer-mediated transfection 
 
The transient introduction of DNA into HEK293T or Flp-InTM T-Rex 293 cells was 
conducted mainly by using a standard polyethylenimine (PEI) protocol 207. For a 6-well 
transfection, 5x105 cells were seeded in 2.5 mL DMEMFPS into 6-well plates the day 
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before transfection. On the following day, the cultivation medium was replaced with 1 
mL serum-free medium (DMEM without supplements). A total of 2 µg plasmid DNA was 
diluted in 100 µL DMEM containing 10 µL polyethylenimine (PEI, 1 µg/µL) solution, 
mixed thoroughly by vortexing and incubated for 10 minutes at room temperature. The 
DNA-PEI-mixture was then added to the cells. After 6 hours, the medium was replaced 
with 2 mL DMEMFPS. 24 hours post transfection the cells were harvested and analyzed. 
For transfection in a 96-well format, 4x105 cells per well were seeded in 200 µL 
DMEMFPS into a 96-well flat bottom plate. On the following day, medium was exchanged 
with 30 µL DMEM without supplements. A transfection mixture containing 200 ng DNA, 
0.8 µL PEI and 30 µL DMEM with no additives was incubated for ten minutes and 
subsequently pipetted on the cells. Six hours post transfection, the medium was replaced 
with DMEMFPS. 
 
 
3.3.2.2 Determination of optimal ratios between DNA and various transfection 
reagents 
 
Apart from cationic polymer-mediated introduction of DNA by PEI or PEI Max, other 
transfection methods and reagents were also utilized to test for improved transfection 
efficiency. For this purpose, the optimal ratio between DNA and transfection reagent 
needed to be determined before the actual experiments could be performed. In general, 
DNA to transfection reagent ratios of 1:2, 1:3, 1:4 and 1:5 (µg DNA:µL reagent) were 
tested while the amount of DNA was kept constant (2 µg per well). A negative control 
containing only DNA was also prepared (“1:0” ratio). All transfections were carried out 
following common protocols or the manufacturers’ instructions, respectively. 
Lipofection was conducted with Lipofectamine 2000 or Lipofectamine 3000. For the 
lipofection with Lipofectamine 2000, 5x105 adherent cells were seeded in a 6-well flat 
bottom plate approximately 18-24 hours prior transfection. The next day, five different 
amounts of Lipofectamine (0, 6, 9, 12, 15 µL) and 2.5 µg DNA were diluted separately in 
150 µL Opti-MEMTM, respectively. 150 µL of diluted DNA was then resuspended in the 
Lipofectamine mixture, incubated for five minutes at room temperature and added to 
the cells. A change of medium after transfection was not required according to the 
manufacturers’ instructions. 48 hours post tranfection, cells were harvested by 
centrifugation (100xg, 4°C, 5 min), discarding the supernatant and resuspension in 1 mL 
FACS buffer for analysis of the transfection efficiency by flow cytometry. 
The day before lipofection with Lipofectamine 3000, 5x105 cells were seeded in a 6-well 
flat bottom plate. Five different amounts of Lipofectamine 3000 (0, 5, 7.5, 10, 12.5 µL) 
and 2.5 µg DNA were diluted separately in 125 µL Opti-MEMTM, respectively. Diluted 
DNA was added to the Lipofectamine mixture and then supplemented with 5 µL P3000TM 
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Reagent (2 µL/µg DNA). After incubating for 15 minutes, 200 µL of the -solution was 
pipetted on the cells. There was no medium change required according ot the 
manufacturer. Harvest and analysis was conducted 48 hours post-tranfection. 
Additionally, Fugene6-mediated transfection was performed. For this purpose, 5x105 
cells were seeded in a 6-well flat bottom the day before transfection. 18 to 24 hours later, 
medium was replaced with 2.7 mL DMEM without supplements. Five different amounts 
of Fugene6 reagent (0, 4, 6, 8, 10 µL) and 2 µg DNA were separately diluted in 150 µL 
DMEM, respectively, and incubated for five minutes at room temperature. Subsequently 
the DNA solution was added to the transfection mixture, incubated for 15 minutes and 
pipetted on the cells. Medium was changed 6 hours after transfection. 
In comparison to all previously mentioned transfection protocols, all reagents involved 
in the calcium phosphate-mediated transfection were kept constant while the amount of 
DNA (0, 2, 3, 4, 5 µg) was altered. 24 hours prior to transfection, 5x105 cells were seeded 
in a 6-well flat bottom plate. The following day, medium was replaced with DMEM with 
no supplements one hour before DNA dilutions were added. For this purpose, 5 µg DNA 
was resuspended in 135 µL H2O and 15 µL 2.5 M CaCl2. The mixture was then slowly 
dribbled into a 5 mL corning polystyrene round bottom tube containing 150 µL HeBS 
while being vortexed simultaneously. After an incubation period of 15 minutes, the DNA 
solution was gradually added to the cells. Six hours post transfection, medium was 
replaced with DMEMFPS. 
 
Polyethylenimine (PEI) Polysciences, 23966-2 
Polyethylenimine MAX (PEI MAX) Polysciences, 24765-1 
LipofectamineTM 2000 Transfection Reagent Thermo Fisher Scientific, 11668030 
LipofecatmineTM 3000 Transfection Reagent Thermo Fisher Scientific, L3000001 
Fugene6 Transfection Reagent Promega, E2693 
2xHeBS 0.28 M NaCl, 1.5 mM NaHPO4, 50 mM Hepes, pH 7.1 
 
 
3.3.3 Expression of antibodies 
 
In general, the expression of antibodies was done by co-transfecting two plasmids 
carrying the variable heavy (CMVR VRC01 H) and light chain (CMVR VRC01 L) in a 1:1 
ratio into Expi293FTM suspension cells. The transfection was performed by using the Exp 
FectamineTM 293 Transfection Kit according to the manufacturers’ instructions. Before 
transfection, two million cells per mL were seeded in 300 mL Expi293 expression 
medium and cultivated in a 1 L Corning flask for six to eight hours at 125 rpm until a 
density of 2.5 million cells/mL was reached. 300 µg plasmid DNA (150 µg of CMVR 
VRC01 H and 150 µg CMVR VRC01 L) and 802.5 µL ExpiFectamine were diluted 
separately in 15 mL OptiMEM each, and incubated for five minutes at room temperature. 
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The two solutions were briefly vortexed and incubated for 20-30 minutes to allow the 
DNA-ExpiFectamine complexes to form, followed by the supplementation of the mixture 
to the cells. After cultivation for 16-18 hours at 37°C, 8% CO2 and 125 rpm, 1.5 mL 
Enhancer I and 15 mL Enhancer II (both enhancers were provided with the Kit) were 
added. The duration of antibody expression lasted usually five days. 
 
CMVR VRC01 H NIH AIDS Reagent Program, 12035 
CMVR VRC01 L NIH AIDS Reagent Program, 12036 
Expi293FTM cells Ad5-transformed immortalized human kidney fibroblast cell line, 
variant from the 293 cell line, Thermo Fisher Scientific A14527 
Expi Fectamine TM 293 
Transfection Kit 
Thermo Fisher Scientific, A14524 
Expi293TM Expression Medium Thermo Fisher Scientific, A1435102 
 
 
3.3.4 Generation of stable cell lines 
 
The SeqPer library (see 4.1), previously cloned into the plasmid pQL13, was utilized as 
foundation for the generation of the respective inducible stable cell line library (SCL 
library) (see 4.2). This was achieved by targeted transfection of the library into Flp-InTM 
T-Rex 293 cells. Briefly, 24 hours prior transfection, a density of 5x105 Flp-InTM T-Rex 
293 cells resuspended in 2.5 mL cultivation medium (DMEMFlpIn) were seeded into 6-
well plates. On the following day, medium was replaced with 1 mL DMEM without 
supplements. Subsequently, 0.4 µg of the helper plasmid pOG44 carrying a Flp 
recombinase (Thermo Fisher Scientific) was mixed with 1.6 µg of pQL13-SeqPer DNA 
and 10 µL PEI (1 µg/µl) in 2.5 mL DMEM. After incubation for five minutes at room 
temperature, Flp-InTM T-Rex 293 cells were supplemented with the DNA-PEI solution. 
Six hours post transfection, DMEM was replaced with medium containing 5% FCS and 
1% Pen/Strep. After 48 hours, medium was aspirated, replaced with 1 mL fresh DMEM 
and cells were detached by pipetting up and down. Subsequently, cells were transferred 
into T75 flask and resuspended in 15 mL DMEM containing 5% tetracycline free FCS, 1% 
Pen/Strep, 15 µg/mL blasticidin and 100 µg/mL hygromycin. Addition of hygromycin 
started the process of positive selection which was carried out the following 25 days, 
with the medium being replaced every three days. It should be noted that the majority 
of stable cell lines was generated by Anja Schütz prior to this thesis. 
 
DMEMFlpIn DMEM + 5% FCS, 1% Pen/Strep, 100 µg/µL zeocin, 
15 µg/mL basticidin 
Zeocin InvivoGen, ant-zn 
pOG44 Flp-Recombinase Expression Vector Thermo Fisher Scientific, V600520  
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3.3.4.1 Cryopreservation and storage of stable cell lines 
 
After the antibiotic selection was completed, stable cell lines were cryopreserved and 
stored. Prior to storing, a cryoprotective medium (storage medium) was prepared 
containing 50% DMEM, 30% FCS and 20% DMSO. Upon reaching a confluency of about 
80% cells were washed with PBS, detached from the flask with Trypsin/EDTA solution 
and resuspended in cold DMEMSCL. Cell count was then determined and batches of one 
million cells in 500 µL DMEMSCL were pipetted into cryotubes. Finally, 500 µL of the 
cryoprotectant were added to the cells, the tubes were placed into a freezing container 
and stored overnight at -20°C. On the following day, the samples were transferred to a 
nitrogen tank for longterm storage. 
 
Storage medium 50% DMEM, 30% FCS, 20% DMSO 
Dimethyl sulfoxide (DMSO) SigmaAldrich, C6164-50ML 
Mr FrostyTM Freezing Container ThermoFisher Scientific, 5100-0001 
 
 
3.3.4.2 Thawing of stable cell lines 
 
Stable cell lines were resuscitated in a quick thawing process to reduce cell death due to 
the presence of DMSO. For this purpose, cryotubes were placed in a water bath without 
submersing the top of the tube and incubated in a 37°C water bath for three to five 
minutes. The cell suspension was then transferred into a falcon containing 10 mL 
preheated DMEMSCL and centrifuged at 100 rpm for five minutes. Subsequently, 
supernatant was discarded, the cell pellet was resuspended in 15 mL DMEMSCL and 
transferred into a T75 flask. 
 
 
3.3.5 Flow cytometry of mammalian cells 
 
Flow cytometry is an analytical tool for the characterization of cells based on their 
specific light scattering and fluorescent characteristics. As the cells travel in a thin 
capillary along a laminar stream of liquid, they are singularized and scanned individually 
by a laser. The scattering of light provides information on the size and granularity of 
cells. Simultaneously, fluorescent molecules are excited and their emission spectrum can 
be measured by various detectors 208. 
Affinity of antibodies to Env was analyzed by flow cytometry using the Attune NxT 
(Applied Biosystems, Thermo Fisher Scientific) cytometer. For titration experiments, a 
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two-fold serial dilution of screening antibody was prepared with a starting 
concentration of 400 nM (assuming a molecular weight of 150 kDa) that was diluted in 
12 steps to a minimal concentration of 0.2 nM. In general, antibodies carried an 
Alexa647-conjugate that was attached by using the Alexa Fluor® 647 Protein Labeling 
Kit as described in section 3.4.2. 
Prior to every measurement, 4x104 transiently transfected cells (see 3.2.1) were washed 
with 200 µL PBE. For this, cells were centrifuged at 500xg for five minutes at 4°C, the 
supernatant was decanted and cells were resuspended in 200 µL PBE. After removal of 
the supernatant, cells were incubated for one hour at 4°C with 25 µL PBE containing the 
bnAb VRC01 at the concentrations given above. Following three washing steps with ice 
cold 200 µL PBE, cells were resuspended in 200 µL PBE and analyzed with the Attune 
NxT device.  
In respect to titrations performed on stable cell lines, cells were induced 24 hours prior 
FACS analysis to express GFP and Env by supplementing the medium with 1 µg/mL 
doxycycline. All following steps were conducted as described above. 
In general, cells were gated for living, single cells displaying envelope (signal in APC 
channel - RL1) and GFP (signal in FITC channel – BL1) expression. As GFP and Env 
expression were genetically coupled, ratios of the mean fluorescence intensities (MFI) 
of APC- and FITC-signals were calculated to normalize for varying Env expression levels 
(relative MFI). The results were then compared with a wildtype control that underwent 
the same treatment as described above. Negative controls, represented by Env-negative 
cells that were subjected to the very same antibody titration as the other cells, were 
substracted to set the starting point of the curves to zero. The resulting titration curves 
were fitted using the option non-linear least squares regression (hyperbolar one-site 
binding) in the program GraphPad Prism 5.0. 
 
PBE PBS + 2mM EDTA + 0.5% FCS 
Alexa Fluor® 647 Protein Labeling Kit Life Technologies, A20173  
Doxycycline SigmaAldrich, D9891-1G 
 
 
3.3.6 Cell sorting 
 
Cell sorting is a specialized type of flow cytometry that allows the sorting of a 
heterogeneous mixture of cells. In the course of this work, this method was utilized to 
screen the previously generated stable cell line library for Env variants that exhibited 
enhanced or reduced affinity for the bnAb VRC01. 
In this respect, a total of 30x106 cells, composed of equal amounts of the pools of position 
to be analyzed, were seeded on a 15 cm plate and induced with 1 µg/mL doxycycline 24 
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hours prior to the sorting. On the following day, cells were detached from the plate with 
4 mL chilled PBE by pipetting and washed one time by centrifuging at 250xg for five 
minutes at 4°C, decanting of the supernatant and resuspending in 4 mL PBE. After 
another centrifugation step, the cell pellet was resuspended in 1 mL Alexa647-labeled 
VRC01 solution (10 µg/mL) for 1 hour at 4°C. The cells were washed three times as 
described above, resuspended in 500 µL PBS and singularized by passing the cells 
through a 30 μm separation filter for subsequent sorting on the BD FACS Aria III. 50 µL 
of the sample was retained to serve as an input control. 
Cells were sorted using a FACS Aria IIu (BD), with the instrument set to “single cell 
mode” to discard two-target-events ensuring the most accurate counts of the sorting 
procedure. The gating strategy was applied according to the following setup: i) FCS-A vs. 
SSC-A (P1), ii) FSC-H vs. FSC-W (P2), iii) SSC-H vs. SSC-W (P3), and FITC-A vs. APC-A 
(triangle shaped gates P4 and P5). Triangle shaped gates were chosen to sort cells with 
the highest or lowest VRC01 signal in relation to the GFP signal, thus selecting cells with 
the highest or lowest antibody affinity in relation to Env expression. Unless stated 
otherwise, at least 30.000 cells were sorted per gate into a tube containing 100 µL PBS. 
Genomic DNA from the input sample and sorted cells was recovered as described above 
(see 3.2.2.2) and utilized as a template in the sample preparation for subsequent NGS 
analysis (see sections 3.2.2-3.2.4). 
 
QIAamp DNA Mini Kit Qiagen, 51304 
Doxycycline SigmaAldrich, D9891-1G 
Pre-separation filter Miltenyi Biotech, 130-041-407 
 
 
3.4 Protein Biochemistry 
 
3.4.1 Purification of the HIV-1 specific human bnAbs VRC01 
 
Expression of the bnAb VRC01 was conducted by co-transfecting of two plasmids 
carrying the variable heavy (CMVR VRC01 H, NIH AIDS reagent program) and light chain 
(CMVR VRC01 L, NIH AIDS reagent program) in a 1:1 ratio into Expi293FTM cells as 
described in section 3.3.3. All following steps were performed at 4°C. 
Five days post transfection, the supernatant was collected by centrifugation of the cell 
suspension at 1000 rpm for 10 minutes. The purification of antibodies was accomplished 
by using a 5 mL column that consists of Protein A-Sepharose. Briefly, the column was 
equilibrated by applying 5 column volumes of Protein A buffer using a peristaltic pump. 
The flow rate was maintained at 10 mL per hour for all following steps. After loading of 
the supernatant, the column was washed with 25 mL Protein A buffer to remove 
unbound molecules and the antibodies were eluted in 1 mL fractions with a 0.1 M 
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glycine-HCl buffer (pH 2.7). The fractions were tested spectrophotometrically 
(absorbance at 280 and 650 nm) for their antibody content. All fractions containing 
antibody were pooled and neutralized by gradually adding 0.1 M NaOH in 5 µL steps 
until a pH of 6-7 could be detected with pH indicator strips. Typically, four to five mL 
were added in total. Dialysis of the eluate was carried out in Slide-A-LyzerTM dialysis 
cassettes (molecular weight cutoff 20,000) for two days in 1 L PBS that was changed 
daily. Subsequently, the concentration was measured spectrophotometrically at an 
absorbance of 280 nm and 650 nm (molar extinction coefficient: 210,000 M-1cm-1). 
Typically, concentrations ranged between 2 and 4 mg/mL. The antibodies were stored 
at 4°C. 
 
Protein A-Sepharose from Staphylococcus aureus SigmaAldrich, P3391-1.5G 
Protein A buffer 20 mM NaH2PO4, pH 7.0 
Elution buffer 0.1 M glycine-HCl, pH 2.7 
pHydrion Insta-Check 0-13 Micro Essential Laboratory, HJ-613 
Slide-A-LyzerTM Dialyse Cassette Thermo Fisher Scientific, 66012 
 
 
3.4.2 Labeling of antibodies 
 
Purified antibodies were conjugated with a fluorophore by using the Alexa Fluor® 647 
Protein Labeling Kit according to the manufacturers’ instructions. Briefly, a 1 M solution 
of sodium bicarbonate was prepared by adding 1 mL deionized water to the provided 
vial of sodium bicarbonate and pipetting up and down until fully dissolved. To 0.5 ml of 
the 2 mg/mL antibody solution (usually in PBS), 50 µL of the bicarbonate was added and 
mixed by pipetting. Subsequently, the mixture was transferred to the vial of reactive dye 
which contained a magnetic stir bar and stirred for one hour at room temperature. 
Meanwhile the purification resin was pipetted into the column (provided with the kit) 
and allowed to settle. After the incubated mixture was loaded on the column and the 
solution entered the resin, elution buffer (8 mL of 10-fold diluted elution buffer in water) 
was added continuously until the labeled antibody had been eluted (typically about 30 
minutes). Two colored bands which represented the separation of labeled protein from 
unincorporated dye could be observed. As the first band contained the labeled antibody, 
it was collected into a 2 mL tube and instantly centrifuged at 14.000 rpm, 4°C for 20 
minutes to remove aggregates. The labeling efficiency and concentration of the antibody 
was measured spectrophotometrically at an absorbance of 280 and 650 nm. An aliquot 
of the labeled antibody as well as a 10-fold dilution (in elution buffer) were measured in 
triplicates. The degree of labeling was calculated with the following formula according 
to the manufacturers’ instructions (4): 
𝑚𝑜𝑙𝑒𝑠 𝑑𝑦𝑒 𝑝𝑒𝑟 𝑚𝑜𝑙𝑒 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 =
𝐴650 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
239,000 𝑥 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 [𝑀]
     (4) 
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where 239,000 cm-1M-1 represented the approximate molar extinction coefficient of 
Alexa Fluor 647 dye at 650 nm. Typically, three to five moles of fluorophore per mole of 
antibody could be detected (three to seven moles are optimal). 
 
 
3.4.3 SDS-PAGE 
 
Antibodies were separated according to their size in a sodiumdodecylsulfate-
polyacrylamide gel-electrophoresis (SDS-PAGE). In general, all antibodies were 
analyzed under reducing and non-reducing conditions. For this purpose, 1 µg of purified 
antibody diluted in 20 µL PBS was supplemented with 5x Laemmli buffer and incubated 
at 95°C for five minutes. In respect to non-reducing conditions, 5x Laemmli buffer 
without β-mercaptoethanol was added instead. Subsequently, the samples were loaded 
onto a 10% SDS gel and electrophoresis was performed using a PowerPacTM Basic Power 
Supply (BioRad) at 70V for 20 min, followed by 90V for approximately two hours. 
PageRuler™ Prestained Protein Ladder (Life Technologies) served as a standard for 
estimating the size of the proteins assessed. 
The SDS gel was first placed in a bowl containing Coomassie staining solution for five 
minutes and subsequently in destaining solution over night. 
 
5x SDS-PAGE loading buffer 125 mM Tris, 2 % (w/v) SDS, 10 % (v/v) β-mercaptoethanol, 1 mM 
EDTA, 10 % (w/v) Glycerin, 0,01 % (w/v) Bromphenolblau, pH 6,8 
Laemmli buffer 62.5 mM Tris; 1 % (w/v) SDS; 5 % (v/v) β-mercaptoethanol; 0.5 mM 
EDTA; 5 % (v/v) glycerol; 0.005 % (w/v) bromophenol blue, pH 6.8 
PageRuler™ Plus Prestained 
Protein Ladder 
Life Technologies, 26620 
Coomassie Brialliant Blue R-250 AppliChem, A1092 
Coomassie Staining Solution 0,125 % (w/v) Coomassie Brilliant Blue R-250, 50 % (v/v) ethanol, 
7 % (v/v) acetic acid 
Destaining solution 7 % (v/v) acetic acid 
 
 
3.4.4 Envelope ELISA 
 
All purified antibodies were characterized in respect to their affinity towards a soluble 
HIV-1 BG505 gp140 envelope protein which was previously produced. In addition, the 
binding affinity of the newly generated antibody was compared with a reference 
antibody of the same type, as well as a PBS negative control in triplicates, respectively. 
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High protein-binding ELISA flat bottom plates (Nunc-Maxisorp) were coated with 
200 µL PBS containing 1 µg/µL Galanthus nivalis lectin (SigmaAldrich) per well at 4°C 
overnight. All following steps were performed at room temperature. Wash cycles were 
conducted with PBS/ 0.05 % Tween20 using a Tecan HydroFlex device (HydroControl-
Software Version 1.0.). On the next day, wells were blocked for two hours with 200 µl 
PBS containing 5% skimmed milk powder, 5% heat-inactivated fetal calf serum, and 
0.1% Tween 20 and washed subsequently three times with 200 µL wash solution. 100 µL 
of a solution comprising 1 µg/mL BG505 gp140 envelope protein in PBS was then added 
and incubated for one hour at room temperature. After six washing steps, wells were 
incubated for 1 hour with 100 µL monoclonal antibody that was 5-fold serially diluted 
(starting concentration 20 nM) in PBS containing 1% BSA. The following six washing 
steps ensured that all unbound antibodies were removed. A secondary HRP-conjugated 
rabbit anti-human IgG (100 µL/well in PBS) previously diluted in a ratio 1:5.000 in PBS 
was added to the wells, incubated for one hour and washed ten times. 50 µL of the 
colorimetric HRP substrate 3,3’,5,5’-tetramethylbenzidine (TMB substrate consisting of 
TMB A : TMB B 20:1) was supplemented into each well until a blue color could be 
detected. The reaction was stopped with 25 µL of a 1 M H2SO4 solution followed by the 
measurment of the optical density at 450 nm in triplicates on a microplate reader. All 
curves were corrected by subtracting both the negative control signals obtained without 
addition of envelope gp140 and primary antibody. Furthermore, curves were further 
analyzed with GraphPad Prism 5.0 by fitting with the non-linear least squares regression 
(hyperbolar one site binding). 
 
NUNC Maxisorp ELISA plates Thermo Fisher Scientifc, 442404 
Galanthus nivalis lectin SigmaAldrich, L8275-5MG 
Fetal Calf Serum Merck, S0115 
Tween20 SigmaAldrich, P9416-100ML 
Bovine Serum Albumin Biomol, 01400.100 
Polyclonal Rabbit Anti-Human 
IgG/HRP 
Dako, P0214 
TMB A 30 mM potassium citrate, pH 4.2 
TMB B 10 mM tetramethylbenzidine (Roth 6350.2), 10 % (v/v) acetone, 90 
% (v/v) ethanol, 80 mM H2O2 
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4 Results 
 
4.1 Overview of the sequential permutation library (SeqPer) 
 
Mutant libraries representing a vast diversity of protein variants are increasingly 
utilized to identify structurally critical residues for protein function prediction. 
Considering the benefits of this technology it was decided to apply such a library for the 
selection of HIV envelope variants with improved antigenicity. For this purpose, a 
trimeric Env sequential permuation library was conceived. 
Design and implementation of the library was conducted by Dr. Alexander Kliche in 
cooperation with the International AIDS Vaccine Initiative (IAVI). The trimeric Env 
library was based on the C-clade isolate, 16055 (accession code EF117268) to address 
the globally most prevalent subtype C. Truncation of the cytoplasmic tail (gp145 Env 
trimer) and adaptation of the isolate sequence to human codon usage were implemented 
to ensure efficient Env expression and surface presentation. Additionally, a substitution 
at the furin-cleavage site from REKR to REKS was introduced to prevent processing of 
the precursor protein into the non-covalently linked gp120-gp41 complex prone to 
shedding. Every position of the external envelope was sequentially permuted, i.e. by 
creating a separate plasmid-pool for each position (referred to as pool-of-position). The 
generation was performed by GeneArt using degenerate NNK codons (N = equal molar 
mix of A, C, G and T, and K = equal molar mix of G and T) within the synthesis process to 
allow diversification of DNA sequences. Notably, the first 30 amino acid positions 
representing the signal peptide as well as the cleavage site were excluded from the 
sequential permutation. In accordance with contractual stipulations, the minimal 
requirements regarding the diversity of the library constituted at least 16 amino acids 
per position resulting in a total of 658 sub-libraries, also termed as “pools-of-position”. 
Thus, the whole library comprises approximately 10.528-13.160 individual Env variants 
(figure 11). The library will be henceforth referred to as SeqPer (sequential 
permutation) library. 
The library was inserted into the novel vector system, pQL13 (see 8.2.2), which was 
developed by Dr. Tim-Henrik Bruun during his PhD thesis 209. A unique characteristic of 
this plasmid was represented in the translational coupling of tetracycline inducible Env 
expression with GFP production via a TaV 2A peptide, thus allowing normalization of 
envelope expression by means of GFP fluorescence. Additionally, inherent FRT (flippase 
recombination target) sites allowed the stable insertion of Env variants into Flp-InTM T-
Rex 293 cells via site-directed recombination, enabling the generation of stable cell lines 
(see 3.3.4). 
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Figure 11 – Schematic illustration of the SeqPer library. The library was based on the extracellular 
part (indicated by brackets) of a trimeric C-clade envelope protein. Tubes represent the wild type amino 
acid position of the Env that was substituted by the 20 natural amino acids with the possible composition 
of the sub-library (pool-of-position N30X) illustrated below. Nomenclature of the pools of position was 
defined as follows: first letter (N) represents the wild type (WT) amino acid at the respective position in 
the sequence according to HXB2 numbering (30) and X indicating the randomization of this position, thus 
constituting a sub-library. Depending on the amount of amino acids occurring at every position (16-20) a 
total of 10.528 to 13.160 diverse variants are assumed in the 658 sublibraries. Figure of Env was adapted 
from the Nature Publishing Group 210 with minor modifications. 
 
 
4.2 Generation of the stable cell line SeqPer library 
 
Stable cell lines were created by stable transfection of Flp-InTM T-Rex 293 cells with a 
plasmid-mixture coding for an individual pool-of-position of the SeqPer (see 3.3.4). This 
event was mediated by the constitutively expressed Flp recombinase situated on the 
plasmid pOG44 which was supplemented in conjunction with the Env library during 
transfection. Upon co-transfection, the Flp recombinase mediated homologous 
recombination between the FRT sites in the plasmid and the cell’s genome leading to the 
insertion of the-Env-containing plasmid into the Flp-InTM T-Rex 293 cell genome (figure 
12A). As consequence, the lacZ ZeocinTM fusion gene shifts out of the reading frame and 
is inactivated. The resulting stable cell lines exhibited hygromycin resistance that served 
as antibiotic selection marker for cell with successful integration events. The sole 
integration locus at a predefined FRT site ensures the insertion of only one Env variant 
per cell. In addition, all stable cell lines display a translational coupling of eGFP and Env 
expression that results from a so-called Tav 2A peptide (TaVp2A) present between the 
two genes. The peptide originates from the insect virus Thosea asigna and is responsible 
for the impairment of peptide bond formation by a ribosomal skip mechanism between 
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the 2A glycine and 2B proline of the consensus motif Asp-Val/Ile-Glu-X-Asn-Pro-Gly 
(2A); Pro (2B) 211. As a consequence, an equal expression level for eGFP and Env should 
occur which enables normalization for Env expression in respect to eGFP fluorescence. 
Due to the cytotoxicity of Env 212, a mechanism to regulate the expression was 
implemented comprising a combination of the Tet repressor in Flp-InTM T-Rex 293 cells 
and the doxycycline-inducible chimeric CMV promotor/TetO of the pQL13 plasmid. 
Generally, the functionality of all newly generated stable cell lines was analyzed by 
assessing their ability to express Env and GFP. Expression rates of both proteins were 
measured via flow cytometry after induction of the cells with doxycycline and staining 
with the antibody VRC01 conjugated with an Alexa647 fluorophore (see 3.3.5). The 
relative mean fluorescence intensities were calculated and compared with the WT 
16055 stable cell line. In general, the detected MFIs were comparable to the WT signals 
indicating proper expression of Env and GFP, respectively. The entire stable cell line 
library generation and subsequent analysis of the expression was performed by Anja 
Schütz. 
 
 
Figure 12 – Schematic illustration of the generation of stable cell lines. Linearized genomic 
organization of Flp-InTM T-Rex 293 cells and the pQL13 vector are shown before and after stable 
integration at Flp Recombination target sites (FRT). As a consequence, the hygromycin gene without start 
codon shifted into a reading frame with a start codon (ATG), leading to the acquisition of a hygromycin 
(Hygro) resistance whereas the zeocin resistance disappeared due to the loss of the start codon. Linkage 
between eGFP and Env expression was achieved by a TaV 2A peptide (TaVp2A) in pQL13. Expression of 
eGFP and Env was regulated by the inducible Tet operator/repressor (TetO/TetR) system. Figure was 
freely adapted from 213. 
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4.3 Quality control of the SeqPer library 
 
The sequential permutation library was the basis of the screening for improved 
immunogens. Prior to this thesis, the library has already been analyzed partially by 
Christian Ziegler during his master’s project 214. Unfortunately, his data demonstrated 
several quality-related problems as he could confirm the existence deletions of various 
sizes in the V3 region of the pDNA library. Similarly, Dr. Alexander Kliche revealed a 
considerable loss in the amino acid diversity in the data from the NGS analysis of 
generated stable cell lines (data not shown). Considering the concerning previous 
results, especially in light of the complexity and dimension of the library, a detailed 
quality control should be performed to understand the characteristics and limitations of 
this type of library, as well as to interpret screening results correctly. Therefore, an in-
depth evaluation of the quality was conducted on the level of the plasmid DNA that was 
originally obtained from the gene synthesis provider, and the generated stable cell lines 
at various stages of the generation and screening procedures. 
 
 
4.3.1 Quality of plasmid DNA 
 
Plasmid DNA was obtained by preparation (see 3.1) performed from the DNA stocks that 
were forwarded by GeneArt. 
 
 
4.3.1.1 Purity of plasmid DNA 
 
The general purity of plasmid DNAs was assessed spectrophotometrically. An average 
of 1.95±0.03 for the absorbance ratio at 260 and 280 nm (table S1) could be detected for 
all 658 library positions. The results were within the admissible range in regard of the 
optimal values (OD260/280 ~ 1.8-1.9) for pure DNA according to literature 202. 
 
 
4.3.1.2 Restriction enzyme assay 
 
A restriction enzyme assay was performed on all 658 pools-of-position to evaluate 
potential errors (i.e. larger deletions, insertions, etc.) during the generation and the 
cloning procedure of the library. For this purpose, 1 µg plasmid DNA of every library 
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position was digested with the restriction endonuclease NcoI-HF (NEB) for 2 hours at 
37°C and visualized on a 0.8 % agarose gel. As control, an equal amount of native pDNA 
was also analyzed to assess the content of supercoiled DNA. This was important for the 
generation of stable cell lines as transfection of supercoiled DNA is more efficient than 
open circular or linear DNA 215. 
The expected fragment profile was calculated in silico with the ‘Restriction Site Analysis’ 
function of the CLC Workbench program, resulting in a band of 7937 base pairs for the 
native pDNA and four fragments with the sizes of 3744, 2353, 1519 and 321 base pairs 
for the digested samples, respectively. 
 
 
Figure 13 – Agarose gel electrophoresis of native and digested plasmid DNA. A representative 
restriction assay of various pools-of-position from the SeqPer library is shown. Non-digested DNA (NcoI-
HF) migrated in three forms: i) nicked, ii) linear and iii) supercoiled DNA at the length of 7937 bps, with 
supercoiled DNA representing the biggest fraction. In respect to the digested DNA (NcoI-HF +), four bands 
at 3744, 2353, 1519 and 321 bps were expected. Aberrant fragments are indicated by red arrows.  
 
 
For the majority of the digestions, the resulting patterns displayed the expected 
fragment sizes. However, in 48.3% (318 of 658) of the library, band patterns with 
additional fragments could be detected (figure 13, S1). All aberrant bands however, 
manifested in substantially lower intensities than then wildtype fragments, indicating 
that merely a fractional amount of the respective positions is erroneous. Furthermore, 
the sublibraries 522-532 (figure S2) demonstrated only one distinct band at 3744 bp 
with a multitude of additional smaller low-intensity fragments resulting in a smear-like 
appearance. New preparation of DNA from the stocks or after re-transformation of 
bacteria with the pDNA did not improve the quality of the digestion which indicated 
general issues during the production of these positions. When analyzing non-digested 
DNA, three bands could be detected in most cases: i) nicked, ii) linear and iii) supercoiled 
DNA. Expectedly, the supercoiled pDNA represented the largest fraction in the library. 
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4.3.1.3 Densitometric analysis of aberrational phenotypes 
 
Densitometric analysis of digital gel images provided a cost and time effective 
alternative to analyze relative DNA quantities. In this context, the percentage of visually 
detected aberrations was determined by comparing the band intensities of the wildtype 
fragments with the erroneous fragments to estimate their occurrence in the SeqPer 
library. The results are displayed in figure 14 and revealed an average rate of aberration 
of 6-18% at the 318 visually erroneous sublibraries, with pool-of-position 530 
displaying the highest error rate with about 40%. Furthermore, an increased 
accumulation of aberrations could be identified at two major hot spots located in the 
stretch between the variable loop 5 (V5) and heptad-repeat region 1 (HR1), as well as in 
the center of the gp41 region, indicating poor quality at these library positions. 
 
 
Figure 14 – Depiction of errors in the SeqPer library. Percentage of detected aberrational fragments 
plotted against the respective 318 erroneous pools of position in the SeqPer library. The location of the 
deviating positions on Env is indicated below. Schematic illustration of Env was freely adapted from 37. 
 
 
4.3.1.4 Characterization of selected aberrational phenotypes 
 
In order to analyze the origin of the anomalies, three random sub-libraries (pool-of-
positions 50, 136, 316) exhibiting deviating fragments (figure S2) were selected for an 
in-depth evaluation. Briefly, 100 ng of pool DNA was used for the transformation of 
chemically competent E. coli DH10B cells. The resulting colony forming units 
represented individual Env variants from the pool-of-position, respectively. Plasmid 
DNA from 40 colonies per pool-of-position was extracted and characterized by a 
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restriction enzyme assay. The fragment profile of native and NcoI-HF-treated pDNA (2h, 
37°C) was visualized on a 0.8 % agarose gel. 
 
 
Figure 15 – Restriction enzyme assay profile for sub-library 50. Plasmid DNA of 40 random colony-
forming units (C1-C40) from sub-library 50 in the SeqPer library was analyzed. 1 µg native and digested 
(NcoI-HF, 2h, 37°C) plasmid DNA was visualized on a 0.8 % agarose gel. The wildtype restriction pattern 
from the 16055 gp145 Env mastergene (WT) and the pool-of-position 50 (P50) are also shown. 
Aberrational colony forming units are highlighted in red. 
 
 
The digestion patterns from the individual clones of the three selected positions 
demonstrated mainly the correct phenotype. However, a minority of the analyzed 
colonies proved to be erroneous which is consistent with the lower band intensities of 
the detected aberrations from the restriction enzyme assays of the plasmid pools of 
sublibraries (figure 13, S2). At positions 50 and 316 ten out of 40 colonies displayed 
aberrations, whereas position 136 demonstrated only four faulty clones (figure 15, S3). 
On closer examination of the restriction profile of sub-library 50 (figure 15, P50), an 
additional faint fragment of approximately 1 kbs can be detected, representing a 
contamination of about 6.5% (densitometric analysis, 4.3.1.3) at the whole library 
position. Sanger sequencing of 40 random colony-forming units revealed that eight out 
of ten faulty clones (C2, C8, C11, C17, C23, C35-36 and C38) carried deletions of about 
1.3 kbs within the Env region. This lead to an aberrational digestion pattern of single 
colonies and subsequently caused the emergence of a faint additional fragment that is 
visible for pool-of-position 50 (P50). Furthermore, mutations and deletions within the 
vector occurred, as in the case of clones 22 and 40, however, they were not visible in the 
restriction enzyme assay probably due to their under-representation. Similarly, Sanger 
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sequencing of faulty clones from positions 136 and 316 demonstrated deletions of 
varying sizes and insertions of additional restriction sites in the vector as well as the 
envelope region (figure S3 A and B). This indicated technical limitations during the 
generation of the library or cloning procedure. 
 
 
4.3.2 Establishment and validation of the Next Generation Sequencing library 
sample procedure 
 
In the following, all samples involved in the NGS analysis are termed as ‘NGS library’ or 
‘NGS amplicons’ to prevent confusion with the SeqPer library. Understanding the NGS 
library preparation is important to ensure the highest quality sequencing data. 
Therefore, all relevant conditions regarding library preparation for NGS analysis had to 
be optimized and standardized for quality control of the SeqPer library and for future 
utilization. 
 
 
4.3.2.1 Determination of PCR conditions for NGS library preparation 
 
A successful and efficient NGS analysis strongly relies on high quality NGS amplicons. 
Sufficient quantities of DNA for the denaturation step are just as important as pure and 
faultless samples. Due to the error-prone nature of DNA polymerases, a careful balance 
between the optimal amount of input DNA and PCR cycles had to be determined first. 
Here, the Phusion DNA polymerase was used that has a 3’-5’-exonuclease activity for 
proofreading, for which an error rate of 4.4x10-7 in Phusion HF buffer is given by the 
manufacturer (NEB). Since genomic DNA was often a limiting factor, DNA from different 
amounts of cells (500, 2500 & 12.500) was extracted and amplified with 19, 22 or 25 
cycles, respectively, to establish the conditions for optimal yield of PCR products. In 
general, 10 µL isolated gDNA were utilized for PCR1 as concentrations were below the 
detection limit. Similarly, 10 µL of purified PCR1 product (see 3.2.3) was applied for 
PCR2. Assuming that the extraction of gDNA worked optimally and no DNA degradation 
took place, 10 µL isolated gDNA from 500, 2500 and 12.500 cells, resembling 0.004, 0.02 
and 0.1 pg, respectively, were utilized in the initial PCR. 
__________________________________________________________________________________ 
46 
 
Results 
 
Figure 16 - Analysis of PCR conditions for NGS sample preparation. Sample preparation comprised 
two amplification steps. In the first PCR, NGS-specific primer binding sites were introduced into the target 
DNA template. Fusion of indices and adapters was achieved by the second PCR. To determine optimal 
conditions for NGS sample preparation 19, 22 and 25 cycles were tested in combination with different 
amounts of input DNA. In respect to plasmid DNA, 1 ng was utilized in the initial PCR (1), whereas 0.004 
(2), 0.02 (3) and 0.1 (4) pg genomic DNA previously extracted from 500, 2.500 and 12.500 cells (WT 16055 
gp145 stable cell line) were applied, respectively. Amplification products shown here were visualized 
after the second PCR by agarose gel electrophoresis. 
 
Sample Conc. [ng/µL] A260/280 
19_1 76.4 2.0 
19_2 7.5 3.0 
19_3 20.2 2.1 
19_4 34.3 2.2 
22_1 67.5 1.9 
22_2 29.9 2.1 
22_3 28.9 2.1 
22_4 39.2 2.1 
25_1 48.8 2.1 
25_2 21.9 2.1 
25_3 35.3 2.1 
25_4 36.5 2.0 
 
 
As expected, a higher number of cycles and amount of input material resulted in a 
greater yield of final DNA after gel extraction of the corresponding bands. Whereas 
genomic DNA exhibited distinct bands in the gel electrophoresis, the resulting fragment 
from the plasmid DNA displayed a smear-like appearance which indicated unspecific 
binding of primers, probably due to an excess of DNA template applied in the PCR. 
However, neither the number of cycles nor the amount of input material seemed to have 
a direct influence on the quality of the resulting product. The only exception was 
represented in the sample 19_2 which displayed poor quality compared to the other 
specimens indicating potential contamination. Considering the error-prone nature of 
DNA polymerases, less PCR cycles in combination with higher amounts of input DNA 
Table 5 – Quality control of amplification products. 
General purity of PCR products was determined 
spectrophotometrically by measuring the absorbance 
ratios A260/280 and A260/230. Sample names correspond 
to figure 16 and describe the amount of cycles and 
input DNA utilized in the initial PCR (i.e. 19_1 relates to 
19 cycles and 1 ng pDNA). 
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were considered for all further experiments, specifically 22 cycles and target DNA 
template amounts of 1 ng for pDNA and at least 0.1 pg for genomic DNA. 
 
 
4.3.2.2 Adjustment of the purification of amplicons 
 
Although the initial NGS runs demonstrated satisfactory results, in several of the ensuing 
experiments the NGS analysis was terminated by the MiSeq device. The reason for the 
failed sequencing was presumed to be an overloading of the flow cell which can occur in 
cases of extreme overclustering. In this respect, a cluster density of over 1.000 K/mm² 
(between 600 and 800 K clusters per mm² are optimal) was detected, indicating an 
excessive overclustering. As optimal NGS strongly relies on accurate quantification, the 
sample composition was analyzed to assess probable sources of error. This was achieved 
by closer inspection of the Bioanalyzer data of individual samples obtained after the 
purification procedure with magnetic beads. In addition to the expected amplicon in the 
size of approximately 400 bps, an additional peak at about 130 bps was detected with 
the Bioanalyzer in most of the samples (figure 17 A). Notably, the band was also faintly 
visible in the agarose gel (figure 16). This impurity might have led to inaccurate 
quantification by qPCR and consequently, to overloading of the flow cell. The additional 
peak was attributed to an accumulation of adapter or primer dimers, as the forward and 
reverse primers utilized in the second PCR amplification during NGS sample preparation 
featured a length of 63 bps, respectively. Since magnetic beads are unable to remove 
fragments longer than 100 bps, the purification approach seemed inefficient. To ensure 
the removal of the dimers, correct bands were excised after agarose gel electrophoresis 
and the DNA was extracted as described above (see 3.2.3.1). The subsequent assessment 
of the samples with the Bioanalyzer demonstrated a single peak at the appropriate 
length (figure 17 B). Since the problem of overloading did not occur in the following NGS 
experiments any more, the purification procedure was adjusted correspondingly to 
include extraction from an agarose gel. 
 
 
Figure 17 – Bioanalyzer data of an exemplary library amplicon after purification via (A) magnetic beads 
and (B) extraction from agarose gel. The x-axis shows the size of the detected samples, whereby 35 and 
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10.380 bps represent the lower and upper markers, respectively. Fluorescence units (FU) indicate the 
intensity of the samples. The arrow denotes the accumulated adapter or primer dimers (approximately 
130 bps). Notably, the dimers are completely removed from the sample after excision of the appropriate 
band and purification from the agarose gel. 
 
 
4.3.2.3 NGS background determination 
 
Before the de facto deep sequencing of samples, a proper consideration of the necessary 
coverage and cluster densities is required since both have large impact on sequencing 
performance in terms of data quality and output. In order to prevent an over- or under-
clustering which can lead to poor run performance or even sequencing failure, an 
accurate estimation of sample amounts to be loaded is essential. While the necessary 
coverage can be easily calculated given a known degree of expected diversity, the 
background level originating from the NGS device and sample preparation represented 
the sole unknown factor. The Illumina platform suffers from numerous biases due to 
imperfect chemistry and sensors 216. The main problems occur in the form of phasing 
and pre-phasing. Phasing refers to failed incorporation of a base in a given cycle leading 
to sequencing that lags behind, whereas pre-phasing refers to synthesis of multiple 
bases in a single cycle 217. This results in base-calling errors which increase with each 
cycle, subsequently, limiting the overall read length. Thus, it was important to determine 
the total number of errors that are introduced during sample preparation and by the 
MiSeq device. Therefore, samples were generated that were used to address both 
potential sources of error. 
The investigation of intrinsic MiSeq device errors was performed on a defined and error-
free reference template. The reference sample was generated by PCR amplification using 
the primers that introduce the required adapters and indices (see 3.2.2), followed by 
blunt end cloning into a pUC18-MlyI plasmid. This vector contained a MlyI-cassette that 
was inserted previously over inherent SmaI restriction sites (see 6.2.3). Correctness of 
the insert was confirmed by Sanger sequencing. Subsequently, the DNA insert was 
extracted by MlyI digestion, purified using AMPure magnetic beads (3.2.3) and could 
directly be used for the NGS sequencing. Thus, the error rate should correspond to the 
inaccuracy of the plasmid replication in E. coli (5x10-10 per base pair/round of 
replication) 218. 
In order to assess errors pertaining to amplicon generation by PCR, the samples from 
the experiment described above (see 4.3.2.1) were compared with the error-free 
reference template in the same NGS run. 
The results are depicted in figure 18 and exhibit the maximal error probability from the 
MiSeq as well as the sample preparation. As expected, the error rate from the NGS device 
(figure 18, sample 1) was relatively low, displaying about 12 mutations per 105 reads. 
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Accuracy of the Phusion DNA Polymerase was apparently only little compromised with 
increased amounts of PCR cycles during the amplification, as no distinct difference in the 
error rates between the various cycles could be identified. Conspicuous, was the 
influence of the utilized DNA quantity. The lower the initial amount of DNA applied in 
the PCR, the more errors were detected, exemplified in the sample with the lowest input 
of genomic DNA (0.004 pg, samples 5-7) displaying the most errors. All in all, the 
maximal error rate (referring to sample 7) originating from the NGS device and Phusion 
DNA Polymerase amounted to a total of 0.0004% per base for a 300 bp long amplicon. 
 
 
 
 
In conclusion, all further NGS samples were generated by amplification with 22 cycles 
for each PCR, respectively. In terms of initial DNA quantity, at least 0.1 pg genomic DNA 
extracted from >12.500 cells were generally utilized, depending on availability. This 
amount was chosen due to the seemingly reduced error susceptibility when gDNA from 
more cells were used in the amplification. Based on the above data, a background 
mutation rate of 0.0004% per base can be estimated under these conditions. 
 
 
4.3.3 Determination of the diversity of the SeqPer library on the example of the 
CD4 binding site 
 
Apart from the general DNA quality of the SeqPer library, quality controls also 
comprised analysis of the diversity. Specifically, this includes the amount of amino acids 
Figure 18 – Total error rate 
expected during an NGS run. The 
number of detected mutations 
(Nmutations) per 105 reads are shown. 
To determine the PCR conditions with 
the lowest error-rate, various 
amounts of cycles (19, 22 and 25) and 
input DNA were analyzed. Errors 
originating from the NGS device were 
assessed on an error-free reference 
sample (ref, 1). 50% PhiX was utilized 
for the NGS run. 
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and the percentage amino acid distribution at every pool-of-position. Ideally, all 20 
amino acids should be detectable for each position. Comprehensive analysis of the codon 
composition of the pDNA library was performed by NGS. Subsequently, the codons were 
translated into amino acids by using a programme that counts every codon at each 
position and delivers the absolute numbers of amino acids (see 3.2.6). In the following, 
the translated codon composition is referred to as the (decoded) amino acid 
composition of pDNA or stable cell lines. Similiary, the respective stable cell lines were 
also analyzed to assess the diversity of the pDNA and stable cell line library. This 
information was important for both the generation of stable cell lines as well as the 
assessment of results from the screening for improved Env immunogens. Low amino 
acid diversity could lead to reduced variability in the stable cell lines, thus, limiting the 
pool from which immunogens are selected. Due to the considerable size and complexity 
of the library, the diversity was determined by Next Generation Sequencing. Over the 
course of this PhD thesis, the analysis of the diversity focused exclusively on the CD4 
binding site region of the SeqPer library, as concentrating solely on this region offered 
various advantages. Firstly, the CD4bs constitutes a small and manageable area that 
demonstrated a good quality regarding the plasmid DNA from quality controls (see 
4.3.1). Additionally, with 46 positions the size was appropriate for the establishment, 
standardization and validation of most of the applied methods (e.g. NGS sample 
preparation and subsequent analysis, FACS-based screening, etc.) while keeping the 
high expenses of NGS to a minimum. Also, the CD4bs represents one of the most 
conserved and thus important regions of HIV-1 bringing forth the most potent bnAbs 
during infection. Last but not least, these CD4bs-specific bnAbs were easily accessible 
due to the established in-house production which proved to be favorable as high 
quantities of antibody that were required for multiple experiments. 
 
 
4.3.3.1 Diversity of the CD4 binding site on the level of plasmid DNA 
 
The CD4bs consists of 46 amino acids that are arranged over a stretch of 579 base pairs 
into the following four discontinuous segments on the envelope: loop D, CD4 binding 
loop, bridging sheet (bs) and variable loop 5 (V5) 219,220. Over the course of this thesis, 
the entire CD4 binding site (CD4bs) of the SeqPer library was analyzed by NGS regarding 
the available amino acid distribution in the plasmid DNA as well as in the corresponding 
stable cell lines. In consequence of the disjointed regions and the limited read length of 
the MiSeq reagent kit v2 (300 bps), the amino acid positions were divided by means of 
their functional segments into the four following DNA regions: i) loop D, ii) CD4 binding 
loop and iii) bridging sheet and iv) variable loop 5. For NGS analysis the segment pools 
were generated by pooling every amino acid position of the respective region in an equal 
ratio. 
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Figure 19 – (A) Schematic illustration of the CD4 binding site. The CD4bs consists of the four 
discontinuous segments Loop D, CD4 binding loop, bridging sheet and V5 loop. HXB2 numbering was 
applied. (B) Amino acid distribution of the complete CD4 binding site on the level of pDNA. Heights 
of the stacked bars (y-axis) represent the detected amino acids in percent at every pool-of-position in the 
SeqPer library (x-axis). To provide a clearer overview, the respective wildtype amino acid at every pool-
of-position was excluded from the data set. 
 
 
As the variable positions of the library were generated by using NNK oligonucleotides 
which encompasses 32 codons, optimally, every codon should be represented with 
3.1%. This scenario changes slightly in the case of amino acids due to the degeneracy of 
codons. For instance, the amino acids Arg, Leu and Ser are encoded by six different 
codons. Consequently, these amino acids should occur with a frequency of 6x3.1%, 
whereas the amino acids encoded by one codon, such as Met and Trp, should be 
represented with 3.1%. Irrespective of the degeneracy of codons, the optimal pool-of-
position should consist of 20 amino acids with a frequency of 3.1% for every amino acid, 
respectively. 
NGS analysis of the CD4bs on the level of plasmid DNA demonstrated a high variability 
at almost every pool-of-position with an average of 19 amino acids (figure 20 A) while 
maintaining nearly optimal distribution of amino acids. The even distribution of amino 
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acids is represented in figure 19 B by the almost equal heights of the stacked bars. In 
general, the wildtype amino acid for every pool-of-position was highly overrepresented 
in the results which was a consequence from the pooling of multiple sub-libraries that 
display variability only in one position, whereas the rest remains constant. Therefore, to 
provide a clearer overview of the frequency for the non-wildtype amino acids, the 
wildtype amino acid data was excluded from the depiction. Only a small minority of the 
pool-of-positions displayed poor diversity. These include sub-libraries S274X (loop D), 
I371X (CD4 binding loop), R432X and M434X (bridging sheet), S462X, I467X and R469X 
(V5 loop), all displaying a lower amount (between 10 to 17 aas) as well as suboptimal 
distribution of amino acids. 
 
 
4.3.3.2 Diversity of the CD4 binding site on the level of stable cell lines 
 
In addition to the diversity of the plasmid DNA, the diversity of the generated stable cell 
lines was analyzed. In this regard, stable the cell lines were investigated in all major 
stages of the overall screening procedure to assess potential changes in the amino acid 
distribution during sample preparation: i) stock directly after thawing, ii) before 
induction with doxycycline and iii) after induction (see 3.2.2.3). Thus, in the following, 
the stable cell line samples analyzed by NGS were termed ‘stock’, ‘non-induced’ and 
‘induced’. 
The results from the NGS analysis demonstrated a significant decrease of diversity by 
approximately 32% in the stable cell lines compared to the plasmid DNA (figure 20 A) 
that was initially utilized for the generation of the stable cell lines. Whereas an average 
of 19 decoded amino acids were detected in the pDNA, 14 were present in the stock and 
non-induced stable and only 12 in the induced stable cell lines (figure 20 A and B). The 
CD4 binding loop exhibited the largest loss in diversity. Furthermore, a general trend 
towards a gradual reduction in diversity could be detected from pDNA>stock/non-
induced>induced cell lines (figure 20 A, table 6). No loss in diversity between stock and 
non-induced stable cell lines was apparent. Strikingly, the nearly optimal decoded amino 
acid distribution in the plasmid DNA underwent an extreme shift towards specific 
variants in all stable cell lines (figure 20 C, S4). The results indicated that the loss of 
diversity occurred during the generation of stable cell lines. 
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Figure 20 – (A) Total number of decoded amino acids in pDNA and stable cell lines. The detected 
amino acids in pDNA and stock, non-induced and induced stable cell lines of the whole CD4bs are shown. 
Red lines and numbers denote the mean of the detected amino acids. Statistical significance (p<0.0001 for 
all samples) is indicated by asterisks and was calculated with Graphpad Prism using a Wilcoxon signed 
rank test. (B) Summary of the variability of the whole CD4 binding site on the level of pDNA and the 
stable cell line (SCL) counterpart. Analysis of SCLs was performed on stock, non-induced and induced 
pools of position. The x-axis denotes the wild type amino acid sequence of the whole CD4bs, y-axis displays 
the amount (N) of the decoded amino acids at every position in the CD4bs library. (C) Amino acid 
distribution of stock (left), non-induced (middle) and induced Loop D (right). Heights of the stacked 
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bars represent the detected amino acids in percent for every pool-of-position in the SeqPer library. To 
provide a clearer overview, the respective wildtype amino acid for every pool-of-position was excluded 
from the data set. 
 
 
4.3.3.3 Quantitative representation of amino acid diversity 
 
Diversity describes a statistical measure of sequence conservation or variation. In the 
case of the SeqPer library, diversity represents the amount of the 20 possible amino 
acids that are observed at a given position. Thus, if the pool-of-position is completely 
conserved (i.e. only one amino acid is present), the diversity is 0.05 (1/20); if the optimal 
position comprises all amino acids, the diversity is 1.0 (20/20) 221. However, possible 
differences in the distribution among the amino acids are not taken into account in this 
representation of diversity, leading to a loss of information. Here, a quantitative measure 
of amino acid variability is introduced in the form of a diversity coefficient that gives an 
estimation on the frequency of amino acids at a given position. Calculation of the 
diversity was deduced from the Wu-Kabat variability coefficient which is defined as 222: 
𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝑁 ∗ 𝑘
𝑛
     (5) 
where N describes the number of sequences, k the number of different amino acids at a 
given position and n the frequency of the most common amino acid at that position 223. 
In general, the NGS output data from all experiments was transcribed into a table listing 
the number of sequences that were assigned a specific amino acid. Since these sequences 
were subsequently converted to represent the percentage amino acid distribution, N 
was set to 1, resulting in the new equation (6): 
𝑑𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦 (𝐷) =  
𝑘
𝑛
     (6) 
with k representing the number of amino acids at a given position and n the frequency 
of the most common amino acid at that position. Notably, the calculation refers solely to 
non-wildtype amino acids. Consequently, the relative diversity Drel was calculated with 
the equation (7): 
𝐷𝑟𝑒𝑙 =  
𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 𝑑𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦
𝑚𝑎𝑥𝑖𝑚𝑎𝑙 𝑑𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦
     (7) 
From the formula (7), it follows that 0 ≤ Drel ≤ 1, with D values near 1 representing high 
variability and those near 0 almost no diversity. 
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Table 6 – Relative diversity (Drel) of the whole CD4 binding site. Diversity coefficients of pDNA and 
stable cell lines were calculated according to equation 3. Intensities of the heatmap denote the extent of 
the variability at every pool-of-position, with 0.0 representing the minimal and 1.0 the maximal relative 
diversity. 
 
 
 
Strikingly, a significant reduction in the relative diversity in the stable cell lines could be 
demonstrated confirming the emergence of an extensive bias in the amino acid 
distribution (table 6, figure 21). In addition, an incremental decrease of diversity, from 
pDNA>stock>non-induced>induced stable cell lines, was detected for most of the pools-
of-position which is consistent with the reduced amount of amino acids in the stable cell 
lines (figure 20 A and figure 21). 
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Figure 21 – Relative diversity of pDNA and the respective stable cell lines. The calculated relative 
diversity of pDNA and stock, non-induced and induced stable cell lines of the whole CD4bs are shown. Red 
lines and numbers denote the mean of the detected amino acids. Statistical significance (p<0.0001 for all 
samples) is indicated by asterisks and was calculated with Graphpad Prism using a Wilcoxon signed rank 
test. 
 
 
As the observed reduction in diversity is not satisfactory, the steps at which the bias was 
introduced during stable cell line generation, as well as appropriate solutions to prevent 
suboptimal outcomes, should be identified. 
 
 
4.3.4 Optimization of stable cell line generation 
 
The stable cell line library provides the basis for the planned screening technology. 
Consequently, any limitations or defects as for example in the case of decreased 
variability could be detrimental during the selection, and thus compromise the final 
results. Hence, an optimization of the stable cell line generation was the most obvious 
step to improve screening results. 
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4.3.4.1 Reproducibility during stable cell line generation 
 
Successful integration as in the case of stable cell line generation is a rare and random 
event. Therefore, it is reasonable to assume that the aforementioned bias could be the 
result of insufficient integration events in combination with inadequate statistical 
coverage of all amino acids. 
To analyze if the bias is randomly introduced during stable cell line generation or the 
result of a natural growth advantage or disadvantage of certain Env variants, three 
different SCLs (N276, L277, N280) were produced in triplicates under identical 
conditions. The stable cell lines were selected due to their distinct shift in bias in the 
three stages of the overall screening procedure. Subsequently, the respective amino acid 
distribution in stock, non-induced and induced samples was determined via NGS as 
described above (see 4.3.3.2). 
Even though an average variability of 19 amino acids was detected in most of the 
generated SCLs in all three stages, the frequencies of occurring amino acids varied 
considerably within all replicates (figure 22, S6). Once again, a striking bias towards 
certain variants could be determined which displayed a slight shift in stock, non-induced 
and induced samples, except for replicate N276-1 that exhibited barely any change in 
the amino acid distribution over time. For instance, in replicate 1, histidine was the 
dominantly encoded amino acid at the variable position, whereas in the other replicates 
histidine was present at low levels, while arginine and stop, or aspartic acid and 
phenylalanine were dominant in replicates 2 and 3, respectively. The results confirmed 
that despite identical conditions, the reproducibility of uniform stable cell lines was not 
possible with the standard procedure used for their generation, most likely due to the 
completely random integration. Thus, the likelihood of growth advantage or 
disadvantage of certain Env variants as cause for the emerging bias is rather low, 
suggesting insufficient statistical coverage instead. 
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4.3.4.2 Impact of the number of integration events 
 
To establish an adequate statistical coverage of all amino acids, it was presumed that the 
frequency of integrations must be increased significantly. In general, about 100-200 foci 
or colony forming units (cfu) could be detected after the completed antibiotic selection. 
However, the 200 foci did not necessarily represent 200 individual integration events. 
The actual number of integration events is likely to be far lower due to one cell division 
cycle that takes place in the time during transfection and begin of antibiotic selection 
(see 3.3.4). In this respect, it was important to determine the required number of foci to 
prevent occurrence of bias and to obtain an approximately even distribution of amino 
acids in a stable cell line. 
An increased yield of foci was suggested to be achieved in two ways: i) upscaling of 
transfection and/or ii) generating and pooling multiple SCLs of the same position. In 
respect to upscaling process, volumes of all transfection reagents and DNA amounts 
were increased ~8-fold to adjust for a transfection from a 6-well flat bottom well (9 cm²) 
to a T75 flask (75 cm²). As cells were usually transferred from 6-well to T75 flask 48 
hours post transfection according to the protocol, for this experiment the cells were split 
equally into eight T75 flask. In the second setting, multiple SCLs (1, 3 and 9) were 
generated based on the library position N276X. After the antibiotic selection procedure 
(25 days), the amounts of foci from one, three or nine T75 flasks were counted and 
pooled. The diversity was assessed by NGS as described above (see 4.3.3). 
Figure 22 – Amino acid distribution 
of stable cell line N276X. Stock, non-
induced and induced samples of SCL 
triplicates compared to the pDNA 
utilized during the generation of the 
stable cell lines. Heights of the stacked 
bars represent detected amino acids 
in percent. 
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The results from the stable cell line generation demonstrated particularly striking 
fluctuations in the yield of foci from the individual 6-well transfections, that ranged from 
four to 305 counted colony forming units (figure 23 B). Differences in the number of foci 
from the upscaled transfection could also be detected (116-404), even though they were 
less substantial than from the 6-well transfections. When looking at the diversity of the 
individual stable cell lines, the expected reduced diversity (11 amino acids) in 
combination with strong bias in the amino acid composition was observed (figure 
23 A+B). Strikingly, the analysis of pooled foci from three (total of 346 foci) and nine 
(total of 1154 foci) transfections revealed an improvement in the relative diversity. This 
was apparent especially in the pool from nine 6-well transfections which displayed a 
relative diversity of 0.31, thus confirming that an increased amount of foci could reduce 
the bias introduced during the generation of stable cell lines. 
 
 
 
 
Upscaling of the transfection by a factor of eight resulted in higher foci yields, however 
the amount of 1836 detected colony forming units was lower than anticipated, which 
Figure 23 – (A) Amino acid distribution of SCL replicates. 
One, three and nine 6-well transfections were performed 
under identical conditions and the amino acid frequency of 
pooled generated stable cell lines was analyzed by NGS. 
Heights of the stacked bars represent detected amino acids 
in percent. (B) Summary of results from the SCL 
generation. Yield of manually counted foci (N(foci)total) from 
the 6-well and T75 flask transfections, mean and standard 
deviation of counted foci from each tranfection (mean), 
amount of differing amino acids detected via NGS (N(Aa)), 
and calculated relative diversity (Drel) from pooled SCLs is 
shown. Unfortunately, no data could be acquired (NA) for the 
pool from the T75 transfection due to insufficient reads from 
the NGS run. 
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ideally should be eight-fold higher. Unfortunately, no data from the T75-pool could be 
acquired due insufficient reads obtained from the NGS run. 
The minimal amount of foci required for an ideal amino acid distribution could not be 
determined since the relative diversity of the pools neither had optimal amino acid 
distribution, nor approached the nearly ideal diversity of the pDNA samples that showed 
an average relative diversity of 0.57 (figure 19 B and table 6). Nevertheless, when 
comparing the relative diversities of pDNA samples and the pool comprising nine 
replicated stable cell lines (Drel = 0.31), a distinct improvement in the diversity could be 
detected. Consequently, the hypothesis that insufficient integration events were 
responsible for the strong bias in the amino acid composition was confirmed. However, 
the bias could be reduced by increasing the numbers of foci. 
 
 
4.3.4.3 Improvement of the transfection efficiency 
 
Another possibility to increase the number of foci could be achieved by increasing the 
transfection efficiency. In this respect, the first approach was to examine the 
effectiveness of six different transfection reagents in an identical experimental setup as 
for the usual generation of stable cell lines, i.e. transfection in a 6-well with5x105 cells. 
As a preliminary step, optimal ratios of transfection reagent and DNA amounts were 
determined for the transfection of Flp-InTM T-Rex 293 cells (see section 3.3.2). 
Analysis of the transfected cells did not reveal substantial differences for the different 
ratios of transfection reagent and DNA utilized, since mean fluorescence intensities and 
GFP positive cells mostly remained on the same level even at higher amounts of 
transfection reagents (figure 24). An exception could be seen for calcium phosphate 
where higher amounts of DNA applied in the transfection seemed to increase efficiency. 
In addition, a reduction of MFIs with increasing reagent volume could be noted for 
Lipofectamine 2000. Among the reagents, Lipofectamine 3000 demonstrated the best 
transfection efficiency, as cells displayed the highest mean fluorescence intensities, as 
well as the largest fraction of GFP positive cells (about 40%). Approximately 37% 
transfected cells were achieved with PEI and PEI Max and no difference could be seen 
between them. Lipofectamine 2000 and Fugene 6 exhibited mediocre results (~ 22%), 
whereas calcium phosphate displayed the worst transection efficiency. Considering the 
results, a 3:1 ratio of transfection reagent volume and DNA amount was utilized during 
the generation of stable cell lines in further experiments. In respect to calcium 
phosphate, 5 µg DNA was applied. 
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Figure 24 – Efficiency of different transfection reagents. Flp-InTM T-Rex 293 cells were transiently 
transfected under identical conditions utilizing six different transfection reagents (PEI, PEI Max, 
Lipofectamine 2000 & 3000, Fugene 6 and calcium phosphate). Different ratios of transfection reagent 
(+TR) were tested. For of calcium phosphate, the amount of DNA was adjusted while keeping the volumes 
of reagents constant. Negative controls (-TR) were included for every tested transfection reagent by 
replacing the reagent with water (or DNA as in the case of calcium phosphate transfection). 48 hours post 
transfection, mean fluorescence intensities (black bars) and the percentage of GFP positive cells (grey 
bars) were measured via flow cytometry. 
 
 
 
Table 7 – Yield of foci obtained 
from different transfection 
reagents. Triplicates of stable cell 
lines were generated with the six 
different transfection reagents PEI, 
PEI Max, Lipofectamine 2000 & 
3000, Fugene 6 and calcium 
phosphate. After the antibiotic 
selection process, the amount of foci 
was counted manually. 
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Strikingly, findings from the preliminary determination of transfection efficiency did not 
correspond with the final results acquired after the selection process of stable cell lines 
(table 7). Contrary to the expectations, Lipofectamine 3000 led to the lowest foci yield 
although it demonstrated the best transfection efficiency before, whereas the previously 
mediocre results of Lipofectamine 2000 produced the highest numbers of foci (448-
521). Interestingly, calcium phosphate also displayed high foci yields while the 
transfection efficiency had been below 20% in the preliminary experiment. However, 
since the efficiency was tested on transiently and not stably transfected cells, this could 
explain the striking differences. Since the limiting steps in the generation of stable cell 
lines involve not only transfection efficiency of cells but also the integration rate, the 
yield of foci could probably be further improved by adjusting transfection conditions 
according to resulting numbers of foci. Nevertheless, Lipofectamine 2000 should be 
considered as transfection reagent for the generation of stable cell lines that require an 
ideal amino acid composition since it leads to about two-fold higher foci yields than cells 
transfected with the commonly used PEI. A combination of upscaled transfection and 
Lipofectamine 2000 could lead to even higher diversity among the stable cell lines than 
observed so far. 
 
 
4.4 High-throughput screening of a stable cell line library to identify improved 
HIV-1 antigen candidates 
 
It is a generally accepted concept that the elicitation of broadly neutralizing antibodies 
could evoke protection against HIV-1 infection. This theory has been confirmed by 
various immunization studies in macaques demonstrating protection against infection 
after passive administration of bnAbs 119,168–171. However, the search for immunogens 
able to induce an efficient humoral immune response still represents a major challenge. 
In addition to the multitude of evasion strategies embodied in the virus, a lack of 
innovative screening technologies able to identify beneficial vaccine candidates are 
among the reasons to the prevailing absence of a HIV-1 vaccine. A promising concept in 
the search for favorable immunogens might be a mammalian cell display and screening 
platform. The basic concept has been developed previously by Dr. Tim-Henrik Bruun as 
part of his PhD thesis 209,224,225. The technique presumably allows the selection of Env 
variants with specific properties, such as higher affinity towards given bnAbs. In the 
course of this PhD thesis, this screening system should be applied to the significantly 
larger SeqPer library, thus enabling the isolation of Env variants with beneficial antibody 
affinity from a vast pool of mutants. Since the technology has not been tested on libraries 
in the size of the SeqPer, the selection process was performed initially on a defined 
section of the generated SCL library, the CD4 binding site, and the well-characterized 
human monoclonal bnAb, VRC01, that potently neutralized HIV via binding to the CD4 
binding site on Env. Cells expressing envelopes with increased or decreased antibody 
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affinity were selected by flow cytometry-based cell sorting, identified via NGS and the 
detected variants were validated by flow cytometric analysis of equilibrium titrations. 
 
 
4.4.1 Overview of the mammalian cell-display-based screening technology 
 
The generated stable cell lines provided the basis for the mammalian cell display-based 
screening technology allowing the identification of favorable Env immunogens from the 
SeqPer library (figure 25, 1-2). The stable cell line library featured a major benefit: due 
to the sole FRT site in the Flp-InTM T-Rex 293 cells, only one Env variant can be integrated 
into the genome, therefore, establishing a linkage between geno- and phenotype 
regarding the proteins on the cell surface. After induction and following expression of 
the Env library (3), the screening procedure could be commenced. In this process, 
surface envelopes were stained with a screening antibody (4) and subsequently, 
variants displaying the highest and lowest affinities towards the antibody were selected 
by cell sorting (5). In this respect, variants with the highest or lowest antibody affinity 
in relation to the eGFP expression were enriched. Since a correlation between eGFP and 
Env expression was observed (according to data from 213), eGFP was utilized as an 
indirect marker to normalize for Env expression. In order to identify the selected 
envelope variants, genomic DNA was recovered, amplified and characterized by Next 
Generation Sequencing (6-7). 
 
 
Figure 25 – Schematic workflow of the mammalian cell-display and screening platform. The 
technology consists of seven steps. Firstly, a stable cell line library (SCL library) is generated based on the 
SeqPer plasmid library by targeted transfection of Flp-InTM T-Rex 293 cells with a pQL13-Env sub-library 
and the helper plasmid pOG44 (1+2). Due to the single integration locus in the cells, only one Env variant 
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is inserted into the host genome, therefore, resulting to a linkage between pheno- and genotype. 
Hygromycin resistance serves as antibiotic selection marker for successful integration. After induction of 
Env expression by addition of doxycycline (3), surface proteins were stained with the screening antibody 
VRC01 (4). Subsequently, the cells underwent flow cytometry-based sorting to select Env variants with 
the desired phenotype (5). Genomic DNA of sorted cells and input controls was recovered for the ensuing 
amplification by PCR (6). Env variants were then analyzed and identified by Next Generation Sequencing 
(7). Figure was freely adapted from 224. 
 
 
4.4.2 Purification and validation of the bnAb VRC01 
 
The CD4bs-specific broadly neutralizing antibody VRC01, utilized in the screening of the 
SeqPer library, was generated by transient transfection of the variable heavy and light 
chains into Expi293FTM suspension cells (see 3.3.3). Purification of 80 mL supernatant 
of transfected cells via a Protein A-Sepharose column (see 3.4.1) resulted in a total 
antibody yield of approximately 19 mg. Proper assembly of the antibody was assessed 
by SDS-PAGE (see 3.4.3). The expected fragment sizes for heavy and light chain could be 
detected at approximately 50 and 25 kDa, respectively (figure 26 A). Analysis of the 
VRC01 affinity for a soluble BG505 gp140 envelope protein by ELISA demonstrated a 
slightly improved binding for Env compared to a VRC01 reference batch (figure 26 B) 
obtained from the NIH AIDS Reagents Programme (#12033). 
 
 
Figure 26 – (A) SDS-PAGE analysis of the monoclonal bnAb VRC01 under non-reducing and 
reducing conditions. 2 µg VRC01 previously purified via Sepharose-A affinity chromatography was 
utilized in the electrophoresis. The left lane represents non-reduced, whole VRC01 (~ 150 kDa). Bands at 
50 and 25 kDa indicate the variable heavy and light chains of the antibody, respectively (reducing 
conditions, right lane). (B) Envelope ELISA of purified VRC01. Binding affinity of newly generated 
antibody toward a soluble HIV-1 BG505 gp140 envelope protein was compared to a VRC01 reference 
batch. PBS served as negative control to determine unspecific binding of the antibody. 
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4.4.3 Identification of Env variants with increased or decreased binding affinity 
for the bnAb VRC01 
 
The screening for Env variants displaying increased or decreased binding affinity 
toward the bnAb VRC01 was performed on batches of induced stable cell lines that 
comprises the variants of the residues forming the CD4 binding site. To determine 
potential limitations of the mammalian screening technology, the four different cell 
batches with increasing numbers of pools-of-position belonging to the CD4bs were 
generated: i) one pool-of-position (T278X), ii) five positions (first part of loop D), iii) 15 
positions (whole loop D + first part of the CD4 binding loop) and iv) 46 positions (whole 
CD4bs). Notably, the T278X position was part of each batch and served as a positive 
control since increased affinity of VRC01 towards the variants T278A and T278H (HXB2 
numbering) has already been confirmed independently by Veronika Grassmann 213 and 
Christina Schmalzl 226 in similar experiments. 
The induced stable cell line batches (i-iv) were sorted individually on the same day with 
identical settings. The gating strategy ensured that only singlets and living cells were 
selected (figure 27 A). In addition, triangular shaped gates were chosen to sort cells with 
the highest or lowest VRC01 signal in relation to the GFP signal, thus selecting cells with 
the presumably highest or lowest antibody affinity in relation to GFP expression (figure 
27 A). Selected variants were subsequently identified by Next Generation Sequencing 
following the procedures described above (see 3.2). Through comparison of the sorted 
samples with input material that was drawn prior to the screening procedure, a fold 
enrichment or depletion of specific Env variants could be calculated 227 (figure 27 B, S4-
6). Mutations demonstrating increased (high affinity gate P4) or decreased affinity (low 
affinity gate P5) toward VRC01 are referred to as ‘gain-of-binding’ (GoB) or ‘loss-of-
binding’ (LoB) variants, respectively. 
The sort was performed with 30x106 cells of which 30.000 cells were sorted into the 
high affinity gate. Sorting of the low affinity gate was stopped after the required number 
of cells in the high affinity gate was collected (usually 2-3x105 cells). When analyzing the 
results from all sorts, a total of 79 individual GoB and 73 LoB candidates were detected 
which exhibited a >1.5-log2-fold enrichment in the high or low affinity gates (figure 27 B, 
S4-6). A wide array of the variants that displayed enrichment in a specific gate originated 
from T278, highlighting it as a particularly sensitive and relevant position for VRC01 
recognition. Notably, mutations T278A and T278H could be detected as GoBs in most of 
the sorts. 
Positions 276 and 278 were of specific interest in the analysis, since they are part of the 
N276-X277-T278 motif, a crucial N-glycosylation site at the CD4 binding site. This glycan 
was previously reported to prevent interaction between germline VRC01 and Env due 
to a steric clash. Thus, a removal of this glycan by substitution of either N276 or T278 
was confirmed to improve accessibility of the CD4 binding site for VRC01 191. Strikingly, 
the sorts resulted in many substitutions at position 278 which displayed increased 
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affinity for mature VRC01, whereas no mutation at position 276 exhibited an influence 
on antibody affinity. Similar results were obtained by Veronika Grassmann which 
indicated that the beneficial effect of glycan removal at N276 could supposedly be 
abolished by a negative structural effect of a mutation on the CD4bs, as mutation showed 
significant reduction of sCD4 binding 213. 
 
 
Figure 27 – (A) Gating strategy of the FACS-based screening procedure. A representative sorting 
experiment is displayed (30.000 events of 30x106 sorted cells shown). First, living, single cells were gated 
(P1-3). The cells separated into populations of uninduced (low GFP/low APC) and induced cells displaying 
high GFP and either high or low APC signals depending on the affinity of VRC01 to the Env variants. 
Induced cells were gated for highest (P4) or lowest (P5) APC signals (VRC01) in relation to GFP, thus 
resulting in triangular-shaped gates. (B) Enrichment rates from the sorting of one and five pools of 
position (gate P4). Enrichment is represented as log2-fold change in the number of the respective NGS 
reads for each variant compared to the input sample drawn prior to the sorting. The extent of enrichment 
(green) or depletion (red) is indicated by the intensity of the respective color. Columns denote the wild 
type amino acid and its position in the library, whereas rows denote the enriched amino acids from the 
respective pool-of-position. Wild type and variants that could not be detected in the sorting were referred 
to as WT or n.d. (not detected), respectively. (C) Summary of variants demonstrating the highest fold 
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change increase or decrease in affinity towards VRC01. With exception of the screening of one pool-
of-position, three mutations (four from the GoB sort iv) from each sorting were selected for further 
characterization. HXB2 numbering was applied. 
 
 
Simultaneously, specifically the variants T278A and T278H were confirmed as gain of 
bindings during similar screenings from another available library (alanine scanning 
library) that were performed by Veronika Grassmann 213 and Christina Schmalzl 226. 
Overall, unfortunately, the results proved to be ambiguous since only five GoBs or LoBs 
were identical in the individual sorts from the different cell batches (i.e. GoBs 
T278Q/T278R from sort i, ii and iv, but not in iii) and none of them could be found in all 
sorts. Furthermore, certain variants were detected as ‘gain’- as well as ‘loss-of-binding’ 
variants, as in the case of T278A (sorts i and ii) and T278H (sorts i, iii and iv) (figure 27, 
S4-6). The inconclusive results indicated potential problems either in the gating strategy 
or limitations of the screening technology (see 5.4). 
To check the screening results, three variants with the highest fold change from every 
sort (i-iv) were selected for further characterization (figure 27 C) 
 
 
4.4.4 Optimization of the gating strategy 
 
One possible cause for the inconsistent sorting results could be an unfavorable gating 
strategy. To obtain more information from cell sorting, a new gating strategy was 
applied to address several points of interest pertaining to: i) analysis of variants 
enriched in all detected populations, ii) reproducibility of results originating from the 
same gate and iii) stringency of placed gates. For this purpose, all populations of the 
induced stable cell line T278X were arranged into specifically set gates (figure 28 A) and 
analyzed via NGS (figure 28 B). Reproducibility was addressed by sorting the cell sample 
from one gate in triplicates (P4), whereas stringency was attained by shifting gate P4 
two times upwards (P9, P10) to obtain variants with the highest measurable binding 
signal for VRC01 in relation to GFP. With a starting population of 90x106 cell, in the 
following, 3x104 cells were acquired from each gate. As there were insufficient cells at 
the end of the sorting, 15x103 cells from the reproducibility gate (P4) and 5.000 cells 
from gates P9 and P10 were collected. 
Notably, even though cells separated into three predominant, easily distinguishable 
populations during the sorting (i.e. cells with high APC/high GFP (gates 
P4/P5/P7/P9/P10), high APC/low GFP (gate P6) and low APC/low GFP signal (gate 
P8)), predominantly the two variants T278A and T278H were unexpectedly enriched 
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irrespective of the placement of the gates. The results could be the cause of too closely 
situated gates in combination with low sensitivity of the sorting device. In respect to 
reproducibility, the sorting displayed very similar enrichment rates among the 
triplicates. More stringent gating seemingly increased the sensitivity for detecting 
specific variants which was noticable in the lower amounts of identified variants and the 
slightly elevated enrichment rates of T278A and T278H. Consequently, the increased 
selectivity of gates P9 and P10 highlighs the necessity of a more stringent gating 
strategy. 
 
 
Figure 28 – (A) Different gating strategies for the FACS-based screening procedure. Living, single 
cells were gated as before (figure 25 A). Gates were chosen to address the whole population (left), 
reproducibility (P4 was sorted in triplicates) and stringency (middle +right). (B) Enrichment rates from 
the sorting of pool-of-position T276X according to the new gating strategy. Enrichment is 
represented as log2-fold change in binding compared to the input sample withdrawn prior to the sorting. 
Extent of enrichment (green) or depletion (red) is indicated by the intensity of the respective color. Wild 
type and variants that could not be detected in the sorting were referred to as WT or n.d. (not detected), 
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respectively. Notably, mutations T278A & H were predominantly detected from every sort irrespective of 
the gate placement (indicated by red boxes). 
 
 
4.4.5 Validation of the detected GoB and LoB variants 
 
Three variants of every screening having the highest fold change increase or decrease in 
affinity towards VRC01 were selected to verify if the screening procedure and if the 
results yielded valid results. For this purpose, single mutation variants as well as the 
respective stable cell lines (figure 27 C) were generated and their affinity profiles for 
VRC01 were analyzed by flow cytometric equilibrium titration. This was achieved by 
staining the transfected cells or induced stable cell lines with a dilution series of VRC01-
Alexa647 (see 3.3.5). 
Titration experiments were intended to determine the dissociation constant (KD) of the 
VRC01 antibody and an Env protein. However, this was not possible in this case since 
none of the binding curves reached saturation levels even at very high antibody 
concentrations (figure S8). However, a slight indication toward saturation could be 
recognized for the binding curves of stable cell lines. Therefore, the area under the curve 
was calculated and used for the analysis  
In general, the titration results between the transiently transfected and stable cell line 
variants did not differ considerably, with the exception that stable cell lines always 
displayed lower mean fluorescence intensities than transiently transfected cells. 
Notwithstanding, this did not influence the outcome of the titrations. 
The overall picture of results for transiently transfected LoB-Env-variants and their 
stable cell line counterparts proved to be almost identical, with six variants displaying a 
loss in affinity towards VRC01 (figure 29 C+D). Notably, variants E275F, E275T and 
D368E demonstrated statistical significance (figure 29 C+D, table S1) in both, transiently 
transfected cells and stable cell lines, whereas L277Q and A365D displayed significance 
only in transiently transfected variants. Although detected as ‘loss of bindings’ during 
the selection procedure, a slight if not significant increase in affinity for VRC01 was 
visible in four variants, with three of them involving position T278. These results were 
in accordance with the findings of Veronika Grassmann, that confirmed a generally 
increased affinity for VRC01 for most amino acid substitutions at position T278 213. 
Additionally, analysis of the GoB-variants demonstrated increased binding for five 
variants at the same position, even though they were apparent only in the stable cell 
lines and did not exhibit statistical significance (figure 29 A+B, table S2). Furthermore, 
transiently transfected GoB-Env-variants did not display a distinct increase of binding, 
but rather a majorly wild type-like affinity. Assumedly, the results might be attributed 
to the high standard deviation of the WT. Many variants unexpectedly even showed a 
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severe loss of binding for VRC01 that could be reproduced in the stable cell lines. In this 
respect, the GoB-variant G367C (p = 0.0004) was highly statistically significant. 
In addition, there seemed to be no connection between the ‘number of amino acid 
positions’ (one, five, 15 or 46 positions) applied in the sorts and the selected GoB- or 
LoB-variants which could have explained the inconsistencies in the selection procedure. 
 
 
Figure 29 – FACS equilibrium titration of GoB- and LoB-variants with the bnAb VRC01. Three 
variants with the highest fold change increase in affinity from one, five, 15 and 46 pool-of-position (N) 
sorts were analyzed. Areas under the curve (AUC) of (A+C) transiently transfected variants and their 
respective (B+D) induced stable cell lines were analyzed and compared with the 16055 gp145 wild type. 
Statistical significance was determined with Excel using a two-sided, homoscedastic t-test and corrected 
according to Bonferroni to adjust for multiple testing. Variants that exhibited p-values <0.0042 were 
considered significant and are indicated by asterisks. 
 
 
 
 
 
 
__________________________________________________________________________________ 
71 
 
Discussion 
5 Discussion 
 
The focus of this PhD thesis was the characterization and optimization of a sequential 
Env permutation library. In a first step, the general quality of the library was analyzed 
on the level of pDNA (see 4.3.1 and 4.3.3). Plasmid DNA was then utilized to generate the 
respective stable cell lines that were characterized regarding their diversity in Env 
variants and their amino acid distribution. As the stable cell lines displayed reduced 
amounts of Env variants which featured also a strongly biased amino acid composition, 
various optimization approaches for the generation of stable cell lines were tested (see 
4.3.4). A novel flow cytometry-based technology was devised to screen the library for 
Env variants with increased or decreased affinity for bnAbs (see 4.4.3). Due to the size 
of the library, only the CD4 binding site was used in the selection procedure as a proof 
of concept and to assess efficiency and possible limitations of the system. Subsequently, 
selected variants that showed a substantial impact on the affinity of the bnAb VRC01 
were validated by flow cytometric analysis of equilibrium titrations (see 4.4.5). 
 
 
5.1 Evaluation of the SeqPer library 
 
5.1.1 Advantages of the sequential permutation library 
 
The design of the SeqPer library provides several benefits. One of the advantages was 
represented in the utilization of the C-clade strain 16055 as it addresses the globally 
most prevalent HIV-1 subtype. A special feature of the library was the sequential 
substitution of every residue in the external part of Env with all 20 aas, resulting in 658 
sublibraries and approximately 10.000-13.000 different Env variants in total. The 
considerable size of the library renders the individual characterization rather difficult, 
thus, a high-throughput screening system is required. In addition, the many different 
Env variants create a vast pool from which mutant proteins with desired properties can 
be selected. In respect to this thesis, the Env library should be utilized to identify 
potential vaccine candidates with specific antigenic profiles. 
Due to the considerable size of the library, comprehensive quality controls have been 
conducted to asses whether the intended diversity was achieved for the plasmid DNAs 
obtained from the gene synthesis provider, and whether this diversity is maintained 
over all steps of stable cell line generation and screening (see figure 25). 
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5.1.2 Quality of the pDNA and the possible implications 
 
In-depth analysis of the pDNA of the SeqPer library revealed deletions that occurred 
majorly in the Env region and to a lesser extent in the vector region as the main problem 
(section 4.3.1). The detected errors affected approximately 48.3% of the library and 
occurred most likely during the DNA manufacturing procedure. Although many of the 
library positions displayed errors, these errors did not afflict the whole sublibrary as the 
plasmid mixture contatined predominantly the correct plasmid and only 6-18% actual 
errors were detected within the affected positions (see 4.3.1.3). Although unfortunate, 
these findings were not too surprising as gene synthesis and the resulting products 
unavoidably contain errors such as deletions, insertions, or base substitutions due to 
mistakes in chemical oligonucleotide synthesis and subsequent enzymatic gene 
assembly procedures 228. However, as only a minor part was affected, the library was 
deemed acceptable for further experiments. Nonetheless, one must be aware that flaws 
in the quality of the library delineated the first line of errors and could have created 
implications for the subsequent experiments. It cannot be ruled out that the generation 
of stable cell lines was affected by deletions in the Env regions since incomplete Env 
sequences might have been integrated into the host genome, thus leading to either 
lacking protein expression or expression of misfolded, non-functional Env variants on 
the cell surface. However, it is unlikely that aberrational and normal variants competed 
for integration as erroneous plasmids represented only a small percentage. Hence, there 
should be merely a minor impact for stable cell line generation. 
Strikingly, the sublibraries demonstrated a high diversity with an average of 19 decoded 
amino acids on the level of pDNA, as well as near optimal amino acid distribution. 
Unfortunately, several sublibraries did not display the ideal composition of 20 amino 
acids. A possible solution might be to generate the positions with the lowest diversity 
anew or if only few variants are missing in the pools, single variants could be generated 
by cloning and supplemented to the respective pools-of-position. In respect to the stable 
cell lines, however, the latter solution might be inefficient, as too many Env variants are 
missing within the pools. Generating new stable cell lines might be less time- and cost-
consuming. 
 
 
5.1.3 Impact of stable cell line quality on cell-display-based screening 
 
The genomic integration of the library vector pQL13 at a single, distinct FRT site, allowed 
the generation of a stable cell line library with linked genotype and phenotype of the 
respective env gene and the corresponding protein per cell. This library was utilized in 
the screening for improved Env immunogens. Unfortunately, a considerable reduction 
in the amino acid diversity on average by 38% alongside a strongly distorted amino acid 
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composition was detected in all analyzed stable cell lines (4.3.3.2). In particular, the CD4 
binding loop was the most affected regarding the loss of diversity (figure 20 B). The 
reason for that could be due to daily experimental fluctuations, as usually batches of 15 
to 20 stable cell lines were generated simultaneously, which might explain why 11 
positions in a row demonstrated such a low diversity. To improve the diversity of the 
CD4 binding loop, the respective stable cell lines should be created anew for further 
experiments. 
As the SCL library represented the basis for cell display and cell sorting-based selection 
for improved immunogens, it can be reasonably assumed that any obtained data 
reflected the stable cell line quality. Reduced variability signified a smaller pool for the 
selection procedure and thus, not the whole spectrum of possible Env candidates was 
available during the screening. In addition, it was highly likely that the strong bias in the 
amino acid composition would result in inaccurate enrichment of immunogens favoring 
amino acids which were strongly overrepresented. In accordance with this hypothesis, 
the data obtained from the cell sorting and flow cytometry experiments revealed several 
discrepancies. This was shown specifically in the enrichment of the variants T278A and 
T278H which were detected as GoB-variants, as well as LoB-variants in some of the 
sorting experiments (see 4.4.3). Also, as every sorting experiment enriched different 
variants, no consensus between the sorted variants was found. T278A and T278H 
represented an exception since they were enriched in almost all sorts (see 4.4.3, S5-S6). 
In addition, although several Env candidates with high or low affinity for VRC01 were 
identified in the sorting experiments, from the 24 tested variants (12 GoB- and 12 LoB-
variants with the highest enrichment factor in the high or low affinity gate) no GoB- and 
five LoB-variants (E275F, E275T, L277Q, D368E and A365D) could be truly validated by 
FACS equilibrium titrations (see 4.4.5). Although unknown limitations of the screening 
technology cannot be ruled out as possible reasons for the outcome of the screening, it 
stands to reason that the quality of stable cell lines was one of the main factors 
influencing the experiments. Thus, optimizing the generation of stable cell lines is 
imperative before accurate data can be obtained. 
 
 
5.2 Improvement of stable cell line generation 
 
5.2.1 Identification of factors influencing SCL generation 
 
Whereas transient transfection is beneficial for quick analysis of genes and protein 
production on smaller scales, stable transfection ensures long-term, reproducible and 
defined gene expression. As described above, stable transfection of multi-variant 
sublibraries were utilized to create cell lines expressing a single Env protein on the 
surface of mammalian cells. Analysis of stable cell lines demonstrated a loss in diversity 
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of amino acids, as well as an excessive shift in the amino acid distribution which 
assumably occurred due to insufficient integration events. However, the generation of 
stable cell lines encompasses many steps as the plasmid with the gene of interest needs 
to be introduced first into the cell, then into the nucleus and finally it needs to be 
integrated into the host’s genome. Accordingly, there are many possible sources that 
could lead to such a bias as described above (see 4.3.4). 
Since stable integration of foreign DNA into the genome is a relatively rare event that is 
aggravated by possible inactivation via epigenetic mechanisms 229, it was hypothesized 
that it represented the most influencing and limiting factor during cell line generation. 
Unfortunately, tracking of integration events proved to be a difficult endeavor, as 
evidence of successful insertion was provided only by the amount of foci or colony 
forming units after the selection process. Furthermore, the resulting amount of foci can 
be misleading because not every colony necessarily represented a different Env variant. 
In addition, it was assumed that the diversity of the resulting foci is further reduced 
during the stable cell line generation. As cells remain in the 6-well for approximately 48 
hours post transfection before they are transferred into a T75 flask, one cell division 
cycle occurs in this period. This fact was revealed by manually counting the amounts of 
cells 24 and 48 hours after transfection for samples that were specifically prepared for 
that purpose (amounts doubled during that time from 5x105 to 1x106 cells). Therefore, 
the diversity of the resulting stable cell lines might be reduced by a factor of two. 
Eventually, it could be confirmed that the bias was introduced during the generation of 
stable cell lines due to inefficient and insufficient integration of Env (4.3.4). Assumably, 
a considerable increase of foci was hypothesized to reduce the occurrence of bias. This 
supposition was confirmed by the incrementally improved relative diversty of 0.03, 0.13 
and 0.31 after pooling the cells from one, three and nine transfections, respectively. In 
particular, the results from nine transfections indicated that the integration events from 
one transfection were not sufficient to generate a satisfactory amino acid diversity. 
Unfortunately, an ideal aa composition was not achieved with 1154 foci (total number 
of foci from nine transfections) (see 4.3.4.2) and the total number of foci to ensure 
optimal distribution could not be determined. In this respect, only a hypothesis can be 
made according to basic mathematical calculations. If 1154 foci generate a relative 
diversity of 0.31, then it might be reasonable to assume that approximately 4000 foci 
might lead to the ideal relative diversity of 1.0 which represents an even amino acid 
distribution. However, standard transfection protocols and utilization of alternative 
reagents failed to create high enough foci yields from a single transfection, although 
several transfection reagents such as Lipofectamine 2000 generated two-fold higher 
numbers of foci. In this respect, only upscaling of the transfection provided a slight 
improvement in the yield (1836 foci from an eight-fold upscaled transfection). If the 
mathematical connection mentioned above can be applied here, two T75-transfections 
might be sufficient to generate the assumedly 4000 required foci. Accordingly, in order 
to further reduce the bias, a combination of upscaled transfection and optimal reagents 
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should be employed during generation of such stable cell lines. Further suggestions for 
optimization are discussed in section 5.2.2. 
There are also many additional factors that could influence transfection efficiency which 
require careful consideration. These include: i) quality of transfected DNA, ii) ratios 
between transfection reagent and DNA, iii) viability of cells and iv) variations in the 
transfection efficiency between different Env variants. It cannot be ruled out that 
additional unknown determinants are involved. 
 
 
5.2.2 Possible optimization approaches 
 
The initial step of stable cell line generation involves the transfer of library constructs 
into the cells. Thus, it stands to reason that improvement of the transfection conditions 
(i.e. optimal ratio of reagent and DNA, ideal DNA quality and cell viability, etc.) and 
efficiency might increase the chance of integration events. Choosing the right 
transfection reagent for the selected cell type is as important as the method of 
transfection to minimize unnecessary damaging of cells. Lipofectamine reagents are 
widely accepted as ‘gold-standard’ for the safe and gentle delivery of DNA into cells due 
to their high transfection efficiency across a broad range of cell lines 230. The increased 
yield of foci that was obtained from transfections performed with Liopfetamine2000 
corroborated this notion. Therefore, transfection protocols should be based on 
Lipofectamine-mediated transfection. 
The advantageous effect of Lipofectamine can be supported by synchronization of the 
cell cycle phase as it has been repeatedly reported that gene transfer into cells is 
dependent on the cell cycle 231–233. Cells arrested in their S- or G2-phase by treatment 
with mimosine, aphidicolin or thymidine demonstrated an at least three-fold increase in 
the percentage of transfected cells compared to untreated cells 231. 
Additionally, it has been reported that nuclear targeting and entry of plasmid DNA can 
be enhanced, for instance, by using a 366 bp sequence of DNA containing the SV40 origin 
of replication and early promoter known to bind to a number of general transcription 
factors. This sequence was reported to favorably promote nuclear import 55,234. Thus, 
implementation of the sequence into the library vector could be a promising approach 
to facilitate transfer of plasmid DNA into the nucleus of cells irrespective of their cell 
cycle phase. 
Tracking and active selection of successful integration events could prove very helpful 
in optimizing the generation of stable cell lines. In this respect, the availability of eGFP 
in the described constructs might be a reliable reporter. Cells with successful insertion 
can be directly identified and isolated by FACS cell sorting according to GFP 
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fluorescence 229. However, this approach relies on a sterile environment during and after 
the cell sorting, as the selected cells would be further cultivated. 
Since the number of foci is assumedly inaccurate to quantify the integration events (see 
5.2.1), insertion of reporter plasmids carrying a distinct index (sufficiently long NNNN-
sequence) might be a possible solution. Due to the fact that every cell integrates a 
different sequence, the total number of integrations that took place during stable cell 
line generation can later be determined by NGS analysis. 
It also might be worth considering creating single mutation stable cell lines and pool 
them equally to create a defined and controlled amino acid composition. However, this 
is not applicable for a library of the size of the SeqPer as this approach is time-and cost-
intensive. Although it can be utilized for a limited amount of interesting positions as in 
the case of the Loop D of Env where the major contact sites for VRC01 reside. 
 
 
5.3 Adaptation of NGS sample preparation for library applications 
 
Due to the considerable size of the SeqPer library, gathering of important data by Next 
Generation Sequencing became indispensable, as it allowed the simultaneous analysis 
of thousands of different sequences. In this PhD thesis, the Illumina MiSeq NGS sample 
preparation was successfully adapted for applications regarding genomic libraries. 
Generally, the core steps in preparing DNA for NGS analysis are: i) fragmentation and/or 
sizing of target sequences to a desired length, ii) attachment of oligonucleotide adapters 
5’ and 3’ of fragments and iii) quantitation of the final library product for sequencing 235. 
Although there are several approaches available to fragment DNA sequences, such as 
physical (i.e. sonication, hydrodynamic shearing), chemical (heat digestion with divalent 
metal cation), and enzymatic (non-specific nuclease, transposase, DNaseI, restriction 
endonuclease) methods, the latter in the form of amplification of DNA sequences by PCR 
was favored in the course of this PhD thesis. The resulting library products had a 
homogeneous and defined fragment size of approximately 300 bps. This was beneficial, 
since the env gene comprising approximately 2.1 kbs cannot be analyzed in its whole 
length with the Illumina technology. Therefore, a smaller fragment was chosen as a 
model that encompassed 300 bps which could be easily obtained by PCR amplification 
and which was eligible for the commonly used MiSeq Reagent Kit v2 (300 cycles). In this 
way, the whole env gene could be covered by creating eight overlappying 300 bp long 
fragments via PCR amplification. Simultaneously, oligonucleotide adapters as well as 
indices could be attached during the amplification steps, therefore bypassing expensive 
adapter ligation kits. Notably, adapter sequences were chosen to provide a well-
balanced AT- and GC- content. 
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Although purification of the PCR samples with magnetic beads (see 3.2.3.2) showed 
initially good results, several NGS runs were aborted by the MiSeq, presumably, due to 
overloading. On closer inspection of the bioanalyzer data after magnetic beads 
purification, the results demonstrated an accumulation of adapter or primer dimers at 
the length of approximately 130 bps (figure 17 A). Since magnetic beads fail to remove 
DNA fragments with >100 bps, it stands to reason that the removal of dimers by 
magnetic bead purification seemed inefficient. In addition, the dimers might be able to 
bind to the NGS flow cell. As a consequence, the flow cell capacity is reduced which could 
have resulted in an overloading of the NGS chip. To prevent this outcome, gel purification 
after the second PCR to remove adapter dimers (see 3.2.3.1) proved to be successful 
(figure 17 B), since the problem of overloading did not occur in the following NGS 
experiments. 
As amplification can be susceptible to a bias resulting from the error-prone nature of 
polymerases, careful selection of enzymes for PCR, thermocycling conditions as well as 
the proper amount of starting material is necessary. A systematic analysis of error rates 
from PCR-related sources obtained under various conditions demonstrated that 22 
cycles were best in terms of yield and the occurring error rate (see 4.3.2). Although the 
amount of DNA has to be chosen according to availability, however, not less than 1 pg is 
advisable regarding genomic DNA, as an increase in errors was associated with lower 
quantities of input genetic material. 
Moreover, an accurate library quantification is required to prevent over- and 
underloading of the NGS flowcell. In this respect, the Kapa Library Quantification Kit was 
favored for qPCR due to the provided highly stable standards and the polymerase that 
was specifically engineered to amplify diverse DNA fragments with similar 
efficiencies°236. 
A total of 9-10 pM sample was usually loaded on the flow cell. Higher amounts lead to 
overloading and to abortion of the NGS run, whereas lower amounts resulted in 
decreased generation of clusters as well as reads. 
In general, a spike-in of 5-10% of a PhiX library is performed into the prepared library 
samples to provide a quality control for cluster generation. However, this amount is only 
applicable for samples with an evenly balanced AT and GC content. This was not the case 
for the SeqPer library as merely one position of the whole env gene was substituted in 
each sublibrary. Thus, the rest of env sequence remained constant and resulted in an 
unbalanced base composition of NGS samples. Unfortunately, the Illumina system has 
been reported to be sensitive regarding extreme base compositions (i.e. GC-poor or GC-
rich sequences), often leading to an uneven coverage or no coverage of reads across the 
genome due to phasing 237–240 (see 4.3.2.3 for more details). To prevent such an outcome, 
20-30% PhiX library were usually added to the NGS samples. 
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5.4 Analysis of a mammalian cell-display-based screening technology 
 
5.4.1 Advantages of the mammalian cell-display technique 
 
The herein described mammalian cell-display technology provided several advantages 
compared to other currently used methods. In contrast to yeast 241,242 or phage display 
243,244, Env proteins are expressed in their trimeric conformation on widely used Hek293 
cells which ensure mammalian glycosolyation as well as native folding. This is 
particularly beneficial since glycan-dependent epitopes 138,140 on Env are preserved. To 
prevent shedding of gp120, the furin cleavage site was mutated from REKR to REKS. 
Unfortunately, it was recently reported that the mutation of cleavage sites disturbs the 
quaternary structure of Env 245 and thus, analysis with certain structure-dependent 
antibodies such as PG145 or 35O22 is excluded. Nevertheless, antibodies recognizing 
monomeric Env, as in the case of VRC01 and PG9, are not affected by this conformational 
change and are eligible for the screening technology. In the case of conformational-
dependent antibodies, however, Env proteins with the correct conformation are 
required which is achieved either by efficient cleavage complemented by additional 
stabilization as in the case of the SOSIP-variants (see 1.8.1). 
In addition, the library vector pQL13 featured several benefits. Firstly, translational 
coupling of Env and eGFP was achieved by insertion of a TaV 2A peptide 211 between the 
genes. Therefore, GFP represented an independent component that could be utilized to 
normalize deviations in expression levels of different Env variants. This bypasses 
normalization via co-staining with secondary reagents and the problems that could arise 
due to sterical constraints caused by simultaneous staining with two antibodies (i.e. 
screening- and reference antibody). The described normalization approach has been 
successfully demonstrated previously by Dr. Tim-Henrik Bruun 209,224,225. Due to 
regulation of the eGFP and Env expression by an inducible Tat operator/repressor 
system, Env cytotoxicity effects during cell cultivation could be eliminated. 
 
 
5.4.2 Evaluation of the screening technology 
 
Env variants with increased and decreased affinity for bnAbs were selected with a FACS 
cell sorting-based screening technology which was described above (see 3.3.6 and 4.4.1). 
In an initial sorting experiment, an enrichment of several Env candidates with the 
desired characteristics was demonstrated by screening the CD4bs using the CD4bs-
directed antibody VRC01. To assess possible limitations of the selection system, one, 
five, 15 and 46 permutated positions of the CD4bs, i.e. approximately 14, 70, 210 and 
644 different variants (numbers were based on the average of 14 detected amino acids 
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in the stable cell lines) were used in the screening, respectively. Among the enriched Env 
mutants, the GoB-variants T278A and T278H proved to be the most promising 
candidates with increased affinity to the VRC01 antibody as they were also identified 
independently by Veronika Grassmann and Christina Schmalzl 226 with another library 
using the same screening technology. Corresponding with their data, T278H was slightly 
superior to the T278A mutant (one to three-fold increased affinity), as it showed a 
slightly higher affinity for VRC01 which ranged between two to four-fold increase 
depending on the sort. The superiority of T278H also correlated with the structural 
analysis and is discussed in section 5.4.3. Unexpectedly, there was only a statistically 
significant difference in the antibody binding in flow cytometric equilibrium titration 
experiments for three of the LoB-variants and none for the 12 GoB-variants as compared 
to the wildype Env. Whereas loss in binding can easily occur due to structurally 
detrimental mutations, gain of binding is more difficult to achieve. It has been suggested 
previously that several mutations are necessary to evoke a distinctly increased affinity 
for VRC01 191,246. Thus, a single point mutation is unlikely to accomplish enhanced 
binding for the antibody. 
Furthermore, results were often not reproducible as none of the variants were detected 
in all screened pools. Also, several substitutions were enriched as both, GoB and LoB 
variants, such as in the case of T278A and H. The incongruent data indicated limitations 
or problems with the screening technology, probably in combination with an 
unfavorable gating strategy. The latter was demonstrated by the same enriched variants 
(T278A & H) irrespective of the gate placement, so even in the LoB gate (see 4.4.4). 
Additionally, the unequal amino acid composition and diversity of stable cell lines might 
largely contribute to the inconclusive results. In this respect, measurements should be 
repeated with newly generated and improved stable cell lines to assess in what way an 
extreme composition in stable cell lines might influence data from screening procedures. 
The selection technology was developed and tested by Tim-Henrik Bruun and Veronika 
Grassmann on a small and highly defined library containing only five Env variants where 
it yielded good results. For instance, the equimolar mixture of five Env variants (the 
wildtype variable loop 3 was replaced with the V3 regions of isolates MN, RF, CDC42, 
HXB2 or SF33) that previously showed a differential binding to the antibody 447-52D 139 
were subjected to the flow cytometry-based cell sorting and NGS analysis. The results 
demonstrated a statistically significant enrichment of high affinity Env/V3 variant MN 
from an equal distribution of all variants for each analysis which corresponded to the 
previous results 139 and confirmed the validity of the selection technology for the five-
variant library. However, it it possible that the screening still requires further 
improvement when using more complex libraries and thus, warrants specific 
optimizations in respect to ideal duration of induction, amounts of sorted cells, gating 
strategy as well as analysis approaches. 
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5.4.3 Structural analysis of envelope interactions with the bnAb VRC01 
 
Structural analysis of Env interactions with VRC01 was performed by using Pymol in 
order to assess structural impact of amino acid substitutions. 
According to the data obtained from the sorting experiments, T278 seems to be a key 
residue of Env for VRC01 binding as many substitutions lead to increased affinity for the 
antibody. Two effects might have contributed to this phenomenon: i) direct contact to 
the light chain of VRC01 via the residue Y91 (figure 28 B) and ii) removal of the glycan 
by disrupting the NxT278 sequon. As many substitutions lead to improved if not 
statistically significant affinity for VRC01 (see 4.4.5), it appears that knock-out of the N-
glycosylation sites was most likely responsible for the increase in binding. However, due 
to several inconsistencies in the data, this could not be confirmed. For instance, removal 
of the glycan seemed not to be the unequivocal reason for beneficial effects on VRC01 
binding, as substitutions at N276 would also eliminate the glycosylation. Yet, no 
favorable mutations were enriched at this position during the screening procedure. 
There is also the possibility that position N276 represents an important contact residue 
irrespective of the glycan, or that other amino acids disrupt the structure leading to 
reduced antibody binding. Thus, it was not possible to determine unequivocally if glycan 
removal improves affinity for VRC01 according to the acquired data from 
flowcytometric equilibrium titrations and structural analysis. 
The GoB-variants T278H and T278R represented the most promising variants exhibiting 
improved antibody binding, though the difference to the wildtype was not significant 
(figure 29 A+B). The benefit might be the result of a cation-π interaction formed between 
VRC01 Y91 and the histidine/arginine at position 278 (figure 30 B). This is a strong, 
noncovalent binding interaction that can arise between phenylalanine, tyrosine or 
tryptophan as the π component and lysine, arginine or histidine as the cation. In this 
respect, the π component provides a surface of negative electrostatic potential that can 
bind to positively charged residues through a predominantly electrostatic interaction 
247. Furthermore, even though the T278K substitution was detected as a LoB-variant in 
the screening, flowcytometric equilibrium titrations revealed a slight increase in VRC01 
binding, thus supporting the cation-π interaction as possible reason for higher antibody 
affinity. 
It stands to reason that the substitution of hydrophobic amino acids with ones carrying 
a charge would lead to detrimental structural effects. Such a situation presumably 
occurred with the LoB variants L277K and A368D. The replacement of hydrophobic 
leucine with positively charged lysine probably lead to rearrangement of loop D, and 
thus resulted in loss of affinity for VRC01. Similarly, decreased binding of the variant 
A368D might be attributed to a possible disruption of the CD4 binding loop due to the 
introduction of the negative charge of aspartate. A beneficial case of charged amino acids 
was assumed for the GoB-variant E275K, where the positive charge of lysine could lead 
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to a slight rearrangement in the structure and subsequently the formation of a salt 
bridge with the D99 (figure 30 C). 
 
 
Figure 30 – Structural analysis of Env interactions with VRC01. (A) Contact residues between VRC01 
and GoB/LoB variants according to published data from 249. Amino acid numbering of mutants is based on 
the HIV-1 HXB2 sequence. Contact residues for VRC01 identified in the crystal structure are denoted with 
open circles (○) designating gp120 main-chain-only contacts, filled circles (●) representing both main-
chain and side-chain contacts, and asterisks (*) denoting gp120 side-chain-only contacts. Residues that 
have no direct contact with VRC01 are indicated by (-). Environment of residues (B) T278 and (C) 
E275/V281 in the co-crystal of VRC01 and ZM176.66 gp120 (PDB 4LST). As there is no co-crystallization 
of VRC01 with 16055 available, the gp120 structure of 16055 (PDB 5UM8) was superimposed (green) on 
the ZM176.66 model (light orange). Black dashed lines illustrate the distance between residues in 
Angström. Structures were generated with Pymol. 
 
Even though G367C has been detected as a GoB-variant in the screening procedure, 
flowcytometric equilibrium titration experiments claimed the opposite since a 
statistically significant loss in VRC01 affinity (p= 0.0004) could be confirmed. As 
cysteines usually serve an important structural role in many proteins by forming 
disulfide-bridges, introduction of this amino acid most likely disrupted the Env structure 
and therefore lead to reduced VRC01 binding. A similar case is represented in the LoB-
variant P437N. Proline is known to play a key role in the rate-determining steps of 
protein folding 248, hence a replacement with asparagine supposedly had a destabilizing 
effect and resulted in decreased antibody affinity. 
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6 Summary and conclusions 
 
This PhD thesis focused on the characterization and improvement of an Env-based 
sequential permuation library. In the first part, the general quality of the SeqPer library 
was assessed with different methods (see 4.3.1 and 4.3.3). The quality of the pDNA 
demonstrated errors in the form of deletions mainly in the Env region in 48% of the 
library (see 4.3.1.2). However, when looking at the sublibraries individually, the 
majority of the pools-of-position showed the correct pDNA and only a small portion of 
the sublibrary (6-18%) was actually affected by the deletions (see 4.3.1.3 and 4.3.1.4). 
Thus, the quality of the pDNA was deemed acceptable for further experiments. 
In the following, the diversity and general amino acid composition of the CD4 binding 
site of the SeqPer library were analyzed on the level of the pDNA and the generated 
respective stable cell lines (see 4.3.3). The pDNA demonstrated a nearly even decoded 
amino acid composition with an average of 19 detected amino acids in every sublibrary. 
However, a closer examination of the stable cell lines revealed a significant loss in 
diversity by 32% (from an average of 19 to 14 amino acids in the stock/non-induced and 
12 aas in the induced stable cell lines). In addition, a considerable bias in the amino acid 
composition was detected in every stable cell line (see 4.3.3). These results could be 
attributed to limitations in the procedure of the generation of stable cell lines due to 
insufficient integration events. As the quality of stable cell lines proved to be 
unsatisfactory, various approaches were undertaken to optimize their production. It 
was shown that the relative diversity of an average of 0.05 (maximal relative diversity 
1.0) could be improved to 0.31 by upscaling of the transfection to generate more foci 
(see 4.3.4). Although the diversity did not reach the value from the pDNA (Drel=0.59), the 
distinct improvement indicated that further optimizations for the generation of stable 
cell lines can be achieved (discussed in section 5.2). 
The second part of this dissertation focused on the application of the CD4bs of the SeqPer 
library in the described cell sorting-based screening technology (see 4.4) to identify Env 
variants with increased or decreased binding affinity for the bnAb VRC01. The results 
showed that the library could be successfully utilized in the screening procedure, as an 
enrichment of the GoB-variants T278A and T278H was demonstrated. These variants in 
particular were previously reported to increase affinity for the bnAb VRC01 213,226. 
Unexpectedly, no GoB- and only three LoB-variants proved to be statistically significant 
and additionally, the selection of individual variants was not reproducible in every cell-
sorting. For instance, T278A was enriched in two cell sorting experiments, whereas 
T278H was found in three. Additionaly, T278A and T278H could be detected as GoB- and 
LoB-variants. This indicated limitations of the screening technology which previously 
was tested on only a five-variant library 209,213. Therefore, the screening procedure and 
gating approach probably require adaptations for usage of more complex and large 
libraries. 
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7 Perspective 
 
The usage of the SeqPer library was limited due to suboptimal amino acid composition 
of stable cell lines thus, the next steps should address the improvement of stable cell line 
generation. As part of Benjamin Zimmers PhD thesis, single variant stable cell lines 
representing a BG505 SOSIP gp145 library are currently generated. Variants will be 
pooled equally to create the desired amino acid composition. The library consists of 56 
variants in which all glycosylation motifs (NxT/NxS) are substituted by alanine. This 
concept was designed to assess glycan-dependence of antibodies and to identify 
germline-targeting Env candidates. 
The herein described mammalian cell display and FACS-based cell sorting technology 
was tested on the small and defined CD4 binding site of the library to assess possible 
limitations. With improvement of stable cell lines, the screening should eventually be 
applicable on the complete SeqPer library of approximately 13.000 variants. In addition, 
screening antibodies could be expanded to identify germline-targeting Env variants that 
can be utilized in sequential immunization approaches. As a fact, a well-folded BG505 
SOSIP library is currently under development which is intended to partake in projects 
within the EHVA (European HIV Vaccine Association) consortium. 
As it is unlikely that a singular mutation leads to elicitation of bnAbs, detected favorable 
substitutions could be combined within a Env immunogen in order to utilize possible 
synergistic effects 191,246. This was successfully achieved by Veronika Grassman with 
membrane-bound gp145 and soluble gp140 Env proteins containing L11A and T278A/H 
mutations. The variants not only demonstratd increased affinity for bnAbs, but also 
reduced recognition of non-neutralzing antibodies and improved Env trimerization. 
Currently, 16055 L111A/T278H Env immunogens, alongside 16055 WT, 16055 SOSIP 
WT and 16055 SOSIP L111A/T278H proteins, are tested in a prime boost immunization 
study with white rabbits. 
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8 Appendix 
 
8.1 List of Abbreviations 
 
The respective IUPAC (International Union of Pure and Applied Chemistry) single letter 
codes were used for designation of amino acids 250 and nucleotides 251. 
 
Aa Amino acids  HVTN HIV Vaccine Trials Network 
   IAVI International AIDS Vaccine Initiative 
Ad5 Adenovirus 5  ICTV International Committee on Taxonomy of 
Viruses 
ADCC Antibody-Dependent Cellular Cytotoxicity  Ig Immunoglobulin 
AIDS Acquired Immune Deficiency Syndrome  IN Integrase 
ART Anti-Retroviral Therapy  kb Kilobases 
AUC Area under the Curve  KD Dissociation Constant 
bnAb Broadly Neutralizing Antibody  kDa Kilo Dalton 
bp Base pair  LB Lysogeny Broth 
bs Bridging sheet  LoB Loss of Binding 
BSA Bovine Serum Albumine  MA Matrix 
C1-C5 Constant Regions of HIV-1 Envelope  MFI Mean Fluorescence Intensity 
CA Capsid  MPER Membrane Proximal External Region 
CCR5 C-C Chemokine Receptor Type 5  NC Nucleocapsid 
CDC Center for Disease Control and Prevention  NGS Next Generation Sequencing 
CD4 Cluster of Differentiation 4 (receptor)  NIH National Institute of Health 
CD4bs CD4 binding site  OD Optical Density 
CD4bl CD4 binding loop  PAGE Polyacrylamide Gel Electrophoresis 
CDR H3 Complementarity Determining Region 3 of 
the Antibody Heavy Chain 
 PBS Phosphate Buffered Saline 
Cfu Colony forming unit  PCR Polymerase Chain Reaction 
CIP Calf Intestinal Phosphatase  PCP Pneumocystic Carinii Pneumonia 
CMV Cytomegalovirus  pDNA Plasmid Deoxyribonucleic Acid 
CRF Circulating Recombinant Form  PEI Polyethylenimine 
CT Cytoplasmic Tail of HIV-1 Envelope  Pen/Strep Penicillin/Streptomycin 
CTL Cytotoxic T-Lymphocytes  PIC Pre-Integration Complex 
CXCR4 C-X-C Chemokine Receptor Type 4  PNK Polynucleotide Kinase 
DMEM Dulbecco`s Modified Eagle Medium  Poly dA Polyadenylic Acid 
DMSO Dimethyl Sulfoxide  PR Protease 
DNA Deoxyribonucleic Acid  RNA Ribonucleic Acid 
Drel Relative Diversity  RT Reverse Transcriptase 
E. coli Escherichia Coli  SBS Sequencing by Synthesis 
EDTA Ethylenediaminetetraacetic acid  SCL Stable Cell Line 
Env HIV-1 Envelope protein  SDS Sodium Dodecyl Sulfate 
FACS Fluorescence-Activated Cell Sorting  SeqPer Sequential Permutation Library 
FCS Fetal Calf Serum  SHM Somatic Hypermutation 
FP Fusion Peptide  SIV Simian Immunodeficiency Virus 
FRT Flippase Recombination Target  SP Spacer Peptide 
gDNA genomic Deoxyribonucleic Acid  TB Terrific Broth 
GFP Green Fluorescent Protein  TGN Trans -Golgi Network 
GoB Gain of Binding  TMB Tetramethylbenzidine 
gp Glycoprotein  TMD Transmembrane Domain 
HAART Highly Active Anti-Retroviral Therapy  V1-V5 Variable Loops of HIV-1 Envelope 
HEK Human Embryonic Kidney  w/v weight per volume 
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HIV-1 Human Immunodeficiency Virus type 1  WHO World Health Organization 
HR1/2 Heptad Repeats / Helical Regions 1 and 2 of 
HIV-1 Envelope 
 WT Wildtype 
HRP Horse-Raddish Peroxidase    
 
 
8.2 DNA constructs 
 
8.2.1 Oligonucleotides 
 
Oligonucleotides for Cloning and Sequencing 
 
Name Sequence 5‘  3‘ Name Sequence 5‘  3‘ 
fw_Mly-link-
pUC 
AGCTTGAGTCCGCCCGGGCGGACT
CG 
16055-QL-For ATAATAGCTAGCCGTCTCCCTAGC
ATGAGAGTGCGGGGCATCCTGCG 
rev_Mly-link-
pUC 
AATTCGAGTCCGCCCGGGCGGACT
CA 
16055-gp145-
QL-Rev 
ATATATACTCGAGCGTCTCGTCGA
GTCATCAGCTGTATCCCTGCCGC 
MlyI-Linker-
pUC18 
AGCTTGAGCCGCCCGGGCGGACTG #108_DP TCACTCATTAGGCACCCCA 
pC-CMV-For GTAGGCGTGTACGGTGGGAGG #109_DP AGAAAATACCGCATCAGGC 
pC-BGH-Rev GCAACTAGAAGGCACAGTCGAGG 9F1 ATATATACTCGAGCGTCTCGTCGA
GTCATCAGCTGTATCCCTGCCGC 
THB-8D9-seq-f CATGGTCCTGCTGGAGTTCGTG 9F3 ATAATAGCTAGCCGTCTCCCTAGC
ATGAGAGTGCGGGGCATCCTGCG 
T276S fwd TCATCAGAAGCGAGAACCTGAGCA
ACAACGTGAAAACCATCGT 
T276N_fwd_LoB
1p 
TCATCAGAAGCGAGAACCTGAACA
ACAACGTGAAAACCATCAT 
T276S rev ACGATGGTTTTCACGTTGTTGCTC
AGGTTCTCGCTTCTGATGA 
T276N_rev_LoB
1p 
ATGATGGTTTTCACGTTGTTGTTC
AGGTTCTCGCTTCTGATGA 
T276R fwd TCATCAGAAGCGAGAACCTGAGAA
ACAACGTGAAAACCATCGT 
T276E_fwd_LoB
1p 
TCATCAGAAGCGAGAACCTGGAGA
ACAACGTGAAAACCATCAT 
T276R rev ACGATGGTTTTCACGTTGTTTCTC
AGGTTCTCGCTTCTGATGA 
T276_rev_LoB1
p 
ATGATGGTTTTCACGTTGTTCTCC
AGGTTCTCGCTTCTGATGA 
T276Q fwd TCATCAGAAGCGAGAACCTGCAGA
ACAACGTGAAAACCATCGT 
E273T_fwd_LoB
5p 
GCGAGATCATCATCAGAAGCAACA
ACCTGACCAACAACGTGAA 
T276Q rev ACGATGGTTTTCACGTTGTTCTGC
AGGTTCTCGCTTCTGATGA 
E273T_rev_LoB
5p 
TTCACGTTGTTGGTCAGGTTGTTG
CTTCTGATGATGATCTCGC 
T369I fwd CGGCGACCTGGAAATCACCATCCA
CAGCTTCAACTGCA 
E273F_fwd_LoB
5p 
GCGAGATCATCATCAGAAGCTTCA
ACCTGACCAACAACGTGAA 
T369I rev TGCAGTTGAAGCTGTGGATGGTGA
TTTCCAGGTCGCCG 
E273F_rev_LoB
5p 
TTCACGTTGTTGGTCAGGTTGAAG
CTTCTGATGATGATCTCGC 
T369N fwd CGGCGACCTGGAAATCACCAACCA
CAGCTTCAACTGCA 
L275K_fwd_LoB
5p 
TCATCATCAGAAGCGAGAACAAGA
CCAACAACGTGAAAACCAT 
T369N rev TGCAGTTGAAGCTGTGGTTGGTGA
TTTCCAGGTCGCCG 
L275K_rev_LoB
5p 
ATGGTTTTCACGTTGTTGGTCTTG
TTCTCGCTTCTGATGATGA 
H370Y fwd3 GCGACCTGGAAATCACCACCTACA
GCTTCAACTGCAGAGGCGA 
V279E_fwd_LoB
15p 
GCGAGAACCTGACCAACAACGAGA
AAACCATCATCGTGCACCT 
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H370Y rev3 TCGCCTCTGCAGTTGAAGCTGTAG
GTGGTGATTTCCAGGTCGC 
V279E_rev_LoB
15p 
AGGTGCACGATGATGGTTTTCTCG
TTGTTGGTCAGGTTCTCGC 
E273K fwd GCGAGATCATCATCAGAAGCAAAA
ACCTGACCAACAACGTGAA 
L275Q_fwd_LoB
15p 
TCATCATCAGAAGCGAGAACCAGA
CCAACAACGTGAAAACCAT 
E273K rev TTCACGTTGTTGGTCAGGTTTTTG
CTTCTGATGATGATCTCGC 
L275Q_rev_LoB
15p 
ATGGTTTTCACGTTGTTGGTCTGG
TTCTCGCTTCTGATGATGA 
G362D fwd TCAACTTCACCAGCCCCGCTGATG
GCGACCTGGAAATCAC 
D364E_fwd_LoB
15p 
TCACCAGCCCCGCTGGCGGCGAGC
TGGAAATCACCACCCACAG 
G362D rev GTGATTTCCAGGTCGCCATCAGCG
GGGCTGGTGAAGTTGA 
D364E_rev_LoB
15p 
CTGTGGGTGGTGATTTCCAGCTCG
CCGCCAGCGGGGCTGGTGA 
G363C fwd ACTTCACCAGCCCCGCTGGCTGCG
ACCTGGAAATCACCA 
A361D_fwd_LoB
46p 
TCATCAACTTCACCAGCCCCGACG
GCGGCGACCTGGAAATCAC 
G363C rev TGGTGATTTCCAGGTCGCAGCCAG
CGGGGCTGGTGAAGT 
A361D_rev_LoB
46p 
GTGATTTCCAGGTCGCCGCCGTCG
GGGCTGGTGAAGTTGATGA 
E273N fwd GCGAGATCATCATCAGAAGCAACA
ACCTGACCAACAACGTGAA 
E459I_fwd_LoB
46p 
ACGGCGGCGTGGAAAGCAACATCA
CAGAGATCTTCAGACCCGG 
E273N rev TTCACGTTGTTGGTCAGGTTGTTG
CTTCTGATGATGATCTCGC 
E459I_rev_LoB4
6p 
CCGGGTCTGAAGATCTCTGTGATG
TTGCTTTCCACGCCGCCGT 
T276K_fwd_LoB
1p 
TCATCAGAAGCGAGAACCTGAAGA
ACAACGTGAAAACCATCAT 
P432N_fwd_LoB
46p 
TGGGCAGAGCTATGTACGCCAACC
CCATCGAGGGCAACATCAC 
T276K_rev_LoB
1p 
ATGATGGTTTTCACGTTGTTCTTC
AGGTTCTCGCTTCTGATGA 
P432N_rev_LoB
46p 
GTGATGTTGCCCTCGATGGGGTTG
GCGTACATAGCTCTGCCCA 
 
 
Oligonucleotides for NGS library preparation 
 
Name Sequence 5‘  3‘ Name Sequence 5‘  3‘ 
B2#3 fwd+ILL AGTTCTACAGTCCGACGATCCAAG
GCCTACGAGAAAGAGG 
B9 fwd+ILL AGTTCTACAGTCCGACGATCGCAA
CAACAAGACCTTCAACG 
B2#3 rev+ILL CTTGGCACCCGAGAATTCCACGTT
GGTGGTGTTGACCTG 
B9 rev+ILL CTTGGCACCCGAGAATTCCAATTT
CCACGCTCTCGTTCAG 
B4fwd+ILL AGTTCTACAGTCCGACGATCTCTA
TCGGCTGCTGGAAGAT 
B10_fwd+ILL AGTTCTACAGTCCGACGATCGAGG
GCGAGATCATCATCAG 
B4rev+ILL CTTGGCACCCGAGAATTCCAACTC
TGTTCACCACGCTCAG 
B10_rev+ILL CTTGGCACCCGAGAATTCCAGATG
ATCCGTCTGGGGAAGT 
B5fwd+ILL AGTTCTACAGTCCGACGATCGGCC
ATCGAGAGATACCTGA 
B11 fwd +ILL AGTTCTACAGTCCGACGATCCGGA
CCCTGCAGAGAGTG 
B5rev+ILL CTTGGCACCCGAGAATTCCATCTC
GTTCTGTTCTTGCTGGT 
B11 rev+ILL CTTGGCACCCGAGAATTCCACTGT
TGCTGTTGGTGTCGTT 
B6 fwd+ILL AGTTCTACAGTCCGACGATCCTGT
GCGTGACCCTGGAAT 
B12 fwd+ILL AGTTCTACAGTCCGACGATCAAAT
CACCACCCACAGCTTC 
B6 rev+ILL CTTGGCACCCGAGAATTCCAGCAG
TTGATCAGCCGGTACT 
B12rev+ILL CTTGGCACCCGAGAATTCCAGCTC
TTGCATGTGATGTTGC 
B7fwd+ILL AGTTCTACAGTCCGACGATCCAAT
GCCACCACCGAGAT 
B13fwd+ILL AGTTCTACAGTCCGACGATCCAGC
CTGGACATCACCATC 
B7rev+ILL CTTGGCACCCGAGAATTCCAGCCG
TTGAAGGTCTTGTTGT 
B14fwd+ILL AGTTCTACAGTCCGACGATCTGCA
AGAGCAACATCACC 
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B15fwd+ILL AGTTCTACAGTCCGACGATCACAA
GGTGGTGGAAATCAAG 
B14rev+ILL CTTGGCACCCGAGAATTCCACAGA
AAGCCGAAGATCACG 
B15rev+ILL CTTGGCACCCGAGAATTCCACCTT
CAGCAGGTTGCTCTG 
B15fwd+ILL AGTTCTACAGTCCGACGATCACAA
GGTGGTGGAAATCAAG 
B16fwd+ILL AGTTCTACAGTCCGACGATCGTGA
TCTTCGGCTTTCTGG 
B15rev+ILL CTTGGCACCCGAGAATTCCACCTT
CAGCAGGTTGCTCTG 
B16rev+ILL CTTGGCACCCGAGAATTCCAGAGC
TGCTGATCCTTCAGGT 
B16fwd+ILL AGTTCTACAGTCCGACGATCGTGA
TCTTCGGCTTTCTGG 
B2#1_fwd+ILL AGTTCTACAGTCCGACGATCCTTC
TGGGTGCTGATGATCT 
B16rev+ILL CTTGGCACCCGAGAATTCCAGAGC
TGCTGATCCTTCAGGT 
V3Pool_f2+ILL AGTTCTACAGTCCGACGATCGAGG
GCGAGATCATCATCAG 
B17fwd+ILL AGTTCTACAGTCCGACGATCATCG
AGGCCCAGCAGCAT 
V3Pool_r2+ILL CTTGGCACCCGAGAATTCCACAGC
TTCTTGCCCACTCTCT 
B17rev+ILL CTTGGCACCCGAGAATTCCAATCT
CGTCGTGGCTCTTGTT 
B2#1_fwd+ILL AGTTCTACAGTCCGACGATCCTTC
TGGGTGCTGATGATCT 
B18fwd+ILL AGTTCTACAGTCCGACGATCGGAT
CAGCAGCTCCTGGGCATCT 
B2#1_rev+ILL CTTGGCACCCGAGAATTCCAACGT
TTTCCAGCACCATTTC 
B18rev+ILL CTTGGCACCCGAGAATTCCACTAC
ACCAACACCATCTATCG 
ILLUMINAseq_f
wd 
AATGATACGGCGACCACCGAGATC
TACACGTTCAGAGTTCTACAGTCC
GACGATC 
ILLUMINAseq_r
ev_Index20 
CAAGCAGAAGACGGCATACGAGAT
GGCCACGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index1 
CAAGCAGAAGACGGCATACGAGAT
CGTGATGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index21_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
CGAAACGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index2 
CAAGCAGAAGACGGCATACGAGAT
ACATCGGTGACTGGAGTTCC 
Index22_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
CGTACGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index3 
CAAGCAGAAGACGGCATACGAGAT
GCCTAAGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index23_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
CCACTCGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index4 
CAAGCAGAAGACGGCATACGAGAT
TGGTCAGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index24_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
GCTACCGTGACTGGAGTTCC 
ILLUMINAseq_r
ev_Index5 
CAAGCAGAAGACGGCATACGAGAT
CACTGTGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index25_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
ATCAGTGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index6 
CAAGCAGAAGACGGCATACGAGAT
ATTGGCGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index26_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
GCTCATGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index7 
CAAGCAGAAGACGGCATACGAGAT
GATCTGGTGACTGGAGTTCC 
Index27_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
AGGAATGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index8 
CAAGCAGAAGACGGCATACGAGAT
TCAAGTGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index28_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
CTTTTGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index9 
CAAGCAGAAGACGGCATACGAGAT
CTGATCGTGACTGGAGTTCC 
Index29_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
TAGTTGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index10 
CAAGCAGAAGACGGCATACGAGAT
AAGCTAGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index30_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
CCGGTGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
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ILLUMINAseq_r
ev_Index11 
CAAGCAGAAGACGGCATACGAGAT
GTAGCCGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index31_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
ATCGTGGTGACTGGAGTTCC 
ILLUMINAseq_r
ev_Index12 
CAAGCAGAAGACGGCATACGAGAT
TACAAGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index32_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
TGAGTGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index13 
CAAGCAGAAGACGGCATACGAGAT
TTGACTGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index33_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
CGCCTGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index14 
CAAGCAGAAGACGGCATACGAGAT
GGAACTGTGACTGGAGTTCC 
Index34_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
GCCATGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index15 
CAAGCAGAAGACGGCATACGAGAT
TGACATGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index35_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
AAAATGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index16 
CAAGCAGAAGACGGCATACGAGAT
GGACGGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index36_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
TGTTGGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index17 
CAAGCAGAAGACGGCATACGAGAT
CTCTACGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index37_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
ATTCCGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
ILLUMINAseq_r
ev_Index18 
CAAGCAGAAGACGGCATACGAGAT
GCGGACGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index38_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
AGCTAGGTGACTGGAGTTCC 
ILLUMINAseq_r
ev_Index19 
CAAGCAGAAGACGGCATACGAGAT
TTTCACGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
Index39_ILL_re
v 
CAAGCAGAAGACGGCATACGAGAT
GTATAGGTGACTGGAGTTCCTTGG
CACCCGAGAATTCCA 
 
 
 
8.2.2 Plasmids 
 
 
Name: pQL13 
 
The plasmid was developed by Dr. Tim-
Henrik Bruun during his PhD thesis. 
 
The vector is eligible for stable cell line 
generation due to the inherent FRT site. 
Insertion of target DNA can be performed 
by using BsmBI restriction sites that 
frame the toxic ccdB cassette. 
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Name: pUC18 
 
Commercially available plasmid acquired 
from GenScript, Catalog number SD1162. 
 
Plasmid cloning vector is isolated from E. 
coli strain DH5α by standard procedures.  
 
Name: CMVR VRC01 L 
 
Commercially available plasmid at NIH 
AIDS Reagent Program, Catalog number 
12036 
 
Expression of leader, variable & constant 
regions of VRC01 light chain under the 
control of the CMV promoter. 
 
Name: CMVR VRC01 H 
 
Commercially available plasmid at NIH 
AIDS Reagent Program, Catalog number 
12035 
 
Expression of leader, variable & constant 
regions of VRC01 heavy chain under the 
control of the CMV promoter 
 
 
8.2.3 Cloning Constructs 
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Name: pQL13-16055-gp145 
 
The pQL13 plasmid was developed by Dr. 
Tim-Henrik Bruun during his PhD thesis. 
Cloning of Env was performed by using 
BsmBI restriction sites leading to removal 
of the toxic ccdB cassette.  
 
Name: pUC18_MlyI-linker 
 
Insertion of a cassette framed by MlyI 
restriction sites. Env was inserted into the 
MlyI cassette by using SmaI which was 
part of the cassette. The construct was 
generated specifically to produce an 
error-free blunt end Env-fragment for the 
background determination of the NGS 
device (4.3.2.2). 
 
 
8.3 Supplemental Material 
 
Table S1 – Purity of the pDNA SeqPer library. Absorbance ratios at 260 and 280 (OD260/280) as well as 
260 and 230 (OD260/230) at each pool-of-position were measured with the NanoDrop 1000 
spectrophotometer to assess probable contaminations. 
Position OD260/280 Position OD260/280 Position OD260/280 
N30X 1,94 V240X 1,93 V450X 1,94 
L31X 1,97 S241X 1,93 R451X 1,93 
W32X 1,95 T242X 1,93 D452X 1,95 
V33X 1,97 V243X 1,94 G453X 1,96 
T34X 1,95 Q244X 1,93 G454X 1,96 
V35X 2,00 C245X 1,94 V455X 1,98 
Y36X 1,88 T246X 1,97 E456X 1,96 
Y37X 1,95 H247X 1,96 S457X 1,94 
G38X 1,97 G248X 1,95 N458X 1,97 
V39X 1,97 I249X 1,95 E459X 1,95 
P40X 1,97 K250X 1,97 T460X 1,95 
V41X 1,94 P251X 1,88 E461X 1,96 
W42X 1,94 V252X 1,97 I462X 1,96 
K43X 1,89 V253X 1,95 F463X 1,95 
E44X 1,96 S254X 1,97 R464X 1,93 
A45X 1,91 T255X 1,95 P465X 1,95 
K46X 1,95 Q256X 1,90 G466X 1,87 
__________________________________________________________________________________ 
91 
 
Appendix 
T47X 1,90 L257X 1,86 G467X 1,89 
T48X 1,95 L258X 1,98 G468X 1,98 
L49X 1,96 L259X 1,88 D469X 1,92 
F50X 1,97 N260X 1,92 M470X 2,00 
C51X 1,96 G261X 1,94 R471X 1,99 
A52X 1,94 S262X 1,88 N472X 2,01 
S53X 1,98 L263X 1,91 N473X 1,98 
D54X 1,96 A264X 1,93 W474X 1,97 
A55X 1,97 E265X 1,92 R475X 1,95 
K56X 1,94 G266X 1,90 S476X 1,96 
A57X 1,96 E267X 1,90 E477X 1,98 
Y58X 1,95 I268X 1,97 L478X 1,89 
E59X 1,97 I269X 2,00 Y479X 1,90 
K60X 1,97 I270X 1,99 K480X 1,96 
E61X 1,96 R271X 1,91 Y481X 2,00 
V62X 1,97 S272X 1,97 K482X 1,98 
H63X 1,95 E273X 1,91 V483X 1,96 
N64X 1,97 N274X 1,99 V484X 1,97 
V65X 1,96 L275X 1,94 E485X 1,98 
W66X 1,96 T276X 1,95 I486X 2,00 
A67X 1,93 N277X 1,93 K487X 2,00 
T68X 1,97 N278X 1,90 P488X 2,01 
H69X 1,97 V279X 1,96 L489X 2,01 
A70X 1,96 K280X 1,95 G490X 1,97 
C71X 1,97 T281X 1,91 I491X 1,97 
V72X 1,97 I282X 1,93 A492X 2,00 
P73X 1,94 I283X 1,91 P493X 1,94 
T74X 1,97 V284X 1,90 T494X 2,00 
D75X 1,93 H285X 1,98 A495X 1,96 
P76X 1,94 L286X 1,95 A496X 1,98 
N77X 1,91 N287X 1,90 K497X 1,97 
P78X 1,95 E288X 1,90 R498X 1,96 
Q79X 1,96 S289X 1,96 R499X 1,99 
E80X 1,99 V290X 1,95 V500X 1,98 
M81X 1,97 E291X 1,97 V501X 1,96 
V82X 1,93 I292X 1,99 E502X 1,97 
L83X 1,94 V293X 2,00 R503X 1,98 
E84X 2,00 C294X 1,96 E504X 1,98 
N85X 1,99 T295X 1,93 K505X 1,95 
V86X 1,97 R296X 2,00 S506X 1,98 
T87X 1,96 P297X 2,01 A507X 1,96 
E88X 1,97 N298X 1,93 V508X 2,00 
N89X 1,97 N299X 1,99 G509X 1,96 
F90X 1,98 N300X 1,98 L510X 1,97 
N91X 1,98 T301X 1,97 G511X 1,96 
M92X 1,98 R302X 1,97 A512X 1,96 
W93X 1,97 K303X 1,98 V513X 1,98 
K94X 1,99 S304X 1,97 I514X 1,95 
N95X 1,98 I305X 1,96 F515X 1,96 
D96X 1,97 R306X 1,95 G516X 1,96 
M97X 1,92 I307X 1,94 F517X 1,94 
V98X 1,89 G308X 1,94 L518X 1,96 
E99X 1,95 P309X 1,93 G519X 1,99 
Q100X 1,91 G310X 1,95 A520X 1,95 
M101X 1,91 Q311X 1,94 A521X 1,95 
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H102X 1,96 T312X 1,93 G522X 1,97 
E103X 1,91 F313X 1,94 S523X 1,97 
D104X 1,94 Y314X 1,93 T524X 1,99 
V105X 1,95 A315X 1,95 M525X 1,96 
I106X 1,90 T316X 1,94 G526X 1,97 
S107X 1,89 G317X 1,94 A527X 1,95 
L108X 1,98 D318X 1,95 A528X 1,96 
W109X 1,95 I319X 1,94 S529X 2,00 
D110X 1,95 I320X 1,95 I530X 1,90 
Q111X 2,00 G321X 1,93 T531X 1,96 
S112X 1,92 N322X 1,93 L532X 1,99 
L113X 1,88 I323X 1,96 T533X 1,96 
K114X 1,93 R324X 1,94 V534X 1,95 
P115X 1,91 Q325X 2,02 Q535X 1,96 
C116X 1,96 A326X 1,99 A536X 1,95 
V117X 1,96 Y327X 1,99 R537X 1,98 
K118X 1,93 C328X 1,97 Q538X 1,94 
L119X 1,89 N329X 1,97 L539X 1,95 
T120X 1,95 I330X 1,99 L540X 1,96 
P121X 1,94 K331X 1,96 S541X 1,94 
L122X 1,93 K332X 1,97 G542X 1,96 
C123X 1,94 D333X 1,95 I543X 1,97 
V124X 1,94 D334X 1,93 V544X 1,97 
T125X 1,93 W335X 1,99 Q545X 1,97 
L126X 1,95 I336X 1,93 Q546X 1,96 
E127X 1,94 R337X 1,96 Q547X 1,98 
C128X 1,88 T338X 1,94 S548X 1,97 
R129X 1,95 L339X 1,99 N549X 1,96 
Q130X 1,86 Q340X 1,71 L550X 1,95 
V131X 1,87 R341X 1,97 L551X 1,95 
N132X 1,93 V342X 1,96 K552X 1,97 
T133X 1,94 G343X 1,96 A553X 1,98 
T134X 1,85 K344X 1,97 I554X 1,97 
N135X 1,96 K345X 1,96 E555X 1,97 
A136X 1,88 L346X 1,95 A556X 1,95 
T137X 1,89 A347X 1,95 Q557X 1,97 
S138X 1,89 E348X 1,96 Q558X 1,97 
S139X 1,97 H349X 1,96 H559X 1,98 
V140X 1,96 F350X 1,97 L560X 2,00 
N141X 1,86 P351X 1,94 L561X 1,98 
V142X 1,90 R352X 1,95 Q562X 2,02 
T143X 1,89 R353X 1,91 L563X 1,99 
N144X 1,92 I354X 1,98 T564X 1,98 
G145X 1,93 I355X 1,99 V565X 1,99 
E146X 1,98 N356X 2,00 W566X 1,93 
E147X 1,96 F357X 1,98 G567X 1,98 
I148X 1,89 T358X 1,94 I568X 1,95 
K149X 1,99 S359X 1,92 K569X 2,00 
N150X 1,93 P360X 1,99 Q570X 1,96 
C151X 1,94 A361X 1,94 L571X 1,94 
S152X 1,89 G362X 1,90 Q572X 1,95 
F153X 1,97 G363X 1,94 T573X 1,94 
N154X 1,90 D364X 2,09 R574X 1,97 
A155X 1,94 L365X 1,99 V575X 1,93 
T156X 1,94 E366X 1,95 L576X 2,02 
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T157X 1,91 I367X 1,97 A577X 1,93 
E158X 1,90 T368X 1,96 I578X 1,92 
I159X 1,88 T369X 2,05 E579X 2,02 
R160X 1,90 H370X 1,97 R580X 1,95 
D161X 1,91 S371X 1,98 Y581X 1,93 
K162X 1,90 F372X 1,95 L582X 1,99 
K163X 1,91 N373X 1,99 K583X 1,90 
Q164X 2,00 C374X 1,95 D584X 2,02 
K165X 1,98 R375X 1,94 Q585X 1,95 
V166X 1,99 G376X 1,94 Q586X 1,98 
Y167X 1,93 E377X 1,95 L587X 1,97 
A168X 1,94 F378X 1,98 L588X 1,94 
L169X 1,89 F379X 1,97 G589X 1,96 
F170X 1,89 Y380X 1,97 I590X 2,00 
Y171X 2,04 C381X 1,97 W591X 1,97 
R172X 1,92 N382X 1,97 G592X 1,97 
L173X 1,89 T383X 1,98 C593X 1,99 
D174X 1,95 S384X 1,98 S594X 1,99 
I175X 1,94 S385X 1,97 G595X 1,92 
V176X 1,94 L386X 1,97 K596X 1,94 
P177X 1,89 F387X 1,96 L597X 1,98 
L178X 1,99 N388X 1,97 I598X 1,98 
E179X 1,94 S389X 1,96 C599X 1,97 
E180X 1,93 T390X 1,97 T600X 1,91 
E181X 1,96 Y391X 1,98 T601X 1,99 
R182X 1,96 N392X 1,99 A602X 1,98 
K183X 2,00 P393X 1,97 V603X 1,97 
G184X 1,93 N394X 1,99 P604X 2,00 
N185X 1,93 D395X 1,98 W605X 1,95 
S186X 1,91 T396X 1,99 N606X 1,93 
S187X 1,90 N397X 1,99 S607X 1,95 
K188X 1,94 S398X 1,97 S608X 1,94 
Y189X 1,93 N399X 1,95 W609X 1,94 
R190X 1,92 S400X 1,99 S610X 1,94 
L191X 1,91 S401X 1,98 N611X 1,95 
I192X 1,91 S402X 1,97 K612X 1,94 
N193X 1,92 S403X 1,97 S613X 1,96 
C194X 1,91 N404X 1,97 H614X 1,88 
N195X 1,92 S405X 1,93 D615X 1,97 
T196X 1,95 S406X 1,99 E616X 1,96 
S197X 1,93 L407X 1,98 I617X 1,95 
A198X 1,91 D408X 1,93 W618X 1,93 
I199X 1,92 I409X 1,98 G619X 1,95 
T200X 1,94 T410X 2,00 N620X 1,95 
Q201X 1,93 I411X 1,97 M621X 1,89 
A202X 1,93 P412X 1,98 T622X 1,97 
C203X 1,93 C413X 1,98 W623X 1,94 
P204X 1,92 R414X 1,95 M624X 1,99 
K205X 1,94 I415X 1,93 Q625X 1,95 
V206X 1,94 K416X 1,94 W626X 1,96 
T207X 1,92 Q417X 1,95 D627X 1,96 
F208X 1,96 I418X 1,95 R628X 1,93 
D209X 1,92 I419X 1,94 E629X 1,91 
P210X 1,92 N420X 1,94 I630X 1,94 
I211X 1,90 M421X 1,97 S631X 1,93 
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P212X 1,91 W422X 2,00 N632X 1,92 
I213X 1,89 Q423X 2,00 Y633X 1,93 
H214X 1,96 E424X 2,01 T634X 1,94 
Y215X 1,91 V425X 1,98 N635X 1,95 
C216X 1,95 G426X 1,98 T636X 1,93 
A217X 1,89 R427X 1,98 I637X 1,93 
P218X 1,94 A428X 1,96 Y638X 1,94 
A219X 1,93 M429X 1,92 R639X 1,93 
G220X 1,94 Y430X 1,99 L640X 1,93 
Y221X 1,94 A431X 2,04 L641X 1,94 
A222X 1,88 P432X 1,88 E642X 1,95 
I223X 1,89 P433X 1,91 D643X 1,93 
L224X 1,95 I434X 1,91 S644X 1,93 
K225X 1,94 E435X 1,89 Q645X 1,95 
C226X 1,94 G436X 1,91 N646X 1,94 
N227X 1,92 N437X 1,99 Q647X 1,93 
N228X 1,97 I438X 1,99 Q648X 1,94 
K229X 1,93 T439X 1,91 E649X 1,97 
T230X 1,95 C440X 2,05 Q650X 1,94 
F231X 1,92 K441X 1,89 N651X 1,92 
N232X 1,94 S442X 1,89 E652X 1,95 
G233X 1,90 N443X 2,07 K653X 1,93 
T234X 1,93 I444X 1,92 D654X 1,93 
G235X 1,92 T445X 1,93 L655X 1,93 
P236X 1,92 G446X 1,94 L656X 1,92 
C237X 1,93 L447X 1,94 A657X 1,93 
N238X 1,92 L448X 1,95 L658X 1,92 
N239X 1,93 L449X 1,96   
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Figure S2 - Agarose gel electrophoresis of native and digested plasmid DNA. Restriction assay 
profiles of all pools-of-position from the SeqPer library are shown. One band at the length of 7937 bps for 
the native (NcoI-HF -) and four bands at 3744, 2353, 1519 and 321 base pairs for the digested pDNA (NcoI-
HF +) were expected. 
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Figure S3 - Restriction enzyme assay profile for (A) sub-library 136 and (B) sub-library 316. 
Plasmid DNA of 40 random colony-forming units from (C1-C40) sub-library 136 and 316 of the SeqPer 
library was analyzed. 1 µg native and digested (NcoI-HF, 2h, 37°C) plasmid DNA was visualized on a 0.8 
% agarose gel. The wildtype restriction pattern from the 16055 gp145 Env (WT) and the pools-of-position 
135 (P136) and 316 (P316) are also shown. Aberrational colony forming units are denoted in red. 
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Figure S4 – Amino acid distribution in stable cell lines. Amino acid distribution of stock, non-induced 
and induced stable cell lines of the (A) CD4 binding loop, (B) bridging sheet and (C) V5 loop is shown. 
Height of the stacked bars (y-axis) represent the detected amino acids in percent at every pool-of-position 
(x-axis) in the SeqPer library. To provide a clearer overview, the respective wildtype amino acid at every 
pool-of-position was excluded from the data set. 
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Figure S7 –Amino acid distribution of stable cell lines L275X and N280X. Stock, non-induced and 
induced samples of SCL triplicates were compared to the respective pDNA utilized during the generation 
of the stable cell lines. Height of the stacked bars represents detected amino acids in percent (y-axis). 
 
 
 
Figure S8 – FACS equilibrium titration curves of GoB and LoB variants. Relative mean fluorescence 
intensities of (A+C) transiently transfected variants and their respective (B+D) induced stable cell lines 
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were compared with 16055 gp145 WT. Signals were normalized on the fluorescence of GFP. Notably, none 
of the variants displayed distinct saturation. 
 
 
Table S2 – Statistics of FACS equilibrium titrations. Statistical significance of transiently transfected 
GoB and LoB variants and their respective stable cell lines was determined with excel using a two-sided, 
homoscedastic t-test and corrected according to Bonferroni to adjust for multiple testing. Variants that 
exhibited p-values <0.0042 were considered significant and are indicated by asterisks. 
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